/*! For license information please see main.a4f15c66.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function c(e,t){return e.indexOf(t)}function u(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function f(e){return e.length}function p(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,b=0,y=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function k(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function S(){return g=y>0?u(_,--y):0,v--,10===g&&(v=1,h--),g}function C(){return g=y<b?u(_,y++):0,v++,10===g&&(v=1,h++),g}function T(){return u(_,y)}function x(){return y}function F(e,t){return d(_,e,t)}function P(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function E(e){return h=v=1,b=f(_=e),y=0,[]}function R(e){return _="",e}function A(e){return s(F(y-1,O(91===e?e+2:40===e?e+1:e)))}function N(e){for(;(g=T())&&g<33;)C();return P(e)>2||P(g)>3?"":" "}function I(e,t){for(;--t&&C()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return F(e,x()+(t<6&&32==T()&&32==C()))}function O(e){for(;C();)switch(g){case e:return y;case 34:case 39:34!==e&&39!==e&&O(g);break;case 40:41===e&&O(e);break;case 92:C()}return y}function D(e,t){for(;C()&&e+g!==57&&(e+g!==84||47!==T()););return"/*"+F(t,y-1)+"*"+o(47===e?e:C())}function M(e){for(;!P(T());)C();return F(e,y)}var z="-ms-",L="-moz-",Z="-webkit-",j="comm",B="rule",W="decl",U="@keyframes";function H(e,t){for(var n="",r=p(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function V(e,t,n,r){switch(e.type){case"@import":case W:return e.return=e.return||e.value;case j:return"";case U:return e.return=e.value+"{"+H(e.children,r)+"}";case B:e.value=e.props.join(",")}return f(n=H(e.children,r))?e.return=e.value+"{"+n+"}":""}function J(e,t){switch(function(e,t){return(((t<<2^u(e,0))<<2^u(e,1))<<2^u(e,2))<<2^u(e,3)}(e,t)){case 5103:return Z+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Z+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Z+e+L+e+z+e+e;case 6828:case 4268:return Z+e+z+e+e;case 6165:return Z+e+z+"flex-"+e+e;case 5187:return Z+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Z+e+z+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return Z+e+z+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return Z+e+z+l(e,"shrink","negative")+e;case 5292:return Z+e+z+l(e,"basis","preferred-size")+e;case 6060:return Z+"box-"+l(e,"-grow","")+Z+e+z+l(e,"grow","positive")+e;case 4554:return Z+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,Z+"$1"),/(image-set)/,Z+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,Z+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Z+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,Z+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(f(e)-1-t>6)switch(u(e,t+1)){case 109:if(45!==u(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+L+(108==u(e,t+3)?"$3":"$2-$3"))+e;case 115:return~c(e,"stretch")?J(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==u(e,t+1))break;case 6444:switch(u(e,f(e)-3-(~c(e,"!important")&&10))){case 107:return l(e,":",":"+Z)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Z+(45===u(e,14)?"inline-":"")+"box$3$1"+Z+"$2$3$1"+z+"$2box$3")+e}break;case 5936:switch(u(e,t+11)){case 114:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Z+e+z+e+e}return e}function $(e){return R(G("",null,null,null,[""],e=E(e),0,[0],e))}function G(e,t,n,r,a,i,s,u,d){for(var p=0,h=0,v=s,b=0,y=0,g=0,_=1,w=1,k=1,F=0,P="",E=a,R=i,O=r,z=P;w;)switch(g=F,F=C()){case 40:if(108!=g&&58==z.charCodeAt(v-1)){-1!=c(z+=l(A(F),"&","&\f"),"&\f")&&(k=-1);break}case 34:case 39:case 91:z+=A(F);break;case 9:case 10:case 13:case 32:z+=N(g);break;case 92:z+=I(x()-1,7);continue;case 47:switch(T()){case 42:case 47:m(K(D(C(),x()),t,n),d);break;default:z+="/"}break;case 123*_:u[p++]=f(z)*k;case 125*_:case 59:case 0:switch(F){case 0:case 125:w=0;case 59+h:y>0&&f(z)-v&&m(y>32?Q(z+";",r,n,v-1):Q(l(z," ","")+";",r,n,v-2),d);break;case 59:z+=";";default:if(m(O=q(z,t,n,p,h,a,u,P,E=[],R=[],v),i),123===F)if(0===h)G(z,t,O,O,E,i,v,u,R);else switch(b){case 100:case 109:case 115:G(e,O,O,r&&m(q(e,O,O,0,0,a,u,P,a,E=[],v),R),a,R,v,u,r?E:R);break;default:G(z,O,O,O,[""],R,0,u,R)}}p=h=y=0,_=k=1,P=z="",v=s;break;case 58:v=1+f(z),y=g;default:if(_<1)if(123==F)--_;else if(125==F&&0==_++&&125==S())continue;switch(z+=o(F),F*_){case 38:k=h>0?1:(z+="\f",-1);break;case 44:u[p++]=(f(z)-1)*k,k=1;break;case 64:45===T()&&(z+=A(C())),b=T(),h=v=f(P=z+=M(x())),F++;break;case 45:45===g&&2==f(z)&&(_=0)}}return i}function q(e,t,n,r,o,i,c,u,f,m,h){for(var v=o-1,b=0===o?i:[""],y=p(b),g=0,_=0,k=0;g<r;++g)for(var S=0,C=d(e,v+1,v=a(_=c[g])),T=e;S<y;++S)(T=s(_>0?b[S]+" "+C:l(C,/&\f/g,b[S])))&&(f[k++]=T);return w(e,t,n,0===o?B:u,f,m,h)}function K(e,t,n){return w(e,t,n,j,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,W,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,a=0;r=a,a=T(),38===r&&12===a&&(t[n]=1),!P(a);)C();return F(e,y)},X=function(e,t){return R(function(e,t){var n=-1,r=44;do{switch(P(r)){case 0:38===r&&12===T()&&(t[n]=1),e[n]+=Y(y-1,t,n);break;case 2:e[n]+=A(r);break;case 4:if(44===r){e[++n]=58===T()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=C());return e}(E(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var c=0;c<i.length;c++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[c]):i[c]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case W:e.return=J(e.value,e.length);break;case U:return H([k(e,{value:l(e.value,"@","@"+Z)})],r);case B:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return H([k(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return H([k(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),k(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),k(e,{props:[l(t,/:(plac\w+)/,z+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var c,u,d=[V,(u=function(e){c.insert(e)},function(e){e.root||(e=e.return)&&u(e)})],f=function(e){var t=p(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){c=n,H($(e?e+"{"+t.styles+"}":t.styles),f),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},c=function(e){return null!=e&&"boolean"!==typeof e},u=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return p={name:t,styles:n,next:p},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function f(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return p={name:n.name,styles:n.styles,next:p},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)p={name:r.name,styles:r.styles,next:p},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=f(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":c(i)&&(r+=u(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=f(e,t,i);switch(o){case"animation":case"animationName":r+=u(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)c(i[l])&&(r+=u(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=p,o=n(e);return p=a,f(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var p,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";p=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=f(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=f(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,c="";null!==(l=m.exec(o));)c+="-"+l[1];return{name:r(o)+c,styles:o,next:p}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return Z}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function c(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var u=n(2065),d={black:"#000",white:"#fff"},f={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},p={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},b={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},y={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function k(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,u.$n)(e.main,a):"dark"===t&&(e.dark=(0,u._j)(e.main,o)))}function S(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,c=e.tonalOffset,S=void 0===c?.2:c,C=(0,a.Z)(e,g),T=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),x=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:p[200],light:p[50],dark:p[400]}:{main:p[500],light:p[300],dark:p[700]}}(n),F=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),P=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[700],light:b[500],dark:b[900]}}(n),E=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[800],light:y[500],dark:y[900]}}(n),R=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function A(e){return(0,u.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var N=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,c=e.darkShade,u=void 0===c?700:c;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return k(t,"light",l,S),k(t,"dark",u,S),t.contrastText||(t.contrastText=A(t.main)),t},I={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:N({color:T,name:"primary"}),secondary:N({color:x,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:N({color:F,name:"error"}),warning:N({color:R,name:"warning"}),info:N({color:P,name:"info"}),success:N({color:E,name:"success"}),grey:f,contrastThreshold:l,getContrastText:A,augmentColor:N,tonalOffset:S},I[n]),C)}var C=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var T={textTransform:"uppercase"},x='"Roboto", "Helvetica", "Arial", sans-serif';function F(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?x:o,l=n.fontSize,c=void 0===l?14:l,u=n.fontWeightLight,d=void 0===u?300:u,f=n.fontWeightRegular,p=void 0===f?400:f,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,b=void 0===v?700:v,y=n.htmlFontSize,g=void 0===y?16:y,_=n.allVariants,w=n.pxToRem,k=(0,a.Z)(n,C);var S=c/14,F=w||function(e){return"".concat(e/g*S,"rem")},P=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:F(t),lineHeight:n},s===x?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},E={h1:P(d,96,1.167,-1.5),h2:P(d,60,1.2,-.5),h3:P(p,48,1.167,0),h4:P(p,34,1.235,.25),h5:P(p,24,1.334,0),h6:P(h,20,1.6,.15),subtitle1:P(p,16,1.75,.15),subtitle2:P(h,14,1.57,.1),body1:P(p,16,1.5,.15),body2:P(p,14,1.43,.15),button:P(h,14,1.75,.4,T),caption:P(p,12,1.66,.4),overline:P(p,12,2.66,1,T)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:F,fontFamily:s,fontSize:c,fontWeightLight:d,fontWeightRegular:p,fontWeightMedium:h,fontWeightBold:b},E),k,{clone:!1})}function P(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var E=["none",P(0,2,1,-1,0,1,1,0,0,1,3,0),P(0,3,1,-2,0,2,2,0,0,1,5,0),P(0,3,3,-2,0,3,4,0,0,1,8,0),P(0,2,4,-1,0,4,5,0,0,1,10,0),P(0,3,5,-1,0,5,8,0,0,1,14,0),P(0,3,5,-1,0,6,10,0,0,1,18,0),P(0,4,5,-2,0,7,10,1,0,2,16,1),P(0,5,5,-3,0,8,10,1,0,3,14,2),P(0,5,6,-3,0,9,12,1,0,3,16,2),P(0,6,6,-3,0,10,14,1,0,4,18,3),P(0,6,7,-4,0,11,15,1,0,4,20,3),P(0,7,8,-4,0,12,17,2,0,5,22,4),P(0,7,8,-4,0,13,19,2,0,5,24,4),P(0,7,9,-4,0,14,21,2,0,5,26,4),P(0,8,9,-5,0,15,22,2,0,6,28,5),P(0,8,10,-5,0,16,24,2,0,6,30,5),P(0,8,11,-5,0,17,26,2,0,6,32,5),P(0,9,11,-5,0,18,28,2,0,7,34,6),P(0,9,12,-6,0,19,29,2,0,7,36,6),P(0,10,13,-6,0,20,31,3,0,8,38,7),P(0,10,13,-6,0,21,33,3,0,8,40,7),P(0,10,14,-6,0,22,35,3,0,8,42,7),P(0,11,14,-7,0,23,36,3,0,9,44,8),P(0,11,15,-7,0,24,38,3,0,9,46,8)],R=["duration","easing","delay"],A={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},N={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function I(e){return"".concat(Math.round(e),"ms")}function O(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function D(e){var t=(0,r.Z)({},A,e.easing),n=(0,r.Z)({},N,e.duration);return(0,r.Z)({getAutoHeightDuration:O,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,c=r.delay,u=void 0===c?0:c;(0,a.Z)(r,R);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:I(i)," ").concat(l," ").concat("string"===typeof u?u:I(u))})).join(",")}},e,{easing:t,duration:n})}var M={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},z=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function L(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,u=void 0===l?{}:l,d=e.transitions,f=void 0===d?{}:d,p=e.typography,m=void 0===p?{}:p,h=(0,a.Z)(e,z);if(e.vars)throw new Error((0,o.Z)(18));var v=S(u),b=(0,s.Z)(e),y=(0,i.Z)(b,{mixins:c(b.breakpoints,n),palette:v,shadows:E.slice(),typography:F(v,m),transitions:D(f),zIndex:(0,r.Z)({},M)});y=(0,i.Z)(y,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,i.Z)(e,t)}),y)}var Z=L},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return k},deprecatedPropType:function(){return S},isMuiElement:function(){return C},ownerDocument:function(){return x},ownerWindow:function(){return F},requirePropFactory:function(){return P},setRef:function(){return E},unstable_ClassNameGenerator:function(){return j},unstable_useEnhancedEffect:function(){return R},unstable_useId:function(){return O},unsupportedProp:function(){return D},useControlled:function(){return M},useEventCallback:function(){return z.Z},useForkRef:function(){return L.Z},useIsFocusVisible:function(){return Z.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),c=n(3366),u=n(8182),d=n(4419),f=n(5513),p=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),b=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],y=(0,p.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,c,u,d,f,p,m,h,v,b,y=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=y.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=y.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=y.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=y.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(c=y.typography)||null==(u=c.pxToRem)?void 0:u.call(c,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(f=(y.vars||y).palette)||null==(p=f[g.color])?void 0:p.main)?d:{action:null==(m=(y.vars||y).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(y.vars||y).palette)||null==(b=v.action)?void 0:b.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,f.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,p=n.component,m=void 0===p?"svg":p,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,k=n.inheritViewBox,S=void 0!==k&&k,C=n.titleAccess,T=n.viewBox,x=void 0===T?"0 0 24 24":T,F=(0,c.Z)(n,b),P=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:S,viewBox:x}),E={};S||(E.viewBox=x);var R=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(P);return(0,v.jsxs)(y,(0,i.Z)({as:m,className:(0,u.Z)(R.root,o),focusable:"false",color:w,"aria-hidden":!C||void 0,role:C?"img":void 0,ref:t},E,F,{ownerState:P,children:[r,C?(0,v.jsx)("title",{children:C}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var k=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var S=function(e,t){return function(){return null}};var C=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function T(e){return e&&e.ownerDocument||document}var x=T;var F=function(e){return T(e).defaultView||window};var P=function(e,t){return function(){return null}},E=n(2971).Z,R=n(5721).Z,A=n(885),N=0;var I=l.useId;var O=function(e){if(void 0!==I){var t=I();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,A.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(N+=1))}),[r]),o}(e)};var D=function(e,t,n,r,a){return null};var M=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,A.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},z=n(6702),L=n(792),Z=n(2763),j={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function c(){o=!1}function u(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var f=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",c,!0),t.addEventListener("pointerdown",c,!0),t.addEventListener("touchstart",c,!0),t.addEventListener("visibilitychange",u,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),c=n(5438),u=n(9140),d=n(2561),f=s,p=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?f:p},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,c.hC)(t,n,r);(0,d.L)((function(){return(0,c.My)(t,n,r)}));return null},b=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var f=h(t,n,s),p=f||m(d),b=!p("as");return function(){var y=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==y[0]||void 0===y[0].raw)g.push.apply(g,y);else{0,g.push(y[0][0]);for(var _=y.length,w=1;w<_;w++)g.push(y[w],y[0][w])}var k=(0,l.w)((function(e,t,n){var a=b&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var y in h={},e)h[y]=e[y];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,c.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,u.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=b&&void 0===f?m(a):p,k={};for(var S in e)b&&"as"===S||w(S)&&(k[S]=e[S]);return k.className=o,k.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,k))}));return k.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",k.defaultProps=t.defaultProps,k.__emotion_real=k,k.__emotion_base=d,k.__emotion_styles=g,k.__emotion_forwardProp=f,Object.defineProperty(k,"toString",{value:function(){return"."+i}}),k.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(k,r,!0)})).apply(void 0,g)},k}},y=b.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){y[e]=y(e)}));var g=y;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return u},VO:function(){return a},W8:function(){return s},dt:function(){return c},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function c(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function u(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return c},_j:function(){return u},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},c="rgb",u=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(c+="a",u.push(t[3])),i({type:c,values:u})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function c(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function u(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return C},x9:function(){return k}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),c=n(7312),u=["variant"];function d(e){return 0===e.length}function f(e){var t=e.variant,n=(0,o.Z)(e,u),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,c.Z)(e[t]):"".concat(d(r)?t:(0,c.Z)(t)).concat((0,c.Z)(e[t].toString()))})),r}var p=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function b(e){return 0===Object.keys(e).length}function y(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=f(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],c=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return c&&c.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[f(n.props)])})),l};function k(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var S=(0,l.Z)();function C(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?S:t,l=e.rootShouldForwardProp,c=void 0===l?k:l,u=e.slotShouldForwardProp,d=void 0===u?k:u,f=e.styleFunctionSx,C=void 0===f?p.Z:f,T=function(e){var t=b(e.theme)?n:e.theme;return C((0,i.Z)({},e,{theme:t}))};return T.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,u=t.name,f=t.slot,p=t.skipVariantsResolver,S=t.skipSx,C=t.overridesResolver,x=(0,o.Z)(t,m),F=void 0!==p?p:f&&"Root"!==f||!1,P=S||!1;var E=k;"Root"===f?E=c:f?E=d:y(e)&&(E=void 0);var R=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:E,label:l},x)),A=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var c=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:b(r)?n:r},a))}:e})):[],d=e;u&&C&&c.push((function(e){var t=b(e.theme)?n:e.theme,r=g(u,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),C(e,o)}return null})),u&&!F&&c.push((function(e){var t=b(e.theme)?n:e.theme;return w(e,_(u,t),t,u)})),P||c.push(T);var f=c.length-s.length;if(Array.isArray(e)&&f>0){var p=new Array(f).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(p))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(p))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:b(r)?n:r},a))});var m=R.apply(void 0,[d].concat((0,r.Z)(c)));return m};return R.withConfig&&(A.withConfig=R.withConfig),A}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,c=e.step,u=void 0===c?5:c,d=(0,a.Z)(e,s),f=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),p=Object.keys(f);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-u/100).concat(l,")")}function v(e,t){var r=p.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[p[r]]?n[p[r]]:t)-u/100).concat(l,")")}return(0,r.Z)({keys:p,values:f,up:m,down:h,between:v,only:function(e){return p.indexOf(e)+1<p.length?v(e,p[p.indexOf(e)+1]):m(e)},not:function(e){var t=p.indexOf(e);return 0===t?m(p[1]):t===p.length-1?h(p[t]):v(e,p[p.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var c={borderRadius:4},u=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,u.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var f=["breakpoints","palette","spacing","shape"];var p=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,u=e.spacing,p=e.shape,m=void 0===p?{}:p,h=(0,a.Z)(e,f),v=l(n),b=d(u),y=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:b,shape:(0,r.Z)({},c,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,o.Z)(e,t)}),y)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return G}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var c=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),u=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(c,u,d,f,p,m,h,v,b,y,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),k=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),S=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};S.propTypes={},S.filterProps=["gap"];var C=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};C.propTypes={},C.filterProps=["columnGap"];var T=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["rowGap"];var x=o(S,C,T,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),F=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),P=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),E=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function R(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var A=(0,r.Z)({prop:"width",transform:R}),N=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||R(t)}}))}return null};N.filterProps=["maxWidth"];var I=(0,r.Z)({prop:"minWidth",transform:R}),O=(0,r.Z)({prop:"height",transform:R}),D=(0,r.Z)({prop:"maxHeight",transform:R}),M=(0,r.Z)({prop:"minHeight",transform:R}),z=((0,r.Z)({prop:"size",cssProperty:"width",transform:R}),(0,r.Z)({prop:"size",cssProperty:"height",transform:R}),o(A,N,I,O,D,M,(0,r.Z)({prop:"boxSizing"}))),L=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),j=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),B=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),W=(0,r.Z)({prop:"letterSpacing"}),U=(0,r.Z)({prop:"textTransform"}),H=(0,r.Z)({prop:"lineHeight"}),V=(0,r.Z)({prop:"textAlign"}),J=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),L,Z,j,B,W,H,V,U),$={borders:_.filterProps,display:w.filterProps,flexbox:k.filterProps,grid:x.filterProps,positions:F.filterProps,palette:P.filterProps,shadows:E.filterProps,sizing:z.filterProps,spacing:i.ZP.filterProps,typography:J.filterProps},G={borders:_,display:w,flexbox:k,grid:x,positions:F,palette:P,shadows:E,sizing:z,spacing:i.ZP,typography:J},q=Object.keys($).reduce((function(e,t){return $[t].forEach((function(n){e[n]=G[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return k},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},c={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},u=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!c[e])return[e];e=c[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],u=l[o]||"";return Array.isArray(u)?u.map((function(e){return i+e})):[i+u]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],f=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],p=[].concat(d,f);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function b(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(u(n),r),i=e[n];return(0,a.k9)(e,i,o)}function y(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return b(e,t,r,n)})).reduce(i.Z,{})}function g(e){return y(e,d)}function _(e){return y(e,f)}function w(e){return y(e,p)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=f,w.propTypes={},w.filterProps=p;var k=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,c=e.themeKey,u=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,c)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,u,e);return e===n&&"string"===typeof e&&(n=s(d,u,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function c(e){var o=e||{},u=o.sx,d=o.theme,f=void 0===d?{}:d;if(!u)return null;function p(e){var o=e;if("function"===typeof e)o=e(f);else if("object"!==typeof e)return e;if(!o)return null;var u=(0,i.W8)(f.breakpoints),d=Object.keys(u),p=u;return Object.keys(o).forEach((function(e){var u=l(o[e],f);if(null!==u&&void 0!==u)if("object"===typeof u)if(t[e])p=(0,a.Z)(p,n(e,u,f));else{var d=(0,i.k9)({theme:f},u,(function(t){return(0,r.Z)({},e,t)}));s(d,u)?p[e]=c({sx:u,theme:f}):p=(0,a.Z)(p,d)}else p=(0,a.Z)(p,n(e,u,f))})),(0,i.L7)(d,p)}return Array.isArray(u)?u.map(p):p(u)}return c}();c.filterProps=["sx"],t.Z=c},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return u}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},c=(0,r.Z)();var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:c;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var c=t[o];if(c.removed){if(c.value=e.join(r.slice(l,l+c.count)),l+=c.count,o&&t[o-1].added){var u=t[o-1];t[o-1]=t[o],t[o]=u}}else{if(!c.added&&a){var d=n.slice(s,s+c.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),c.value=e.join(d)}else c.value=e.join(n.slice(s,s+c.count));s+=c.count,c.added||(l+=c.count)}}var f=t[i-1];return i>1&&"string"===typeof f.value&&(f.added||f.removed)&&e.equals("",f.value)&&(t[i-2].value+=f.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,c=e.length,u=1,d=l+c,f=[{newPos:-1,components:[]}],p=this.extractCommon(f[0],t,e,0);if(f[0].newPos+1>=l&&p+1>=c)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*u;a<=u;a+=2){var o=void 0,d=f[a-1],p=f[a+1],m=(p?p.newPos:0)-a;d&&(f[a-1]=void 0);var h=d&&d.newPos+1<l,v=p&&0<=m&&m<c;if(h||v){if(!h||v&&d.newPos<p.newPos?(o=r(p),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=c)return s(n(i,o.components,t,e,i.useLongestToken));f[a]=o}else f[a]=void 0}u++}if(o)!function e(){setTimeout((function(){if(u>d)return o();m()||e()}),0)}();else for(;u<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,c=new t;function u(e,t,n){return n=i(n,{ignoreWhitespace:!0}),c.diff(e,t,n)}function d(e,t,n){return c.diff(e,t,n)}c.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},c.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var f=new t;function p(e,t,n){return f.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return f.diff(e,t,r)}f.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var b=new t;function y(e,t,n){return b.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||k(e)||S()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function k(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function S(){throw new TypeError("Invalid attempt to spread non-iterable instance")}b.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var C=Object.prototype.toString,T=new t;function x(e,t,n){return T.diff(e,t,n)}function F(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===C.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=F(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=F(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}T.useLongestToken=!0,T.tokenize=f.tokenize,T.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(F(e,null,null,a),a,"  ")},T.equals=function(e,n){return t.prototype.equals.call(T,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var P=new t;function E(e,t,n){return P.diff(e,t,n)}function R(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var c=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(c))break;if(/^@@/.test(c))e.hunks.push(l());else{if(c&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(c));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var c=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==c&&"-"!==c&&" "!==c&&"\\"!==c)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===c?s++:"-"===c?l++:" "===c&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function A(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function N(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=R(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},c=0,u=n.fuzzFactor||0,d=0,f=0;function p(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++c>u)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,b=0,y=f+h.oldStart-1,g=A(y,d,v);void 0!==b;b=g())if(p(h,y+b)){h.offset=f+=b;break}if(void 0===b)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var k=s[w],S=k.oldStart+k.offset+_-1;_+=k.newLines-k.oldLines,S<0&&(S=0);for(var C=0;C<k.lines.length;C++){var T=k.lines[C],x=T.length>0?T[0]:" ",F=T.length>0?T.substr(1):T,P=k.linedelimiters[C];if(" "===x)S++;else if("-"===x)o.splice(S,1),i.splice(S,1);else if("+"===x)o.splice(S,0,F),i.splice(S,0,P),S++;else if("\\"===x){var E=k.lines[C-1]?k.lines[C-1][0]:null;"+"===E?r=!0:"-"===E&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var N=0;N<o.length-1;N++)o[N]=o[N]+i[N];return o.join("")}function I(e,t){"string"===typeof e&&(e=R(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=N(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function O(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=p(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var c=[],u=0,d=0,f=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!u){var p=s[e-1];u=m,d=h,p&&(f=i.context>0?l(p.lines.slice(-i.context)):[],u-=f.length,d-=f.length)}(o=f).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(u)if(a.length<=2*i.context&&e<s.length-2){var v;(v=f).push.apply(v,_(l(a)))}else{var b,y=Math.min(a.length,i.context);(b=f).push.apply(b,_(l(a.slice(0,y))));var g={oldStart:u,oldLines:m-u+y,newStart:d,newLines:h-d+y,lines:f};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),k=/\n$/.test(r),S=0==a.length&&f.length>g.oldLines;!w&&S&&f.splice(g.oldLines,0,"\\ No newline at end of file"),(w||S)&&k||f.push("\\ No newline at end of file")}c.push(g),u=0,d=0,f=[]}m+=a.length,h+=a.length}},b=0;b<s.length;b++)v(b);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:c}}function D(e,t,n,r,a,o,i){var s=O(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var c=0;c<s.hunks.length;c++){var u=s.hunks[c];l.push("@@ -"+u.oldStart+","+u.oldLines+" +"+u.newStart+","+u.newLines+" @@"),l.push.apply(l,u.lines)}return l.join("\n")+"\n"}function M(e,t,n,r,a,o){return D(e,e,t,n,r,a,o)}function z(e,t){return e.length===t.length&&L(e,t)}function L(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function Z(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function j(e,t,n){e=B(e,n),t=B(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(W(e)?W(t)?(r.oldFileName=U(r,e.oldFileName,t.oldFileName),r.newFileName=U(r,e.newFileName,t.newFileName),r.oldHeader=U(r,e.oldHeader,t.oldHeader),r.newHeader=U(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},c=t.hunks[o]||{oldStart:1/0};if(H(l,c))r.hunks.push(V(l,i)),a++,s+=l.newLines-l.oldLines;else if(H(c,l))r.hunks.push(V(c,s)),o++,i+=c.newLines-c.oldLines;else{var u={oldStart:Math.min(l.oldStart,c.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,c.oldStart+s),newLines:0,lines:[]};J(u,l.oldStart,l.lines,c.oldStart,c.lines),o++,a++,r.hunks.push(u)}}return r}function B(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return R(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return O(void 0,void 0,t,e)}return e}function W(e){return e.newFileName&&e.newFileName!==e.oldFileName}function U(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function H(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function V(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function J(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var c;(c=e.lines).push.apply(c,_(Y(o)))}else if("+"===l[0]&&" "===s[0]){var u;(u=e.lines).push.apply(u,_(Y(i)))}else"-"===s[0]&&" "===l[0]?G(e,o,i):"-"===l[0]&&" "===s[0]?G(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Y(o),Y(i));else $(e,o,i)}Q(e,o),Q(e,i),Z(e)}function $(e,t,n){var r=Y(t),a=Y(n);if(ee(r)&&ee(a)){var o,i;if(L(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(L(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(z(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function G(e,t,n,r){var a,o=Y(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}P.tokenize=function(e){return e.slice()},P.join=P.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=u,e.diffWordsWithSpace=d,e.diffLines=p,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=y,e.diffJson=x,e.diffArrays=E,e.structuredPatch=O,e.createTwoFilesPatch=D,e.createPatch=M,e.applyPatch=N,e.applyPatches=I,e.parsePatch=R,e.merge=j,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=F,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return Z},css:function(){return z},cx:function(){return N},flush:function(){return R},getRegisteredStyles:function(){return O},hydrate:function(){return A},injectGlobal:function(){return D},keyframes:function(){return M},merge:function(){return I},sheet:function(){return L}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,c,f){for(var p,m,h,v,_,k=0,S=0,C=0,T=0,x=0,N=0,O=h=p=0,M=0,z=0,L=0,Z=0,j=l.length,B=j-1,W="",U="",H="",V="";M<j;){if(m=l.charCodeAt(M),M===B&&0!==S+T+C+k&&(0!==S&&(m=47===S?10:47),T=C=k=0,j++,B++),0===S+T+C+k){if(M===B&&(0<z&&(W=W.replace(d,"")),0<W.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:W+=l.charAt(M)}m=59}switch(m){case 123:for(p=(W=W.trim()).charCodeAt(0),h=1,Z=++M;M<j;){switch(m=l.charCodeAt(M)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(M+1)){case 42:case 47:e:{for(O=M+1;O<B;++O)switch(l.charCodeAt(O)){case 47:if(42===m&&42===l.charCodeAt(O-1)&&M+2!==O){M=O+1;break e}break;case 10:if(47===m){M=O+1;break e}}M=O}}break;case 91:m++;case 40:m++;case 34:case 39:for(;M++<B&&l.charCodeAt(M)!==m;);}if(0===h)break;M++}if(h=l.substring(Z,M),0===p&&(p=(W=W.replace(u,"").trim()).charCodeAt(0)),64===p){switch(0<z&&(W=W.replace(d,"")),m=W.charCodeAt(1)){case 100:case 109:case 115:case 45:z=r;break;default:z=A}if(Z=(h=t(r,z,h,m,f+1)).length,0<I&&(_=s(3,h,z=n(A,W,L),r,P,F,Z,m,f,c),W=z.join(""),void 0!==_&&0===(Z=(h=_.trim()).length)&&(m=0,h="")),0<Z)switch(m){case 115:W=W.replace(w,i);case 100:case 109:case 45:h=W+"{"+h+"}";break;case 107:h=(W=W.replace(b,"$1 $2"))+"{"+h+"}",h=1===R||2===R&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=W+h,112===c&&(U+=h,h="")}else h=""}else h=t(r,n(r,W,L),h,c,f+1);H+=h,h=L=z=O=p=0,W="",m=l.charCodeAt(++M);break;case 125:case 59:if(1<(Z=(W=(0<z?W.replace(d,""):W).trim()).length))switch(0===O&&(p=W.charCodeAt(0),45===p||96<p&&123>p)&&(Z=(W=W.replace(" ",":")).length),0<I&&void 0!==(_=s(1,W,r,e,P,F,U.length,c,f,c))&&0===(Z=(W=_.trim()).length)&&(W="\0\0"),p=W.charCodeAt(0),m=W.charCodeAt(1),p){case 0:break;case 64:if(105===m||99===m){V+=W+l.charAt(M);break}default:58!==W.charCodeAt(Z-1)&&(U+=a(W,p,m,W.charCodeAt(2)))}L=z=O=p=0,W="",m=l.charCodeAt(++M)}}switch(m){case 13:case 10:47===S?S=0:0===1+p&&107!==c&&0<W.length&&(z=1,W+="\0"),0<I*D&&s(0,W,r,e,P,F,U.length,c,f,c),F=1,P++;break;case 59:case 125:if(0===S+T+C+k){F++;break}default:switch(F++,v=l.charAt(M),m){case 9:case 32:if(0===T+k+S)switch(x){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===T+S+k&&(z=L=1,v="\f"+v);break;case 108:if(0===T+S+k+E&&0<O)switch(M-O){case 2:112===x&&58===l.charCodeAt(M-3)&&(E=x);case 8:111===N&&(E=N)}break;case 58:0===T+S+k&&(O=M);break;case 44:0===S+C+T+k&&(z=1,v+="\r");break;case 34:case 39:0===S&&(T=T===m?0:0===T?m:T);break;case 91:0===T+S+C&&k++;break;case 93:0===T+S+C&&k--;break;case 41:0===T+S+k&&C--;break;case 40:if(0===T+S+k){if(0===p)if(2*x+3*N===533);else p=1;C++}break;case 64:0===S+C+T+k+O+h&&(h=1);break;case 42:case 47:if(!(0<T+k+C))switch(S){case 0:switch(2*m+3*l.charCodeAt(M+1)){case 235:S=47;break;case 220:Z=M,S=42}break;case 42:47===m&&42===x&&Z+2!==M&&(33===l.charCodeAt(Z+2)&&(U+=l.substring(Z,M+1)),v="",S=0)}}0===S&&(W+=v)}N=x,x=m,M++}if(0<(Z=U.length)){if(z=r,0<I&&(void 0!==(_=s(2,U,z,e,P,F,Z,c,f,c))&&0===(U=_).length))return V+U+H;if(U=z.join(",")+"{"+U+"}",0!==R*E){switch(2!==R||o(U,2)||(E=0),E){case 111:U=U.replace(g,":-moz-$1")+U;break;case 112:U=U.replace(y,"::-webkit-input-$1")+U.replace(y,"::-moz-$1")+U.replace(y,":-ms-input-$1")+U}E=0}}return V+U+H}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var c=0;c<i;++c)t[l++]=r(e[c]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===R||2===R&&o(l,1)?"-webkit-"+l+l:l}if(0===R||2===R&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(x,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return p.test(i)?i.replace(f,":-webkit-")+i.replace(f,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(S,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(S,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===T.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),O(2!==t?r:r.replace(C,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(k," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,u){for(var d,f=0,p=t;f<I;++f)switch(d=N[f].call(c,e,p,n,r,a,o,i,s,l,u)){case void 0:case!1:case!0:case null:break;default:p=d}if(p!==t)return p}function l(e){return void 0!==(e=e.prefix)&&(O=null,e?"function"!==typeof e?R=1:(R=2,O=e):R=0),l}function c(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<I){var a=s(-1,n,r,r,P,F,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(A,r,n,0,0);return 0<I&&(void 0!==(a=s(-2,o,r,r,P,F,o.length,0,0,0))&&(o=a)),"",E=0,F=P=1,o}var u=/^\0+/g,d=/[\0\r\f]/g,f=/: */g,p=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,b=/@(k\w+)\s*(\S*)\s*/,y=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,k=/([\s\S]*?);/g,S=/-self|flex-/g,C=/[^]*?(:[rp][el]a[\w-]+)[^]*/,T=/stretch|:\s*\w+\-(?:conte|avail)/,x=/([^-])(image-set\()/,F=1,P=1,E=0,R=1,A=[],N=[],I=0,O=null,D=0;return c.use=function e(t){switch(t){case void 0:case null:I=N.length=0;break;default:if("function"===typeof t)N[I++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else D=0|!!t}return e},c.set=l,void 0!==e&&l(e),c},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,c,u,d,f){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===u)return t+o;break;case 3:switch(u){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===f?o:"")}case-2:t.split("/*|*/}").forEach(i)}},c=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,c={};i=e.container||document.head;var u,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){c[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),u=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(f.inserted[a]=!0)};var f={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:c,registered:{},insert:u};return f};var u=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var f=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},p=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},b=f((function(e){return h(e)?e:e.replace(p,"-$&").toLowerCase()})),y=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=b(o)+":"+y(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=b(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=b(o)+":"+y(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var k=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:u(a)+l,styles:a,next:_}};function S(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var C=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function T(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function x(e,t,n){var r=[],a=S(e,r,n);return r.length<2?n:a+t(r)}var F=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},P=function(e){var t=c(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=k(n,t.registered,void 0);return C(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return x(t.registered,n,F(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=k(n,t.registered);T(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=k(n,t.registered),o="animation-"+a.name;return T(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:S.bind(null,t.registered),merge:x.bind(null,t.registered,n)}},E=P(),R=E.flush,A=E.hydrate,N=E.cx,I=E.merge,O=E.getRegisteredStyles,D=E.injectGlobal,M=E.keyframes,z=E.css,L=E.sheet,Z=E.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var c=Object.defineProperty,u=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,f=Object.getOwnPropertyDescriptor,p=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=p(n);a&&a!==m&&e(t,a,r)}var i=u(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var b=i[v];if(!o[b]&&(!r||!r[b])&&(!h||!h[b])&&(!s||!s[b])){var y=f(n,b);try{c(t,b,y)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,c=n?Symbol.for("react.context"):60110,u=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,f=n?Symbol.for("react.forward_ref"):60112,p=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,b=n?Symbol.for("react.block"):60121,y=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case u:case d:case o:case s:case i:case p:return e;default:switch(e=e&&e.$$typeof){case c:case f:case v:case h:case l:return e;default:return t}}case a:return t}}}function k(e){return w(e)===d}t.AsyncMode=u,t.ConcurrentMode=d,t.ContextConsumer=c,t.ContextProvider=l,t.Element=r,t.ForwardRef=f,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=p,t.isAsyncMode=function(e){return k(e)||w(e)===u},t.isConcurrentMode=k,t.isContextConsumer=function(e){return w(e)===c},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===f},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===p},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===p||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===c||e.$$typeof===f||e.$$typeof===y||e.$$typeof===g||e.$$typeof===_||e.$$typeof===b)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);c.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),c.propTypes=l.propTypes,t.default=c},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),c=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,c=n.uFEFF,u=t&&"function"===typeof r?r():r,d=new Blob([c?"\ufeff":"",(0,l.toCSV)(u,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,c=t.children,u=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),f="undefined"===typeof window?"":this.buildURI(n,l,r,o,u);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:f,onClick:this.handleClick()}),c)}}]),t}(s.default.Component);u.defaultProps=c.defaultProps,u.propTypes=c.propTypes,t.default=u},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return c(t,e)}))}));return[n].concat(r(i))},c=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},u=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return u(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},f=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},p=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return p(e,t,n,r);if(i(e))return f(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),c="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,u=window.URL||window.webkitURL;return"undefined"===typeof u.createObjectURL?c:u.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var c=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,u){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===u&&(u=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),f=u,p=u,m=[],h=0,v=[],b=[],y=function e(t,a,s,u,m){return c(t).map((function(t,y){var g={},_={};if(!(b.includes(a+"-"+y)||m&&0!==y)){if(s||u)if(v.includes(h)||v.push(h),u){p+=1,g.lineNumber=p,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(c(w.value)[y]){var k=e(w.value,a,!0,!1,!0)[0].right,S=k.value,C=k.lineNumber,T=k.type;if(b.push(a+1+"-"+y),_.lineNumber=C,_.type=T,n)_.value=S;else{var x=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,S,r);_.value=x.right,g.value=x.left}}}else f+=1,_.lineNumber=f,_.type=o.ADDED,_.value=t;else p+=1,f+=1,g.lineNumber=p,g.type=o.DEFAULT,g.value=t,_.lineNumber=f,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,y(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,c=n(2813),u=n(5781),d=u.default||u;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var f=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(c.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,c){var u,d,f,p,m,h=r+"-"+e,v=c+"-"+l,b=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),y=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(u={},u[n.styles.emptyGutter]=!e,u[n.styles.diffAdded]=y,u[n.styles.diffRemoved]=g,u[n.styles.highlightedGutter]=b,u))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=y,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=b,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=y,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=b,f))},a.createElement("pre",null,y&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=y,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=b,p))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,c=l.hideLineNumbers,u=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),f=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),p=!u&&!c;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!c&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=p,s))}),p?a.createElement(a.Fragment,null,a.createElement("td",null),f):a.createElement(a.Fragment,null,f,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,c=e.linesOffset,u=s.computeLineInformation(t,r,i,l,c),d=u.lineInformation,f=u.diffLines,p=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=f[0],i=r-t;if(n.props.showDiffOnly&&(i===-p&&(m=[],f.shift()),e.left.type===s.DiffType.DEFAULT&&(i>p||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===p&&m.length>0){var c=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(c,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,c=t.rightTitle,u=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var f=n.renderDiff(),p=d?2:3,m=d?2:4,h=(l||c)&&a.createElement("tr",null,a.createElement("td",{colSpan:u?p:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),u&&a.createElement("td",{colSpan:p,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},c)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=u,e))},a.createElement("tbody",null,h,f))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=f},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,c,u,d;void 0===t&&(t=!1);var f=e.variables,p=void 0===f?{}:f,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},p.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},p.dark||{})},v=t?h.dark:h.light,b=o.css({width:"100%",label:"content"}),y=o.css(((n={})["."+b]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),k=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),S=o.css({color:v.gutterColor,label:"line-number"}),C=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+S]={color:v.removedGutterColor},s.label="diff-removed",s)),T=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+S]={color:v.addedGutterColor},l.label="diff-added",l)),x=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),F=o.css({background:v.wordAddedBackground,label:"word-added"}),P=o.css({background:v.wordRemovedBackground,label:"word-removed"}),E=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),R=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),A=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),N=o.css(((c={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+T]={pre:{color:v.addedColor}},c["&."+C]={pre:{color:v.removedColor}},c)),I=o.css(((u={background:v.highlightBackground,label:"highlighted-line"})["."+F+", ."+P]={backgroundColor:"initial"},u)),O=o.css({label:"highlighted-gutter"}),D=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+T]={background:v.addedGutterBackground},d["&."+C]={background:v.removedGutterBackground},d["&."+O]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),M=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),z={diffContainer:g,diffRemoved:C,diffAdded:T,splitView:y,marker:N,highlightedGutter:O,highlightedLine:I,gutter:D,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:x,wordAdded:F,wordRemoved:P,codeFoldGutter:E,codeFold:R,emptyGutter:M,emptyLine:A,lineNumber:S,contentText:w,content:b,codeFoldContent:_,titleBlock:k},L=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(z).reduce((function(e,t){var n;return r({},e,((n={})[t]=L[t]?o.cx(z[t],L[t]):z[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){c(e,t),c(e+"Capture",t)}function c(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var u=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,f=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,p={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var b=/[\-:]([a-z])/g;function y(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(p,e)&&(f.test(e)?m[e]=!0:(p[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),k=Symbol.for("react.portal"),S=Symbol.for("react.fragment"),C=Symbol.for("react.strict_mode"),T=Symbol.for("react.profiler"),x=Symbol.for("react.provider"),F=Symbol.for("react.context"),P=Symbol.for("react.forward_ref"),E=Symbol.for("react.suspense"),R=Symbol.for("react.suspense_list"),A=Symbol.for("react.memo"),N=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var I=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var O=Symbol.iterator;function D(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=O&&e[O]||e["@@iterator"])?e:null}var M,z=Object.assign;function L(e){if(void 0===M)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);M=t&&t[1]||""}return"\n"+M+e}var Z=!1;function j(e,t){if(!e||Z)return"";Z=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(c){var r=c}Reflect.construct(e,[],t)}else{try{t.call()}catch(c){r=c}e.call(t.prototype)}else{try{throw Error()}catch(c){r=c}e()}}catch(c){if(c&&r&&"string"===typeof c.stack){for(var a=c.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{Z=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?L(e):""}function B(e){switch(e.tag){case 5:return L(e.type);case 16:return L("Lazy");case 13:return L("Suspense");case 19:return L("SuspenseList");case 0:case 2:case 15:return e=j(e.type,!1);case 11:return e=j(e.type.render,!1);case 1:return e=j(e.type,!0);default:return""}}function W(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case S:return"Fragment";case k:return"Portal";case T:return"Profiler";case C:return"StrictMode";case E:return"Suspense";case R:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case F:return(e.displayName||"Context")+".Consumer";case x:return(e._context.displayName||"Context")+".Provider";case P:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case A:return null!==(t=e.displayName||null)?t:W(e.type)||"Memo";case N:t=e._payload,e=e._init;try{return W(e(t))}catch(n){}}return null}function U(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return W(t);case 8:return t===C?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function H(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function V(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function J(e){e._valueTracker||(e._valueTracker=function(e){var t=V(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function $(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=V(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function G(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return z({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=H(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=H(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,H(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&G(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+H(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return z({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:H(n)}}function oe(e,t){var n=H(t.value),r=H(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ce,ue,de=(ue=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ce=ce||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ce.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ue(e,t)}))}:ue);function fe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var pe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||pe.hasOwnProperty(e)&&pe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(pe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),pe[t]=pe[e]}))}));var be=z({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function ye(e,t){if(t){if(be[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var ke=null,Se=null,Ce=null;function Te(e){if(e=ga(e)){if("function"!==typeof ke)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),ke(e.stateNode,e.type,t))}}function xe(e){Se?Ce?Ce.push(e):Ce=[e]:Se=e}function Fe(){if(Se){var e=Se,t=Ce;if(Ce=Se=null,Te(e),t)for(e=0;e<t.length;e++)Te(t[e])}}function Pe(e,t){return e(t)}function Ee(){}var Re=!1;function Ae(e,t,n){if(Re)return e(t,n);Re=!0;try{return Pe(e,t,n)}finally{Re=!1,(null!==Se||null!==Ce)&&(Ee(),Fe())}}function Ne(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Ie=!1;if(u)try{var Oe={};Object.defineProperty(Oe,"passive",{get:function(){Ie=!0}}),window.addEventListener("test",Oe,Oe),window.removeEventListener("test",Oe,Oe)}catch(ue){Ie=!1}function De(e,t,n,r,a,o,i,s,l){var c=Array.prototype.slice.call(arguments,3);try{t.apply(n,c)}catch(u){this.onError(u)}}var Me=!1,ze=null,Le=!1,Ze=null,je={onError:function(e){Me=!0,ze=e}};function Be(e,t,n,r,a,o,i,s,l){Me=!1,ze=null,De.apply(je,arguments)}function We(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Ue(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function He(e){if(We(e)!==e)throw Error(o(188))}function Ve(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=We(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return He(a),e;if(i===r)return He(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?Je(e):null}function Je(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=Je(e);if(null!==t)return t;e=e.sibling}return null}var $e=a.unstable_scheduleCallback,Ge=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Ye=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ct=64,ut=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function ft(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function pt(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ct;return 0===(4194240&(ct<<=1))&&(ct=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function bt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function yt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,kt,St,Ct,Tt,xt=!1,Ft=[],Pt=null,Et=null,Rt=null,At=new Map,Nt=new Map,It=[],Ot="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Dt(e,t){switch(e){case"focusin":case"focusout":Pt=null;break;case"dragenter":case"dragleave":Et=null;break;case"mouseover":case"mouseout":Rt=null;break;case"pointerover":case"pointerout":At.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Nt.delete(t.pointerId)}}function Mt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&kt(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function zt(e){var t=ya(e.target);if(null!==t){var n=We(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Ue(n)))return e.blockedOn=t,void Tt(e.priority,(function(){St(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Lt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&kt(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function Zt(e,t,n){Lt(e)&&n.delete(t)}function jt(){xt=!1,null!==Pt&&Lt(Pt)&&(Pt=null),null!==Et&&Lt(Et)&&(Et=null),null!==Rt&&Lt(Rt)&&(Rt=null),At.forEach(Zt),Nt.forEach(Zt)}function Bt(e,t){e.blockedOn===t&&(e.blockedOn=null,xt||(xt=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,jt)))}function Wt(e){function t(t){return Bt(t,e)}if(0<Ft.length){Bt(Ft[0],e);for(var n=1;n<Ft.length;n++){var r=Ft[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Pt&&Bt(Pt,e),null!==Et&&Bt(Et,e),null!==Rt&&Bt(Rt,e),At.forEach(t),Nt.forEach(t),n=0;n<It.length;n++)(r=It[n]).blockedOn===e&&(r.blockedOn=null);for(;0<It.length&&null===(n=It[0]).blockedOn;)zt(n),null===n.blockedOn&&It.shift()}var Ut=_.ReactCurrentBatchConfig,Ht=!0;function Vt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=1,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function Jt(e,t,n,r){var a=gt,o=Ut.transition;Ut.transition=null;try{gt=4,$t(e,t,n,r)}finally{gt=a,Ut.transition=o}}function $t(e,t,n,r){if(Ht){var a=qt(e,t,n,r);if(null===a)Hr(e,t,r,Gt,n),Dt(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Pt=Mt(Pt,e,t,n,r,a),!0;case"dragenter":return Et=Mt(Et,e,t,n,r,a),!0;case"mouseover":return Rt=Mt(Rt,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return At.set(o,Mt(At.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Nt.set(o,Mt(Nt.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(Dt(e,r),4&t&&-1<Ot.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Hr(e,t,r,Gt,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Hr(e,t,r,null,n)}}var Gt=null;function qt(e,t,n,r){if(Gt=null,null!==(e=ya(e=we(r))))if(null===(t=We(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Ue(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Gt=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return z(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,cn={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},un=an(cn),dn=z({},cn,{view:0,detail:0}),fn=an(dn),pn=z({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Tn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(pn),hn=an(z({},pn,{dataTransfer:0})),vn=an(z({},dn,{relatedTarget:0})),bn=an(z({},cn,{animationName:0,elapsedTime:0,pseudoElement:0})),yn=z({},cn,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(yn),_n=an(z({},cn,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},kn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},Sn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Cn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=Sn[e])&&!!t[e]}function Tn(){return Cn}var xn=z({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?kn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Tn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),Fn=an(xn),Pn=an(z({},pn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),En=an(z({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Tn})),Rn=an(z({},cn,{propertyName:0,elapsedTime:0,pseudoElement:0})),An=z({},pn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Nn=an(An),In=[9,13,27,32],On=u&&"CompositionEvent"in window,Dn=null;u&&"documentMode"in document&&(Dn=document.documentMode);var Mn=u&&"TextEvent"in window&&!Dn,zn=u&&(!On||Dn&&8<Dn&&11>=Dn),Ln=String.fromCharCode(32),Zn=!1;function jn(e,t){switch(e){case"keyup":return-1!==In.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Bn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Wn=!1;var Un={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Hn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Un[e.type]:"textarea"===t}function Vn(e,t,n,r){xe(r),0<(t=Jr(t,"onChange")).length&&(n=new un("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Jn=null,$n=null;function Gn(e){Lr(e,0)}function qn(e){if($(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(u){var Yn;if(u){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){Jn&&(Jn.detachEvent("onpropertychange",nr),$n=Jn=null)}function nr(e){if("value"===e.propertyName&&qn($n)){var t=[];Vn(t,$n,e,we(e)),Ae(Gn,t)}}function rr(e,t,n){"focusin"===e?(tr(),$n=n,(Jn=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn($n)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function cr(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function ur(e,t){var n,r=cr(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=cr(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function fr(){for(var e=window,t=G();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=G((e=t.contentWindow).document)}return t}function pr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=fr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&pr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=ur(n,o);var i=ur(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=u&&"documentMode"in document&&11>=document.documentMode,vr=null,br=null,yr=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==G(r)||("selectionStart"in(r=vr)&&pr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},yr&&lr(yr,r)||(yr=r,0<(r=Jr(br,"onSelect")).length&&(t=new un("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var kr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},Sr={},Cr={};function Tr(e){if(Sr[e])return Sr[e];if(!kr[e])return e;var t,n=kr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Cr)return Sr[e]=n[t];return e}u&&(Cr=document.createElement("div").style,"AnimationEvent"in window||(delete kr.animationend.animation,delete kr.animationiteration.animation,delete kr.animationstart.animation),"TransitionEvent"in window||delete kr.transitionend.transition);var xr=Tr("animationend"),Fr=Tr("animationiteration"),Pr=Tr("animationstart"),Er=Tr("transitionend"),Rr=new Map,Ar="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Nr(e,t){Rr.set(e,t),l(t,[e])}for(var Ir=0;Ir<Ar.length;Ir++){var Or=Ar[Ir];Nr(Or.toLowerCase(),"on"+(Or[0].toUpperCase()+Or.slice(1)))}Nr(xr,"onAnimationEnd"),Nr(Fr,"onAnimationIteration"),Nr(Pr,"onAnimationStart"),Nr("dblclick","onDoubleClick"),Nr("focusin","onFocus"),Nr("focusout","onBlur"),Nr(Er,"onTransitionEnd"),c("onMouseEnter",["mouseout","mouseover"]),c("onMouseLeave",["mouseout","mouseover"]),c("onPointerEnter",["pointerout","pointerover"]),c("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Dr="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Mr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Dr));function zr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,c){if(Be.apply(this,arguments),Me){if(!Me)throw Error(o(198));var u=ze;Me=!1,ze=null,Le||(Le=!0,Ze=u)}}(r,t,void 0,e),e.currentTarget=null}function Lr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,c=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;zr(a,s,c),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,c=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;zr(a,s,c),o=l}}}if(Le)throw e=Ze,Le=!1,Ze=null,e}function Zr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Ur(t,e,2,!1),n.add(r))}function jr(e,t,n){var r=0;t&&(r|=4),Ur(n,e,r,t)}var Br="_reactListening"+Math.random().toString(36).slice(2);function Wr(e){if(!e[Br]){e[Br]=!0,i.forEach((function(t){"selectionchange"!==t&&(Mr.has(t)||jr(t,!1,e),jr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Br]||(t[Br]=!0,jr("selectionchange",!1,t))}}function Ur(e,t,n,r){switch(Kt(t)){case 1:var a=Vt;break;case 4:a=Jt;break;default:a=$t}n=a.bind(null,t,n,e),a=void 0,!Ie||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Hr(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ya(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Ae((function(){var r=o,a=we(n),i=[];e:{var s=Rr.get(e);if(void 0!==s){var l=un,c=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=Fn;break;case"focusin":c="focus",l=vn;break;case"focusout":c="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=En;break;case xr:case Fr:case Pr:l=bn;break;case Er:l=Rn;break;case"scroll":l=fn;break;case"wheel":l=Nn;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=Pn}var u=0!==(4&t),d=!u&&"scroll"===e,f=u?null!==s?s+"Capture":null:s;u=[];for(var p,m=r;null!==m;){var h=(p=m).stateNode;if(5===p.tag&&null!==h&&(p=h,null!==f&&(null!=(h=Ne(m,f))&&u.push(Vr(m,h,p)))),d)break;m=m.return}0<u.length&&(s=new l(s,c,null,n,a),i.push({event:s,listeners:u}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(c=n.relatedTarget||n.fromElement)||!ya(c)&&!c[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(c=(c=n.relatedTarget||n.toElement)?ya(c):null)&&(c!==(d=We(c))||5!==c.tag&&6!==c.tag)&&(c=null)):(l=null,c=r),l!==c)){if(u=mn,h="onMouseLeave",f="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(u=Pn,h="onPointerLeave",f="onPointerEnter",m="pointer"),d=null==l?s:_a(l),p=null==c?s:_a(c),(s=new u(h,m+"leave",l,n,a)).target=d,s.relatedTarget=p,h=null,ya(a)===r&&((u=new u(f,m+"enter",c,n,a)).target=p,u.relatedTarget=d,h=u),d=h,l&&c)e:{for(f=c,m=0,p=u=l;p;p=$r(p))m++;for(p=0,h=f;h;h=$r(h))p++;for(;0<m-p;)u=$r(u),m--;for(;0<p-m;)f=$r(f),p--;for(;m--;){if(u===f||null!==f&&u===f.alternate)break e;u=$r(u),f=$r(f)}u=null}else u=null;null!==l&&Gr(i,s,l,u,!1),null!==c&&null!==d&&Gr(i,d,c,u,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Hn(s))if(Qn)v=ir;else{v=ar;var b=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Vn(i,v,n,a):(b&&b(e,s,r),"focusout"===e&&(b=s._wrapperState)&&b.controlled&&"number"===s.type&&ee(s,"number",s.value)),b=r?_a(r):window,e){case"focusin":(Hn(b)||"true"===b.contentEditable)&&(vr=b,br=r,yr=null);break;case"focusout":yr=br=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var y;if(On)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Wn?jn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(zn&&"ko"!==n.locale&&(Wn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Wn&&(y=en()):(Yt="value"in(Qt=a)?Qt.value:Qt.textContent,Wn=!0)),0<(b=Jr(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:b}),y?g.data=y:null!==(y=Bn(n))&&(g.data=y))),(y=Mn?function(e,t){switch(e){case"compositionend":return Bn(t);case"keypress":return 32!==t.which?null:(Zn=!0,Ln);case"textInput":return(e=t.data)===Ln&&Zn?null:e;default:return null}}(e,n):function(e,t){if(Wn)return"compositionend"===e||!On&&jn(e,t)?(e=en(),Xt=Yt=Qt=null,Wn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return zn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Jr(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=y))}Lr(i,t)}))}function Vr(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Jr(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Ne(e,n))&&r.unshift(Vr(e,o,a)),null!=(o=Ne(e,t))&&r.push(Vr(e,o,a))),e=e.return}return r}function $r(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Gr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,c=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==c&&(s=c,a?null!=(l=Ne(n,o))&&i.unshift(Vr(n,l,s)):a||null!=(l=Ne(n,o))&&i.push(Vr(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Wt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Wt(t)}function ca(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ua(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),fa="__reactFiber$"+da,pa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ba="__reactHandles$"+da;function ya(e){var t=e[fa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[fa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ua(e);null!==e;){if(n=e[fa])return n;e=ua(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[fa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[pa]||null}var ka=[],Sa=-1;function Ca(e){return{current:e}}function Ta(e){0>Sa||(e.current=ka[Sa],ka[Sa]=null,Sa--)}function xa(e,t){Sa++,ka[Sa]=e.current,e.current=t}var Fa={},Pa=Ca(Fa),Ea=Ca(!1),Ra=Fa;function Aa(e,t){var n=e.type.contextTypes;if(!n)return Fa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Na(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Ia(){Ta(Ea),Ta(Pa)}function Oa(e,t,n){if(Pa.current!==Fa)throw Error(o(168));xa(Pa,t),xa(Ea,n)}function Da(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,U(e)||"Unknown",a));return z({},n,r)}function Ma(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||Fa,Ra=Pa.current,xa(Pa,e),xa(Ea,Ea.current),!0}function za(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Da(e,t,Ra),r.__reactInternalMemoizedMergedChildContext=e,Ta(Ea),Ta(Pa),xa(Pa,e)):Ta(Ea),xa(Ea,n)}var La=null,Za=!1,ja=!1;function Ba(e){null===La?La=[e]:La.push(e)}function Wa(){if(!ja&&null!==La){ja=!0;var e=0,t=gt;try{var n=La;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}La=null,Za=!1}catch(a){throw null!==La&&(La=La.slice(e+1)),$e(Xe,Wa),a}finally{gt=t,ja=!1}}return null}var Ua=[],Ha=0,Va=null,Ja=0,$a=[],Ga=0,qa=null,Ka=1,Qa="";function Ya(e,t){Ua[Ha++]=Ja,Ua[Ha++]=Va,Va=e,Ja=t}function Xa(e,t,n){$a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Ya(e,1),Xa(e,1,0))}function to(e){for(;e===Va;)Va=Ua[--Ha],Ua[Ha]=null,Ja=Ua[--Ha],Ua[Ha]=null;for(;e===qa;)qa=$a[--Ga],$a[Ga]=null,Qa=$a[--Ga],$a[Ga]=null,Ka=$a[--Ga],$a[Ga]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Ac(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ca(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Ac(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function co(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ca(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function uo(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function fo(e){if(e!==no)return!1;if(!ao)return uo(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw po(),Error(o(418));for(;t;)io(e,t),t=ca(t.nextSibling)}if(uo(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ca(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ca(e.stateNode.nextSibling):null;return!0}function po(){for(var e=ro;e;)e=ca(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function bo(e,t){if(e&&e.defaultProps){for(var n in t=z({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var yo=Ca(null),go=null,_o=null,wo=null;function ko(){wo=_o=go=null}function So(e){var t=yo.current;Ta(yo),e._currentValue=t}function Co(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function To(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function xo(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var Fo=null;function Po(e){null===Fo?Fo=[e]:Fo.push(e)}function Eo(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Po(t)):(n.next=a.next,a.next=n),t.interleaved=n,Ro(e,r)}function Ro(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Ao=!1;function No(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Io(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Oo(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Do(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&Pl)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,Ro(e,n)}return null===(a=r.interleaved)?(t.next=t,Po(r)):(t.next=a.next,a.next=t),r.interleaved=t,Ro(e,n)}function Mo(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}function zo(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Lo(e,t,n,r){var a=e.updateQueue;Ao=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,c=l.next;l.next=null,null===i?o=c:i.next=c,i=l;var u=e.alternate;null!==u&&((s=(u=u.updateQueue).lastBaseUpdate)!==i&&(null===s?u.firstBaseUpdate=c:s.next=c,u.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,u=c=l=null,s=o;;){var f=s.lane,p=s.eventTime;if((r&f)===f){null!==u&&(u=u.next={eventTime:p,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(f=t,p=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(p,d,f);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(f="function"===typeof(m=h.payload)?m.call(p,d,f):m)||void 0===f)break e;d=z({},d,f);break e;case 2:Ao=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(f=a.effects)?a.effects=[s]:f.push(s))}else p={eventTime:p,lane:f,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===u?(c=u=p,l=d):u=u.next=p,i|=f;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(f=s).next,f.next=null,a.lastBaseUpdate=f,a.shared.pending=null}}if(null===u&&(l=d),a.baseState=l,a.firstBaseUpdate=c,a.lastBaseUpdate=u,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);Ml|=i,e.lanes=i,e.memoizedState=d}}function Zo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var jo=(new r.Component).refs;function Bo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:z({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Wo={isMounted:function(e){return!!(e=e._reactInternals)&&We(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=ec(),a=tc(e),o=Oo(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Do(e,o,a))&&(nc(t,e,a,r),Mo(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=ec(),a=tc(e),o=Oo(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Do(e,o,a))&&(nc(t,e,a,r),Mo(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=ec(),r=tc(e),a=Oo(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Do(e,a,r))&&(nc(t,e,r,n),Mo(t,e,r))}};function Uo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Ho(e,t,n){var r=!1,a=Fa,o=t.contextType;return"object"===typeof o&&null!==o?o=xo(o):(a=Na(t)?Ra:Pa.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Aa(e,a):Fa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Wo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Vo(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Wo.enqueueReplaceState(t,t.state,null)}function Jo(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=jo,No(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=xo(o):(o=Na(t)?Ra:Pa.current,a.context=Aa(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Bo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Wo.enqueueReplaceState(a,a.state,null),Lo(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function $o(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===jo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Go(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Ic(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=zc(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function c(e,t,n,r){var o=n.type;return o===S?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===N&&qo(o)===t.type)?((r=a(t,n.props)).ref=$o(e,t,n),r.return=e,r):((r=Oc(n.type,n.key,n.props,null,e.mode,r)).ref=$o(e,t,n),r.return=e,r)}function u(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Lc(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Dc(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function f(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=zc(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Oc(t.type,t.key,t.props,null,e.mode,n)).ref=$o(e,null,t),n.return=e,n;case k:return(t=Lc(t,e.mode,n)).return=e,t;case N:return f(e,(0,t._init)(t._payload),n)}if(te(t)||D(t))return(t=Dc(t,e.mode,n,null)).return=e,t;Go(e,t)}return null}function p(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?c(e,t,n,r):null;case k:return n.key===a?u(e,t,n,r):null;case N:return p(e,t,(a=n._init)(n._payload),r)}if(te(n)||D(n))return null!==a?null:d(e,t,n,r,null);Go(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case k:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case N:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||D(r))return d(t,e=e.get(n)||null,r,a,null);Go(t,r)}return null}function h(a,o,s,l){for(var c=null,u=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var b=p(a,d,s[h],l);if(null===b){null===d&&(d=v);break}e&&d&&null===b.alternate&&t(a,d),o=i(b,o,h),null===u?c=b:u.sibling=b,u=b,d=v}if(h===s.length)return n(a,d),ao&&Ya(a,h),c;if(null===d){for(;h<s.length;h++)null!==(d=f(a,s[h],l))&&(o=i(d,o,h),null===u?c=d:u.sibling=d,u=d);return ao&&Ya(a,h),c}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===u?c=v:u.sibling=v,u=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Ya(a,h),c}function v(a,s,l,c){var u=D(l);if("function"!==typeof u)throw Error(o(150));if(null==(l=u.call(l)))throw Error(o(151));for(var d=u=null,h=s,v=s=0,b=null,y=l.next();null!==h&&!y.done;v++,y=l.next()){h.index>v?(b=h,h=null):b=h.sibling;var g=p(a,h,y.value,c);if(null===g){null===h&&(h=b);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?u=g:d.sibling=g,d=g,h=b}if(y.done)return n(a,h),ao&&Ya(a,v),u;if(null===h){for(;!y.done;v++,y=l.next())null!==(y=f(a,y.value,c))&&(s=i(y,s,v),null===d?u=y:d.sibling=y,d=y);return ao&&Ya(a,v),u}for(h=r(a,h);!y.done;v++,y=l.next())null!==(y=m(h,a,v,y.value,c))&&(e&&null!==y.alternate&&h.delete(null===y.key?v:y.key),s=i(y,s,v),null===d?u=y:d.sibling=y,d=y);return e&&h.forEach((function(e){return t(a,e)})),ao&&Ya(a,v),u}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===S&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var c=i.key,u=o;null!==u;){if(u.key===c){if((c=i.type)===S){if(7===u.tag){n(r,u.sibling),(o=a(u,i.props.children)).return=r,r=o;break e}}else if(u.elementType===c||"object"===typeof c&&null!==c&&c.$$typeof===N&&qo(c)===u.type){n(r,u.sibling),(o=a(u,i.props)).ref=$o(r,u,i),o.return=r,r=o;break e}n(r,u);break}t(r,u),u=u.sibling}i.type===S?((o=Dc(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Oc(i.type,i.key,i.props,null,r.mode,l)).ref=$o(r,o,i),l.return=r,r=l)}return s(r);case k:e:{for(u=i.key;null!==o;){if(o.key===u){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Lc(i,r.mode,l)).return=r,r=o}return s(r);case N:return e(r,o,(u=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(D(i))return v(r,o,i,l);Go(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=zc(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Yo=Ko(!1),Xo={},ei=Ca(Xo),ti=Ca(Xo),ni=Ca(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(xa(ni,t),xa(ti,e),xa(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}Ta(ei),xa(ei,t)}function oi(){Ta(ei),Ta(ti),Ta(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(xa(ti,e),xa(ei,n))}function si(e){ti.current===e&&(Ta(ei),Ta(ti))}var li=Ca(0);function ci(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ui=[];function di(){for(var e=0;e<ui.length;e++)ui[e]._workInProgressVersionPrimary=null;ui.length=0}var fi=_.ReactCurrentDispatcher,pi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,bi=null,yi=!1,gi=!1,_i=0,wi=0;function ki(){throw Error(o(321))}function Si(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ci(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,fi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,bi=vi=null,t.updateQueue=null,fi.current=cs,e=n(r,a)}while(gi)}if(fi.current=is,t=null!==vi&&null!==vi.next,mi=0,bi=vi=hi=null,yi=!1,t)throw Error(o(300));return e}function Ti(){var e=0!==_i;return _i=0,e}function xi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===bi?hi.memoizedState=bi=e:bi=bi.next=e,bi}function Fi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===bi?hi.memoizedState:bi.next;if(null!==t)bi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===bi?hi.memoizedState=bi=e:bi=bi.next=e}return bi}function Pi(e,t){return"function"===typeof t?t(e):t}function Ei(e){var t=Fi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,c=null,u=i;do{var d=u.lane;if((mi&d)===d)null!==c&&(c=c.next={lane:0,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null}),r=u.hasEagerState?u.eagerState:e(r,u.action);else{var f={lane:d,action:u.action,hasEagerState:u.hasEagerState,eagerState:u.eagerState,next:null};null===c?(l=c=f,s=r):c=c.next=f,hi.lanes|=d,Ml|=d}u=u.next}while(null!==u&&u!==i);null===c?s=r:c.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=c,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,Ml|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Ri(e){var t=Fi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Ai(){}function Ni(e,t){var n=hi,r=Fi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Hi(Di.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==bi&&1&bi.memoizedState.tag){if(n.flags|=2048,Zi(9,Oi.bind(null,n,r,a,t),void 0,null),null===El)throw Error(o(349));0!==(30&mi)||Ii(n,t,a)}return a}function Ii(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Oi(e,t,n,r){t.value=n,t.getSnapshot=r,Mi(t)&&zi(e)}function Di(e,t,n){return n((function(){Mi(t)&&zi(e)}))}function Mi(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function zi(e){var t=Ro(e,1);null!==t&&nc(t,e,1,-1)}function Li(e){var t=xi();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Pi,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Zi(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function ji(){return Fi().memoizedState}function Bi(e,t,n,r){var a=xi();hi.flags|=e,a.memoizedState=Zi(1|t,n,void 0,void 0===r?null:r)}function Wi(e,t,n,r){var a=Fi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&Si(r,i.deps))return void(a.memoizedState=Zi(t,n,o,r))}hi.flags|=e,a.memoizedState=Zi(1|t,n,o,r)}function Ui(e,t){return Bi(8390656,8,e,t)}function Hi(e,t){return Wi(2048,8,e,t)}function Vi(e,t){return Wi(4,2,e,t)}function Ji(e,t){return Wi(4,4,e,t)}function $i(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Gi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Wi(4,4,$i.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=Fi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Si(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=Fi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&Si(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,Ml|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=pi.transition;pi.transition={};try{e(!1),t()}finally{gt=n,pi.transition=r}}function es(){return Fi().memoizedState}function ts(e,t,n){var r=tc(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Eo(e,t,n,r))){nc(n,e,r,ec()),os(n,t,r)}}function ns(e,t,n){var r=tc(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Po(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(c){}null!==(n=Eo(e,t,a,r))&&(nc(n,e,r,a=ec()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=yi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}var is={readContext:xo,useCallback:ki,useContext:ki,useEffect:ki,useImperativeHandle:ki,useInsertionEffect:ki,useLayoutEffect:ki,useMemo:ki,useReducer:ki,useRef:ki,useState:ki,useDebugValue:ki,useDeferredValue:ki,useTransition:ki,useMutableSource:ki,useSyncExternalStore:ki,useId:ki,unstable_isNewReconciler:!1},ss={readContext:xo,useCallback:function(e,t){return xi().memoizedState=[e,void 0===t?null:t],e},useContext:xo,useEffect:Ui,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4194308,4,$i.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Bi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Bi(4,2,e,t)},useMemo:function(e,t){var n=xi();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=xi();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},xi().memoizedState=e},useState:Li,useDebugValue:qi,useDeferredValue:function(e){return xi().memoizedState=e},useTransition:function(){var e=Li(!1),t=e[0];return e=Xi.bind(null,e[1]),xi().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=xi();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===El)throw Error(o(349));0!==(30&mi)||Ii(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Ui(Di.bind(null,r,i,e),[e]),r.flags|=2048,Zi(9,Oi.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=xi(),t=El.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Hi,useImperativeHandle:Gi,useInsertionEffect:Vi,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ei,useRef:ji,useState:function(){return Ei(Pi)},useDebugValue:qi,useDeferredValue:function(e){return Yi(Fi(),vi.memoizedState,e)},useTransition:function(){return[Ei(Pi)[0],Fi().memoizedState]},useMutableSource:Ai,useSyncExternalStore:Ni,useId:es,unstable_isNewReconciler:!1},cs={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Hi,useImperativeHandle:Gi,useInsertionEffect:Vi,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ri,useRef:ji,useState:function(){return Ri(Pi)},useDebugValue:qi,useDeferredValue:function(e){var t=Fi();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Ri(Pi)[0],Fi().memoizedState]},useMutableSource:Ai,useSyncExternalStore:Ni,useId:es,unstable_isNewReconciler:!1};function us(e,t){try{var n="",r=t;do{n+=B(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function fs(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var ps="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Oo(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Hl||(Hl=!0,Vl=r),fs(0,t)},n}function hs(e,t,n){(n=Oo(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){fs(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){fs(0,t),"function"!==typeof r&&(null===Jl?Jl=new Set([this]):Jl.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new ps;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=Tc.bind(null,e,t,n),t.then(e,e))}function bs(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function ys(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Oo(-1,1)).tag=2,Do(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Yo(t,null,n,r):Qo(t,e.child,n,r)}function ks(e,t,n,r,a){n=n.render;var o=t.ref;return To(t,a),r=Ci(e,t,n,r,o,a),n=Ti(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Hs(e,t,a))}function Ss(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Nc(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Oc(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Cs(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Hs(e,t,a)}return t.flags|=1,(e=Ic(o,r)).ref=t.ref,e.return=t,t.child=e}function Cs(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Hs(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return Fs(e,t,n,r,a)}function Ts(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},xa(Il,Nl),Nl|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,xa(Il,Nl),Nl|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,xa(Il,Nl),Nl|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,xa(Il,Nl),Nl|=r;return ws(e,t,a,n),t.child}function xs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function Fs(e,t,n,r,a){var o=Na(n)?Ra:Pa.current;return o=Aa(t,o),To(t,a),n=Ci(e,t,n,r,o,a),r=Ti(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Hs(e,t,a))}function Ps(e,t,n,r,a){if(Na(n)){var o=!0;Ma(t)}else o=!1;if(To(t,a),null===t.stateNode)Us(e,t),Ho(t,n,r),Jo(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,c=n.contextType;"object"===typeof c&&null!==c?c=xo(c):c=Aa(t,c=Na(n)?Ra:Pa.current);var u=n.getDerivedStateFromProps,d="function"===typeof u||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==c)&&Vo(t,i,r,c),Ao=!1;var f=t.memoizedState;i.state=f,Lo(t,r,i,a),l=t.memoizedState,s!==r||f!==l||Ea.current||Ao?("function"===typeof u&&(Bo(t,n,u,r),l=t.memoizedState),(s=Ao||Uo(t,n,s,r,f,l,c))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=c,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Io(e,t),s=t.memoizedProps,c=t.type===t.elementType?s:bo(t.type,s),i.props=c,d=t.pendingProps,f=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=xo(l):l=Aa(t,l=Na(n)?Ra:Pa.current);var p=n.getDerivedStateFromProps;(u="function"===typeof p||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||f!==l)&&Vo(t,i,r,l),Ao=!1,f=t.memoizedState,i.state=f,Lo(t,r,i,a);var m=t.memoizedState;s!==d||f!==m||Ea.current||Ao?("function"===typeof p&&(Bo(t,n,p,r),m=t.memoizedState),(c=Ao||Uo(t,n,c,r,f,m,l)||!1)?(u||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=c):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&f===e.memoizedState||(t.flags|=1024),r=!1)}return Es(e,t,n,r,o,a)}function Es(e,t,n,r,a,o){xs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&za(t,n,!1),Hs(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&za(t,n,!0),t.child}function Rs(e){var t=e.stateNode;t.pendingContext?Oa(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Oa(0,t.context,!1),ai(e,t.containerInfo)}function As(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Ns,Is,Os,Ds={dehydrated:null,treeContext:null,retryLane:0};function Ms(e){return{baseLanes:e,cachePool:null,transitions:null}}function zs(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),xa(li,1&i),null===e)return co(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=Mc(l,a,0,null),e=Dc(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=Ms(n),t.memoizedState=Ds,e):Ls(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Zs(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=Mc({mode:"visible",children:r.children},a,0,null),(i=Dc(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=Ms(s),t.memoizedState=Ds,i);if(0===(1&t.mode))return Zs(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Zs(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=El)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,Ro(e,a),nc(r,e,a,-1))}return hc(),Zs(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=Fc.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ca(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&($a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Ls(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var c={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=c,t.deletions=null):(a=Ic(i,c)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Ic(r,s):(s=Dc(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?Ms(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Ds,a}return e=(s=e.child).sibling,a=Ic(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ls(e,t){return(t=Mc({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Zs(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Ls(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function js(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),Co(e.return,t,n)}function Bs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Ws(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&js(e,n,t);else if(19===e.tag)js(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(xa(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ci(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Bs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ci(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Bs(t,!0,n,null,o);break;case"together":Bs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Us(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Hs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),Ml|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Ic(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Ic(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Vs(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Js(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function $s(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Js(t),null;case 1:case 17:return Na(t.type)&&Ia(),Js(t),null;case 3:return r=t.stateNode,oi(),Ta(Ea),Ta(Pa),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(fo(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(ic(oo),oo=null))),Js(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Is(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return Js(t),null}if(e=ri(ei.current),fo(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[fa]=t,r[pa]=i,e=0!==(1&t.mode),n){case"dialog":Zr("cancel",r),Zr("close",r);break;case"iframe":case"object":case"embed":Zr("load",r);break;case"video":case"audio":for(a=0;a<Dr.length;a++)Zr(Dr[a],r);break;case"source":Zr("error",r);break;case"img":case"image":case"link":Zr("error",r),Zr("load",r);break;case"details":Zr("toggle",r);break;case"input":K(r,i),Zr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Zr("invalid",r);break;case"textarea":ae(r,i),Zr("invalid",r)}for(var l in ye(n,i),a=null,i)if(i.hasOwnProperty(l)){var c=i[l];"children"===l?"string"===typeof c?r.textContent!==c&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,c,e),a=["children",c]):"number"===typeof c&&r.textContent!==""+c&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,c,e),a=["children",""+c]):s.hasOwnProperty(l)&&null!=c&&"onScroll"===l&&Zr("scroll",r)}switch(n){case"input":J(r),X(r,i,!0);break;case"textarea":J(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[fa]=t,e[pa]=r,Ns(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Zr("cancel",e),Zr("close",e),a=r;break;case"iframe":case"object":case"embed":Zr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Dr.length;a++)Zr(Dr[a],e);a=r;break;case"source":Zr("error",e),a=r;break;case"img":case"image":case"link":Zr("error",e),Zr("load",e),a=r;break;case"details":Zr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Zr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=z({},r,{value:void 0}),Zr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Zr("invalid",e)}for(i in ye(n,a),c=a)if(c.hasOwnProperty(i)){var u=c[i];"style"===i?ve(e,u):"dangerouslySetInnerHTML"===i?null!=(u=u?u.__html:void 0)&&de(e,u):"children"===i?"string"===typeof u?("textarea"!==n||""!==u)&&fe(e,u):"number"===typeof u&&fe(e,""+u):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=u&&"onScroll"===i&&Zr("scroll",e):null!=u&&g(e,i,u,l))}switch(n){case"input":J(e),X(e,r,!1);break;case"textarea":J(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+H(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Js(t),null;case 6:if(e&&null!=t.stateNode)Os(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),fo(t)){if(r=t.stateNode,n=t.memoizedProps,r[fa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[fa]=t,t.stateNode=r}return Js(t),null;case 13:if(Ta(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))po(),mo(),t.flags|=98560,i=!1;else if(i=fo(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[fa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Js(t),i=!1}else null!==oo&&(ic(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Ol&&(Ol=3):hc())),null!==t.updateQueue&&(t.flags|=4),Js(t),null);case 4:return oi(),null===e&&Wr(t.stateNode.containerInfo),Js(t),null;case 10:return So(t.type._context),Js(t),null;case 19:if(Ta(li),null===(i=t.memoizedState))return Js(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Vs(i,!1);else{if(0!==Ol||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ci(e))){for(t.flags|=128,Vs(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return xa(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Wl&&(t.flags|=128,r=!0,Vs(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ci(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Vs(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return Js(t),null}else 2*Qe()-i.renderingStartTime>Wl&&1073741824!==n&&(t.flags|=128,r=!0,Vs(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,xa(li,r?1&n|2:1&n),t):(Js(t),null);case 22:case 23:return dc(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Nl)&&(Js(t),6&t.subtreeFlags&&(t.flags|=8192)):Js(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Gs(e,t){switch(to(t),t.tag){case 1:return Na(t.type)&&Ia(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),Ta(Ea),Ta(Pa),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(Ta(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return Ta(li),null;case 4:return oi(),null;case 10:return So(t.type._context),null;case 22:case 23:return dc(),null;default:return null}}Ns=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Is=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=z({},a,{value:void 0}),r=z({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(u in ye(n,r),n=null,a)if(!r.hasOwnProperty(u)&&a.hasOwnProperty(u)&&null!=a[u])if("style"===u){var l=a[u];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==u&&"children"!==u&&"suppressContentEditableWarning"!==u&&"suppressHydrationWarning"!==u&&"autoFocus"!==u&&(s.hasOwnProperty(u)?i||(i=[]):(i=i||[]).push(u,null));for(u in r){var c=r[u];if(l=null!=a?a[u]:void 0,r.hasOwnProperty(u)&&c!==l&&(null!=c||null!=l))if("style"===u)if(l){for(o in l)!l.hasOwnProperty(o)||c&&c.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in c)c.hasOwnProperty(o)&&l[o]!==c[o]&&(n||(n={}),n[o]=c[o])}else n||(i||(i=[]),i.push(u,n)),n=c;else"dangerouslySetInnerHTML"===u?(c=c?c.__html:void 0,l=l?l.__html:void 0,null!=c&&l!==c&&(i=i||[]).push(u,c)):"children"===u?"string"!==typeof c&&"number"!==typeof c||(i=i||[]).push(u,""+c):"suppressContentEditableWarning"!==u&&"suppressHydrationWarning"!==u&&(s.hasOwnProperty(u)?(null!=c&&"onScroll"===u&&Zr("scroll",e),i||l===c||(i=[])):(i=i||[]).push(u,c))}n&&(i=i||[]).push("style",n);var u=i;(t.updateQueue=u)&&(t.flags|=4)}},Os=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Cc(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Cc(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[fa],delete t[pa],delete t[ha],delete t[va],delete t[ba])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function cl(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(cl(e,t,n),e=e.sibling;null!==e;)cl(e,t,n),e=e.sibling}var ul=null,dl=!1;function fl(e,t,n){for(n=n.child;null!==n;)pl(e,t,n),n=n.sibling}function pl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=ul,a=dl;ul=null,fl(e,t,n),dl=a,null!==(ul=r)&&(dl?(e=ul,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):ul.removeChild(n.stateNode));break;case 18:null!==ul&&(dl?(e=ul,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Wt(e)):la(ul,n.stateNode));break;case 4:r=ul,a=dl,ul=n.stateNode.containerInfo,dl=!0,fl(e,t,n),ul=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}fl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Cc(n,t,s)}fl(e,t,n);break;case 21:fl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,fl(e,t,n),Ks=r):fl(e,t,n);break;default:fl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Pc.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:ul=l.stateNode,dl=!1;break e;case 3:case 4:ul=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===ul)throw Error(o(160));pl(i,s,a),ul=null,dl=!1;var c=a.alternate;null!==c&&(c.return=null),a.return=null}catch(u){Cc(a,t,u)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),bl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Cc(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Cc(e,e.return,v)}}break;case 1:hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{fe(a,"")}catch(v){Cc(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,c=e.updateQueue;if(e.updateQueue=null,null!==c)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var u=ge(l,i);for(s=0;s<c.length;s+=2){var d=c[s],f=c[s+1];"style"===d?ve(a,f):"dangerouslySetInnerHTML"===d?de(a,f):"children"===d?fe(a,f):g(a,d,f,u)}switch(l){case"input":Y(a,i);break;case"textarea":oe(a,i);break;case"select":var p=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):p!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[pa]=i}catch(v){Cc(e,e.return,v)}}break;case 6:if(hl(t,e),bl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Cc(e,e.return,v)}}break;case 3:if(hl(t,e),bl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Wt(t.containerInfo)}catch(v){Cc(e,e.return,v)}break;case 4:default:hl(t,e),bl(e);break;case 13:hl(t,e),bl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Bl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(u=Ks)||d,hl(t,e),Ks=u):hl(t,e),bl(e),8192&r){if(u=null!==e.memoizedState,(e.stateNode.isHidden=u)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(f=Ys=d;null!==Ys;){switch(m=(p=Ys).child,p.tag){case 0:case 11:case 14:case 15:nl(4,p,p.return);break;case 1:Xs(p,p.return);var h=p.stateNode;if("function"===typeof h.componentWillUnmount){r=p,n=p.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Cc(r,n,v)}}break;case 5:Xs(p,p.return);break;case 22:if(null!==p.memoizedState){wl(f);continue}}null!==m?(m.return=p,Ys=m):wl(f)}d=d.sibling}e:for(d=null,f=e;;){if(5===f.tag){if(null===d){d=f;try{a=f.stateNode,u?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=f.stateNode,s=void 0!==(c=f.memoizedProps.style)&&null!==c&&c.hasOwnProperty("display")?c.display:null,l.style.display=he("display",s))}catch(v){Cc(e,e.return,v)}}}else if(6===f.tag){if(null===d)try{f.stateNode.nodeValue=u?"":f.memoizedProps}catch(v){Cc(e,e.return,v)}}else if((22!==f.tag&&23!==f.tag||null===f.memoizedState||f===e)&&null!==f.child){f.child.return=f,f=f.child;continue}if(f===e)break e;for(;null===f.sibling;){if(null===f.return||f.return===e)break e;d===f&&(d=null),f=f.return}d===f&&(d=null),f.sibling.return=f.return,f=f.sibling}}break;case 19:hl(t,e),bl(e),4&r&&ml(e);case 21:}}function bl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(fe(a,""),r.flags&=-33),cl(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Cc(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function yl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var a=Ys,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var c=Ks;if(qs=i,(Ks=l)&&!c)for(Ys=a;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?kl(a):null!==l?(l.return=i,Ys=l):kl(a);for(;null!==o;)Ys=o,gl(o,t,n),o=o.sibling;Ys=a,qs=s,Ks=c}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Ys=o):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:bo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Zo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Zo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var c=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":c.autoFocus&&n.focus();break;case"img":c.src&&(n.src=c.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var u=t.alternate;if(null!==u){var d=u.memoizedState;if(null!==d){var f=d.dehydrated;null!==f&&Wt(f)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(p){Cc(t,t.return,p)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function kl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Cc(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Cc(t,a,l)}}var o=t.return;try{al(t)}catch(l){Cc(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Cc(t,i,l)}}}catch(l){Cc(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var Sl,Cl=Math.ceil,Tl=_.ReactCurrentDispatcher,xl=_.ReactCurrentOwner,Fl=_.ReactCurrentBatchConfig,Pl=0,El=null,Rl=null,Al=0,Nl=0,Il=Ca(0),Ol=0,Dl=null,Ml=0,zl=0,Ll=0,Zl=null,jl=null,Bl=0,Wl=1/0,Ul=null,Hl=!1,Vl=null,Jl=null,$l=!1,Gl=null,ql=0,Kl=0,Ql=null,Yl=-1,Xl=0;function ec(){return 0!==(6&Pl)?Qe():-1!==Yl?Yl:Yl=Qe()}function tc(e){return 0===(1&e.mode)?1:0!==(2&Pl)&&0!==Al?Al&-Al:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nc(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));bt(e,n,r),0!==(2&Pl)&&e===El||(e===El&&(0===(2&Pl)&&(zl|=n),4===Ol&&sc(e,Al)),rc(e,r),1===n&&0===Pl&&0===(1&t.mode)&&(Wl=Qe()+500,Za&&Wa()))}function rc(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=pt(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=ft(e,e===El?Al:0);if(0===r)null!==n&&Ge(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&Ge(n),1===t)0===e.tag?function(e){Za=!0,Ba(e)}(lc.bind(null,e)):Ba(lc.bind(null,e)),ia((function(){0===(6&Pl)&&Wa()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Ec(n,ac.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function ac(e,t){if(Yl=-1,Xl=0,0!==(6&Pl))throw Error(o(327));var n=e.callbackNode;if(kc()&&e.callbackNode!==n)return null;var r=ft(e,e===El?Al:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vc(e,r);else{t=r;var a=Pl;Pl|=2;var i=mc();for(El===e&&Al===t||(Ul=null,Wl=Qe()+500,fc(e,t));;)try{yc();break}catch(l){pc(e,l)}ko(),Tl.current=i,Pl=a,null!==Rl?t=0:(El=null,Al=0,t=Ol)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=oc(e,a))),1===t)throw n=Dl,fc(e,0),sc(e,r),rc(e,Qe()),n;if(6===t)sc(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vc(e,r))&&(0!==(i=mt(e))&&(r=i,t=oc(e,i))),1===t))throw n=Dl,fc(e,0),sc(e,r),rc(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wc(e,jl,Ul);break;case 3:if(sc(e,r),(130023424&r)===r&&10<(t=Bl+500-Qe())){if(0!==ft(e,0))break;if(((a=e.suspendedLanes)&r)!==r){ec(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wc.bind(null,e,jl,Ul),t);break}wc(e,jl,Ul);break;case 4:if(sc(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Cl(r/1960))-r)){e.timeoutHandle=ra(wc.bind(null,e,jl,Ul),r);break}wc(e,jl,Ul);break;default:throw Error(o(329))}}}return rc(e,Qe()),e.callbackNode===n?ac.bind(null,e):null}function oc(e,t){var n=Zl;return e.current.memoizedState.isDehydrated&&(fc(e,t).flags|=256),2!==(e=vc(e,t))&&(t=jl,jl=n,null!==t&&ic(t)),e}function ic(e){null===jl?jl=e:jl.push.apply(jl,e)}function sc(e,t){for(t&=~Ll,t&=~zl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lc(e){if(0!==(6&Pl))throw Error(o(327));kc();var t=ft(e,0);if(0===(1&t))return rc(e,Qe()),null;var n=vc(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=oc(e,r))}if(1===n)throw n=Dl,fc(e,0),sc(e,t),rc(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wc(e,jl,Ul),rc(e,Qe()),null}function cc(e,t){var n=Pl;Pl|=1;try{return e(t)}finally{0===(Pl=n)&&(Wl=Qe()+500,Za&&Wa())}}function uc(e){null!==Gl&&0===Gl.tag&&0===(6&Pl)&&kc();var t=Pl;Pl|=1;var n=Fl.transition,r=gt;try{if(Fl.transition=null,gt=1,e)return e()}finally{gt=r,Fl.transition=n,0===(6&(Pl=t))&&Wa()}}function dc(){Nl=Il.current,Ta(Il)}function fc(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==Rl)for(n=Rl.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Ia();break;case 3:oi(),Ta(Ea),Ta(Pa),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:Ta(li);break;case 10:So(r.type._context);break;case 22:case 23:dc()}n=n.return}if(El=e,Rl=e=Ic(e.current,null),Al=Nl=t,Ol=0,Dl=null,Ll=zl=Ml=0,jl=Zl=null,null!==Fo){for(t=0;t<Fo.length;t++)if(null!==(r=(n=Fo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}Fo=null}return e}function pc(e,t){for(;;){var n=Rl;try{if(ko(),fi.current=is,yi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}yi=!1}if(mi=0,bi=vi=hi=null,gi=!1,_i=0,xl.current=null,null===n||null===n.return){Ol=1,Dl=t,Rl=null;break}e:{var i=e,s=n.return,l=n,c=t;if(t=Al,l.flags|=32768,null!==c&&"object"===typeof c&&"function"===typeof c.then){var u=c,d=l,f=d.tag;if(0===(1&d.mode)&&(0===f||11===f||15===f)){var p=d.alternate;p?(d.updateQueue=p.updateQueue,d.memoizedState=p.memoizedState,d.lanes=p.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=bs(s);if(null!==m){m.flags&=-257,ys(m,s,l,0,t),1&m.mode&&vs(i,u,t),c=u;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(c),t.updateQueue=v}else h.add(c);break e}if(0===(1&t)){vs(i,u,t),hc();break e}c=Error(o(426))}else if(ao&&1&l.mode){var b=bs(s);if(null!==b){0===(65536&b.flags)&&(b.flags|=256),ys(b,s,l,0,t),ho(us(c,l));break e}}i=c=us(c,l),4!==Ol&&(Ol=2),null===Zl?Zl=[i]:Zl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,zo(i,ms(0,c,t));break e;case 1:l=c;var y=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof y.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Jl||!Jl.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,zo(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_c(n)}catch(_){t=_,Rl===n&&null!==n&&(Rl=n=n.return);continue}break}}function mc(){var e=Tl.current;return Tl.current=is,null===e?is:e}function hc(){0!==Ol&&3!==Ol&&2!==Ol||(Ol=4),null===El||0===(268435455&Ml)&&0===(268435455&zl)||sc(El,Al)}function vc(e,t){var n=Pl;Pl|=2;var r=mc();for(El===e&&Al===t||(Ul=null,fc(e,t));;)try{bc();break}catch(a){pc(e,a)}if(ko(),Pl=n,Tl.current=r,null!==Rl)throw Error(o(261));return El=null,Al=0,Ol}function bc(){for(;null!==Rl;)gc(Rl)}function yc(){for(;null!==Rl&&!qe();)gc(Rl)}function gc(e){var t=Sl(e.alternate,e,Nl);e.memoizedProps=e.pendingProps,null===t?_c(e):Rl=t,xl.current=null}function _c(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=$s(n,t,Nl)))return void(Rl=n)}else{if(null!==(n=Gs(n,t)))return n.flags&=32767,void(Rl=n);if(null===e)return Ol=6,void(Rl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Rl=t);Rl=t=e}while(null!==t);0===Ol&&(Ol=5)}function wc(e,t,n){var r=gt,a=Fl.transition;try{Fl.transition=null,gt=1,function(e,t,n,r){do{kc()}while(null!==Gl);if(0!==(6&Pl))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===El&&(Rl=El=null,Al=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||$l||($l=!0,Ec(tt,(function(){return kc(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=Fl.transition,Fl.transition=null;var s=gt;gt=1;var l=Pl;Pl|=4,xl.current=null,function(e,t){if(ea=Ht,pr(e=fr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,c=-1,u=0,d=0,f=e,p=null;t:for(;;){for(var m;f!==n||0!==a&&3!==f.nodeType||(l=s+a),f!==i||0!==r&&3!==f.nodeType||(c=s+r),3===f.nodeType&&(s+=f.nodeValue.length),null!==(m=f.firstChild);)p=f,f=m;for(;;){if(f===e)break t;if(p===n&&++u===a&&(l=s),p===i&&++d===r&&(c=s),null!==(m=f.nextSibling))break;p=(f=p).parentNode}f=m}n=-1===l||-1===c?null:{start:l,end:c}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Ht=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,b=h.memoizedState,y=t.stateNode,g=y.getSnapshotBeforeUpdate(t.elementType===t.type?v:bo(t.type,v),b);y.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Cc(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Ht=!!ea,ta=ea=null,e.current=n,yl(n,e,a),Ke(),Pl=l,gt=s,Fl.transition=i}else e.current=n;if($l&&($l=!1,Gl=e,ql=a),0===(i=e.pendingLanes)&&(Jl=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),rc(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Hl)throw Hl=!1,e=Vl,Vl=null,e;0!==(1&ql)&&0!==e.tag&&kc(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Wa()}(e,t,n,r)}finally{Fl.transition=a,gt=r}return null}function kc(){if(null!==Gl){var e=_t(ql),t=Fl.transition,n=gt;try{if(Fl.transition=null,gt=16>e?16:e,null===Gl)var r=!1;else{if(e=Gl,Gl=null,ql=0,0!==(6&Pl))throw Error(o(331));var a=Pl;for(Pl|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var c=0;c<l.length;c++){var u=l[c];for(Ys=u;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var f=d.child;if(null!==f)f.return=d,Ys=f;else for(;null!==Ys;){var p=(d=Ys).sibling,m=d.return;if(ol(d),d===u){Ys=null;break}if(null!==p){p.return=m,Ys=p;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var b=v.sibling;v.sibling=null,v=b}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var y=i.sibling;if(null!==y){y.return=i.return,Ys=y;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(k){Cc(l,l.return,k)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(Pl=a,Wa(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(k){}r=!0}return r}finally{gt=n,Fl.transition=t}}return!1}function Sc(e,t,n){e=Do(e,t=ms(0,t=us(n,t),1),1),t=ec(),null!==e&&(bt(e,1,t),rc(e,t))}function Cc(e,t,n){if(3===e.tag)Sc(e,e,n);else for(;null!==t;){if(3===t.tag){Sc(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Jl||!Jl.has(r))){t=Do(t,e=hs(t,e=us(n,e),1),1),e=ec(),null!==t&&(bt(t,1,e),rc(t,e));break}}t=t.return}}function Tc(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=ec(),e.pingedLanes|=e.suspendedLanes&n,El===e&&(Al&n)===n&&(4===Ol||3===Ol&&(130023424&Al)===Al&&500>Qe()-Bl?fc(e,0):Ll|=n),rc(e,t)}function xc(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ut,0===(130023424&(ut<<=1))&&(ut=4194304)));var n=ec();null!==(e=Ro(e,t))&&(bt(e,t,n),rc(e,n))}function Fc(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),xc(e,n)}function Pc(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),xc(e,n)}function Ec(e,t){return $e(e,t)}function Rc(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Ac(e,t,n,r){return new Rc(e,t,n,r)}function Nc(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Ic(e,t){var n=e.alternate;return null===n?((n=Ac(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Oc(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Nc(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case S:return Dc(n.children,a,i,t);case C:s=8,a|=8;break;case T:return(e=Ac(12,n,t,2|a)).elementType=T,e.lanes=i,e;case E:return(e=Ac(13,n,t,a)).elementType=E,e.lanes=i,e;case R:return(e=Ac(19,n,t,a)).elementType=R,e.lanes=i,e;case I:return Mc(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case x:s=10;break e;case F:s=9;break e;case P:s=11;break e;case A:s=14;break e;case N:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Ac(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Dc(e,t,n,r){return(e=Ac(7,e,r,t)).lanes=n,e}function Mc(e,t,n,r){return(e=Ac(22,e,r,t)).elementType=I,e.lanes=n,e.stateNode={isHidden:!1},e}function zc(e,t,n){return(e=Ac(6,e,null,t)).lanes=n,e}function Lc(e,t,n){return(t=Ac(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Zc(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function jc(e,t,n,r,a,o,i,s,l){return e=new Zc(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Ac(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},No(o),e}function Bc(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:k,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Wc(e){if(!e)return Fa;e:{if(We(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Na(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Na(n))return Da(e,n,t)}return t}function Uc(e,t,n,r,a,o,i,s,l){return(e=jc(n,r,!0,e,0,o,0,s,l)).context=Wc(null),n=e.current,(o=Oo(r=ec(),a=tc(n))).callback=void 0!==t&&null!==t?t:null,Do(n,o,a),e.current.lanes=a,bt(e,a,r),rc(e,r),e}function Hc(e,t,n,r){var a=t.current,o=ec(),i=tc(a);return n=Wc(n),null===t.context?t.context=n:t.pendingContext=n,(t=Oo(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Do(a,t,i))&&(nc(e,a,i,o),Mo(e,a,i)),i}function Vc(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Jc(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function $c(e,t){Jc(e,t),(e=e.alternate)&&Jc(e,t)}Sl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Ea.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Rs(t),mo();break;case 5:ii(t);break;case 1:Na(t.type)&&Ma(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;xa(yo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(xa(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?zs(e,t,n):(xa(li,1&li.current),null!==(e=Hs(e,t,n))?e.sibling:null);xa(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Ws(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),xa(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,Ts(e,t,n)}return Hs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,Ja,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Us(e,t),e=t.pendingProps;var a=Aa(t,Pa.current);To(t,n),a=Ci(null,t,r,e,a,n);var i=Ti();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Na(r)?(i=!0,Ma(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,No(t),a.updater=Wo,t.stateNode=a,a._reactInternals=t,Jo(t,r,e,n),t=Es(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Us(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Nc(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===P)return 11;if(e===A)return 14}return 2}(r),e=bo(r,e),a){case 0:t=Fs(null,t,r,e,n);break e;case 1:t=Ps(null,t,r,e,n);break e;case 11:t=ks(null,t,r,e,n);break e;case 14:t=Ss(null,t,r,bo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,Fs(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Ps(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 3:e:{if(Rs(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,Io(e,t),Lo(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=As(e,t,r,n,a=us(Error(o(423)),t));break e}if(r!==a){t=As(e,t,r,n,a=us(Error(o(424)),t));break e}for(ro=ca(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Yo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Hs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&co(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),xs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&co(t),null;case 13:return zs(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,ks(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,xa(yo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Ea.current){t=Hs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var c=l.firstContext;null!==c;){if(c.context===r){if(1===i.tag){(c=Oo(-1,n&-n)).tag=2;var u=i.updateQueue;if(null!==u){var d=(u=u.shared).pending;null===d?c.next=c:(c.next=d.next,d.next=c),u.pending=c}}i.lanes|=n,null!==(c=i.alternate)&&(c.lanes|=n),Co(i.return,n,t),l.lanes|=n;break}c=c.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),Co(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,To(t,n),r=r(a=xo(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=bo(r=t.type,t.pendingProps),Ss(e,t,r,a=bo(r.type,a),n);case 15:return Cs(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:bo(r,a),Us(e,t),t.tag=1,Na(r)?(e=!0,Ma(t)):e=!1,To(t,n),Ho(t,r,a),Jo(t,r,a,n),Es(null,t,r,!0,e,n);case 19:return Ws(e,t,n);case 22:return Ts(e,t,n)}throw Error(o(156,t.tag))};var Gc="function"===typeof reportError?reportError:function(e){console.error(e)};function qc(e){this._internalRoot=e}function Kc(e){this._internalRoot=e}function Qc(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yc(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xc(){}function eu(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Vc(i);s.call(e)}}Hc(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Vc(i);o.call(e)}}var i=Uc(t,r,e,0,null,!1,0,"",Xc);return e._reactRootContainer=i,e[ma]=i.current,Wr(8===e.nodeType?e.parentNode:e),uc(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Vc(l);s.call(e)}}var l=jc(e,0,!1,null,0,!1,0,"",Xc);return e._reactRootContainer=l,e[ma]=l.current,Wr(8===e.nodeType?e.parentNode:e),uc((function(){Hc(t,l,n,r)})),l}(n,t,e,a,r);return Vc(i)}Kc.prototype.render=qc.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Hc(e,t,null,null)},Kc.prototype.unmount=qc.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;uc((function(){Hc(null,e,null,null)})),t[ma]=null}},Kc.prototype.unstable_scheduleHydration=function(e){if(e){var t=Ct();e={blockedOn:null,target:e,priority:t};for(var n=0;n<It.length&&0!==t&&t<It[n].priority;n++);It.splice(n,0,e),0===n&&zt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(yt(t,1|n),rc(t,Qe()),0===(6&Pl)&&(Wl=Qe()+500,Wa()))}break;case 13:uc((function(){var t=Ro(e,1);if(null!==t){var n=ec();nc(t,e,1,n)}})),$c(e,1)}},kt=function(e){if(13===e.tag){var t=Ro(e,134217728);if(null!==t)nc(t,e,134217728,ec());$c(e,134217728)}},St=function(e){if(13===e.tag){var t=tc(e),n=Ro(e,t);if(null!==n)nc(n,e,t,ec());$c(e,t)}},Ct=function(){return gt},Tt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},ke=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));$(r),Y(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Pe=cc,Ee=uc;var tu={usingClientEntryPoint:!1,Events:[ga,_a,wa,xe,Fe,cc]},nu={findFiberByHostInstance:ya,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},ru={bundleType:nu.bundleType,version:nu.version,rendererPackageName:nu.rendererPackageName,rendererConfig:nu.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=Ve(e))?null:e.stateNode},findFiberByHostInstance:nu.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var au=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!au.isDisabled&&au.supportsFiber)try{at=au.inject(ru),ot=au}catch(ue){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tu,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qc(t))throw Error(o(200));return Bc(e,t,null,n)},t.createRoot=function(e,t){if(!Qc(e))throw Error(o(299));var n=!1,r="",a=Gc;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=jc(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Wr(8===e.nodeType?e.parentNode:e),new qc(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=Ve(t))?null:e.stateNode},t.flushSync=function(e){return uc(e)},t.hydrate=function(e,t,n){if(!Yc(t))throw Error(o(200));return eu(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qc(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Gc;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Uc(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Wr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Kc(t)},t.render=function(e,t,n){if(!Yc(t))throw Error(o(200));return eu(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yc(e))throw Error(o(40));return!!e._reactRootContainer&&(uc((function(){eu(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=cc,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yc(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return eu(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function c(e,t,n){var r,o={},c=null,u=null;for(r in void 0!==n&&(c=""+n),void 0!==t.key&&(c=""+t.key),void 0!==t.ref&&(u=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:c,ref:u,props:o,_owner:s.current}}t.Fragment=o,t.jsx=c,t.jsxs=c},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),c=Symbol.for("react.forward_ref"),u=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),f=Symbol.for("react.lazy"),p=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function b(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function y(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}b.prototype.isReactComponent={},b.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},b.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},y.prototype=b.prototype;var _=g.prototype=new y;_.constructor=g,h(_,b.prototype),_.isPureReactComponent=!0;var w=Array.isArray,k=Object.prototype.hasOwnProperty,S={current:null},C={key:!0,ref:!0,__self:!0,__source:!0};function T(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)k.call(t,a)&&!C.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var c=Array(l),u=0;u<l;u++)c[u]=arguments[u+2];o.children=c}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:S.current}}function x(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var F=/\/+/g;function P(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function E(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+P(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(F,"$&/")+"/"),E(i,t,a,"",(function(e){return e}))):null!=i&&(x(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(F,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var c=0;c<e.length;c++){var u=o+P(s=e[c],c);l+=E(s,t,a,u,i)}else if(u=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=p&&e[p]||e["@@iterator"])?e:null}(e),"function"===typeof u)for(e=u.call(e),c=0;!(s=e.next()).done;)l+=E(s=s.value,t,a,u=o+P(s,c++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function R(e,t,n){if(null==e)return e;var r=[],a=0;return E(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function A(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var N={current:null},I={transition:null},O={ReactCurrentDispatcher:N,ReactCurrentBatchConfig:I,ReactCurrentOwner:S};t.Children={map:R,forEach:function(e,t,n){R(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return R(e,(function(){t++})),t},toArray:function(e){return R(e,(function(e){return e}))||[]},only:function(e){if(!x(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=b,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=u,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=O,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=S.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(c in t)k.call(t,c)&&!C.hasOwnProperty(c)&&(a[c]=void 0===t[c]&&void 0!==l?l[c]:t[c])}var c=arguments.length-2;if(1===c)a.children=r;else if(1<c){l=Array(c);for(var u=0;u<c;u++)l[u]=arguments[u+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=T,t.createFactory=function(e){var t=T.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:c,render:e}},t.isValidElement=x,t.lazy=function(e){return{$$typeof:f,_payload:{_status:-1,_result:e},_init:A}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=I.transition;I.transition={};try{e()}finally{I.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return N.current.useCallback(e,t)},t.useContext=function(e){return N.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return N.current.useDeferredValue(e)},t.useEffect=function(e,t){return N.current.useEffect(e,t)},t.useId=function(){return N.current.useId()},t.useImperativeHandle=function(e,t,n){return N.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return N.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return N.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return N.current.useMemo(e,t)},t.useReducer=function(e,t,n){return N.current.useReducer(e,t,n)},t.useRef=function(e){return N.current.useRef(e)},t.useState=function(e){return N.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return N.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return N.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],c=s+1,u=e[c];if(0>o(l,n))c<a&&0>o(u,l)?(e[r]=u,e[c]=n,r=c):(e[r]=l,e[s]=n,r=s);else{if(!(c<a&&0>o(u,n)))break e;e[r]=u,e[c]=n,r=c}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var c=[],u=[],d=1,f=null,p=3,m=!1,h=!1,v=!1,b="function"===typeof setTimeout?setTimeout:null,y="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(u);null!==t;){if(null===t.callback)a(u);else{if(!(t.startTime<=e))break;a(u),t.sortIndex=t.expirationTime,n(c,t)}t=r(u)}}function w(e){if(v=!1,_(e),!h)if(null!==r(c))h=!0,I(k);else{var t=r(u);null!==t&&O(w,t.startTime-e)}}function k(e,n){h=!1,v&&(v=!1,y(x),x=-1),m=!0;var o=p;try{for(_(n),f=r(c);null!==f&&(!(f.expirationTime>n)||e&&!E());){var i=f.callback;if("function"===typeof i){f.callback=null,p=f.priorityLevel;var s=i(f.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?f.callback=s:f===r(c)&&a(c),_(n)}else a(c);f=r(c)}if(null!==f)var l=!0;else{var d=r(u);null!==d&&O(w,d.startTime-n),l=!1}return l}finally{f=null,p=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var S,C=!1,T=null,x=-1,F=5,P=-1;function E(){return!(t.unstable_now()-P<F)}function R(){if(null!==T){var e=t.unstable_now();P=e;var n=!0;try{n=T(!0,e)}finally{n?S():(C=!1,T=null)}}else C=!1}if("function"===typeof g)S=function(){g(R)};else if("undefined"!==typeof MessageChannel){var A=new MessageChannel,N=A.port2;A.port1.onmessage=R,S=function(){N.postMessage(null)}}else S=function(){b(R,0)};function I(e){T=e,C||(C=!0,S())}function O(e,n){x=b((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,I(k))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):F=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return p},t.unstable_getFirstCallbackNode=function(){return r(c)},t.unstable_next=function(e){switch(p){case 1:case 2:case 3:var t=3;break;default:t=p}var n=p;p=t;try{return e()}finally{p=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=p;p=e;try{return t()}finally{p=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(u,e),null===r(c)&&e===r(u)&&(v?(y(x),x=-1):v=!0,O(w,o-i))):(e.sortIndex=s,n(c,e),h||m||(h=!0,I(k))),e},t.unstable_shouldYield=E,t.unstable_wrapCallback=function(e){var t=p;return function(){var n=p;p=t;try{return e.apply(this,arguments)}finally{p=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),c=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),c=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),c.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=c.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function u(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=u.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var f=n(184);function p(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,f.jsx)(c,{styles:a})}var m=n(4205);var h=function(e){return(0,f.jsx)(p,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},b=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var y=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},b(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),k=n(8182),S=n(7312),C=n(1217),T=n(4419),x=n(8691),F=(0,n(4046).ZP)(),P=n(5080),E=["className","component","disableGutters","fixed","maxWidth","classes"],R=(0,P.Z)(),A=F("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,S.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),N=function(e){return(0,x.Z)({props:e,name:"MuiContainer",defaultTheme:R})},I=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,S.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,T.Z)(i,(function(e){return(0,C.Z)(t,e)}),n)};var O=n(9853),D=n(277),M=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?A:n,o=t.useThemeProps,i=void 0===o?N:o,s=t.componentName,l=void 0===s?"MuiContainer":s,c=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),u=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,u=n.disableGutters,d=void 0!==u&&u,p=n.fixed,m=void 0!==p&&p,h=n.maxWidth,v=void 0===h?"lg":h,b=(0,w.Z)(n,E),y=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=I(y,l);return(0,f.jsx)(c,(0,r.Z)({as:s,ownerState:y,className:(0,k.Z)(g.root,a),ref:t},b))}));return u}({createStyledComponent:(0,D.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,O.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),z=M,L=n(2421),Z=n(104),j=n(2982),B=n(2466),W=n(114),U=["sx"];function H(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){W.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,U)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,j.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,B.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var V=n(886),J=["className","component"];var $=n(5902),G=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?Z.Z:s,c=(0,L.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),u=e.forwardRef((function(e,t){var a=(0,V.Z)(n),s=H(e),l=s.className,u=s.component,d=void 0===u?"div":u,p=(0,w.Z)(s,J);return(0,f.jsx)(c,(0,r.Z)({as:d,ref:t,className:(0,k.Z)(l,i?i(o):o),theme:a},p))}));return u}({defaultTheme:(0,G.Z)(),defaultClassName:"MuiBox-root",generateClassName:$.Z.generate}),K=q,Q=JSON.parse('{"e":4,"C":[{"nctid":"NCT00450970","version_a":1,"version_b":2,"version_a_date":"2007-03-21","version_b_date":"2007-03-22","pom_a":[{"label":"1.","content":"The primary objective is to provide access to satraplatin for patients with HRPC who have been treated with one prior cytotoxic chemotherapy regimen and to evaluate the safety of satraplatin in these patients."}],"pom_b":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following one prior cytotoxic chemotherapy regimen for metastatic disease."}],"start_date":"February 2007","primary_completion_date":"March 2009","completion_date":"December 2009","first_posted":"March 22, 2007","last_update_posted":"August 17, 2012"},{"nctid":"NCT00450970","version_a":5,"version_b":6,"version_a_date":"2007-04-17","version_b_date":"2007-05-08","pom_a":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following one prior cytotoxic chemotherapy regimen for metastatic disease."}],"pom_b":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following one prior cytotoxic chemotherapy regimen for metastatic disease.[ Time Frame: Patient evaluation by MD at baseline to determine eligibility. ]"},{"label":"2.","content":"To evaluate the safety of Satraplatin in these patients.[ Time Frame: Weekly blood tests and evaluation by MD prior to each cycle and for thirty days following discontinuation of the therapy. ]"}],"start_date":"February 2007","primary_completion_date":"March 2009","completion_date":"December 2009","first_posted":"March 22, 2007","last_update_posted":"August 17, 2012"},{"nctid":"NCT00450970","version_a":6,"version_b":7,"version_a_date":"2007-05-08","version_b_date":"2007-05-11","pom_a":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following one prior cytotoxic chemotherapy regimen for metastatic disease.[ Time Frame: Patient evaluation by MD at baseline to determine eligibility. ]"},{"label":"2.","content":"To evaluate the safety of Satraplatin in these patients.[ Time Frame: Weekly blood tests and evaluation by MD prior to each cycle and for thirty days following discontinuation of the therapy. ]"}],"pom_b":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited prior cytotoxic chemotherapy regimens for metastatic disease.[ Time Frame: Patient evaluation by MD at baseline to determine eligibility. ]"},{"label":"2.","content":"To evaluate the safety of Satraplatin in these patients.[ Time Frame: Weekly blood tests and evaluation by MD prior to each cycle and for thirty days following discontinuation of the therapy. ]"}],"start_date":"February 2007","primary_completion_date":"March 2009","completion_date":"December 2009","first_posted":"March 22, 2007","last_update_posted":"August 17, 2012"},{"nctid":"NCT00450970","version_a":19,"version_b":20,"version_a_date":"2012-05-09","version_b_date":"2012-07-10","pom_a":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited prior cytotoxic chemotherapy regimens for metastatic disease.[ Time Frame: Patient evaluation by MD at baseline to determine eligibility. ]"},{"label":"2.","content":"To evaluate the safety of Satraplatin in these patients.[ Time Frame: Weekly blood tests and evaluation by MD prior to each cycle and for thirty days following discontinuation of the therapy. ]"}],"pom_b":[{"label":"1.","content":"The SPERA trial is designed to provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited prior cytotoxic chemotherapy regimens for metastatic disease.[ Time Frame: Patient evaluation by MD at baseline to determine eligibility. ]"}],"start_date":"February 2007","primary_completion_date":"March 2009","completion_date":"December 2009","first_posted":"March 22, 2007","last_update_posted":"August 17, 2012"},{"nctid":"NCT03024996","version_a":13,"version_b":14,"version_a_date":"2017-09-14","version_b_date":"2017-12-04","pom_a":[{"label":"1.","content":"Disease-Free Survival (DFS)[ Time Frame: From Baseline until first occurrence of DFS event (up to approximately 64 months) ]DFS is defined as the time from randomization to the first documented DFS event. DFS event includes any of the following: Local recurrence of RCC, New primary RCC, Distant metastasis of RCC, or Death from any cause. Tumor assessment will be as per investigator on the basis of radiographic evidence and whenever possible supported/confirmed by biopsy results."}],"pom_b":[{"label":"1.","content":"IRF-assessed Disease-Free Survival (DFS)[ Time Frame: From Baseline until first documented recurrence event (up to approximately 88 months) ]Independent Review Facility (IRF)-assessed DFS is defined as the time from randomization to the earliest death from any cause or the first documented recurrence event assessed by IRF, defined as any of the following: Local recurrence of renal cell carcinoma (RCC), new primary RCC, or distant metastasis of RCC. Tumor assessment will be as per IRF on the basis of radiographic evidence and whenever possible supported/confirmed by biopsy results."}],"start_date":"January 3, 2017","primary_completion_date":"May 3, 2022","completion_date":"December 31, 2022","first_posted":"January 19, 2017","last_update_posted":"September 14, 2022"},{"nctid":"NCT03024996","version_a":52,"version_b":53,"version_a_date":"2021-10-04","version_b_date":"2021-12-23","pom_a":[{"label":"1.","content":"IRF-assessed Disease-Free Survival (DFS)[ Time Frame: From Baseline until first documented recurrence event (up to approximately 88 months) ]Independent Review Facility (IRF)-assessed DFS is defined as the time from randomization to the earliest death from any cause or the first documented recurrence event assessed by IRF, defined as any of the following: Local recurrence of renal cell carcinoma (RCC), new primary RCC, or distant metastasis of RCC. Tumor assessment will be as per IRF on the basis of radiographic evidence and whenever possible supported/confirmed by biopsy results."}],"pom_b":[{"label":"1.","content":"Investigator-assessed DFS[ Time Frame: From Baseline up to first occurence of event by investigator assessment (up to approximately 88 months) ]Investigator-assessed DFS, defined as the time from randomization to death from any cause or the first documented recurrence assessed by investigator, whichever occurs first. Recurrence is defined as any of the following: Local recurrence of renal cell carcinoma (RCC), new primary RCC, or distant metastasis of RCC. Investigator-assessed DFS will be analyzed similarly to the analysis of IRF-assessed DFS."}],"start_date":"January 3, 2017","primary_completion_date":"May 3, 2022","completion_date":"December 31, 2022","first_posted":"January 19, 2017","last_update_posted":"September 14, 2022"},{"nctid":"NCT02101853","version_a":10,"version_b":11,"version_a_date":"2014-12-01","version_b_date":"2014-12-17","pom_a":[{"label":"1.","content":"2-year DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assesses at 2 years ]"},{"label":"2.","content":"3-year DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last followup for those who are event-free, assessed at 3 years ]"}],"pom_b":[{"label":"1.","content":"DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assesses up to 10 years ]"},{"label":"2.","content":"DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]"}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":37,"version_b":38,"version_a_date":"2015-04-09","version_b_date":"2015-06-01","pom_a":[{"label":"1.","content":"DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assesses up to 10 years ]"},{"label":"2.","content":"DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]"}],"pom_b":[{"label":"1.","content":"DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]"},{"label":"2.","content":"DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]"}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":121,"version_b":122,"version_a_date":"2016-05-18","version_b_date":"2016-06-24","pom_a":[{"label":"1.","content":"DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]"},{"label":"2.","content":"DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]"}],"pom_b":[{"label":"1.","content":"DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."},{"label":"2.","content":"DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":267,"version_b":268,"version_a_date":"2017-09-12","version_b_date":"2017-09-28","pom_a":[{"label":"1.","content":"DFS of HR and IR relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."},{"label":"2.","content":"DFS of LR relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."},{"label":"2.","content":"Disease free survival (DFS) of low risk (LR) relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":473,"version_b":474,"version_a_date":"2020-01-06","version_b_date":"2020-01-20","pom_a":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."},{"label":"2.","content":"Disease free survival (DFS) of low risk (LR) relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":476,"version_b":477,"version_a_date":"2020-03-02","version_b_date":"2020-03-26","pom_a":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: From start of Block 2 of therapy to event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: From start of Block 3 of therapy to first event (relapse, second malignant neoplasm, remission death) or last follow-up for those who are event-free, assessed up to 10 years ]Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries to be used will be based on the O\' Brien-Fleming spending function."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: From randomization to first event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Comparison of DFS rates between treatment arms will be based on log rank test. Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries are based on the O\' Brien-Fleming spending function. The futility boundaries are based on testing the alternative hypothesis at the 0.024 level."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: From randomization to first event (relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Comparison of DFS rates between treatment arms will be based on log rank test. Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries are based on the O\' Brien-Fleming spending function. The futility boundaries are based on testing the alternative hypothesis at the 0.039 level."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":499,"version_b":500,"version_a_date":"2022-03-30","version_b_date":"2022-04-20","pom_a":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: From randomization to first event (treatment failure, relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Comparison of DFS rates between treatment arms will be based on log rank test. Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries are based on the O\' Brien-Fleming spending function. The futility boundaries are based on testing the alternative hypothesis at the 0.024 level."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: From randomization to first event (relapse, second malignancy, death) or last follow-up for those who are event-free, assessed up to 10 years ]Comparison of DFS rates between treatment arms will be based on log rank test. Interim analysis will be conducted to monitor for efficacy and futility. The efficacy stopping boundaries are based on the O\' Brien-Fleming spending function. The futility boundaries are based on testing the alternative hypothesis at the 0.039 level."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: DFS is calculated as time from Up to 2 years from date of randomization ]DFS of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy itoto receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: DFS is calculated as time fUp to 3 years from date of randomization ]DFS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":501,"version_b":502,"version_a_date":"2022-04-21","version_b_date":"2022-04-22","pom_a":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: DFS is calculated as time from Up to 2 years from date of randomization ]DFS of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy itoto receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: DFS is calculated as time fUp to 3 years from date of randomization ]DFS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: DFS is calculated as time from up to 2 years from date of randomization ]DFS of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy itoto receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: DFS is calculated as time from up to 3 years from date of randomization ]DFS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT02101853","version_a":502,"version_b":503,"version_a_date":"2022-04-22","version_b_date":"2022-05-27","pom_a":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: DFS is calculated as time from up to 2 years from date of randomization ]DFS of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy itoto receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: DFS is calculated as time from up to 3 years from date of randomization ]DFS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated."}],"pom_b":[{"label":"1.","content":"Disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR) relapse patients[ Time Frame: Up to 2 years from date of randomization ]DFS of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy itoto receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated."},{"label":"2.","content":"DFS of low risk (LR) relapse patients[ Time Frame: Up to 3 years from date of randomization ]DFS of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated."}],"start_date":"December 8, 2014","primary_completion_date":"June 30, 2021","completion_date":"December 31, 2030","first_posted":"April 2, 2014","last_update_posted":"May 31, 2022"},{"nctid":"NCT01073865","version_a":10,"version_b":11,"version_a_date":"2012-12-21","version_b_date":"2013-12-09","pom_a":[{"label":"1.","content":"Efficacy: The primary outcome variable is Progression Free Survival (PFS) at 24 weeks. A PF patient is defined as a patient for whom neither objective disease progression nor death (due to any cause) has been observed[ Time Frame: At baseline, at week 12 and at week 24 ]"}],"pom_b":[{"label":"1.","content":"Number of Patients With Progression-free Survival (PFS) at 24 Weeks[ Time Frame: 24 weeks after the first dosing ]A patient is judged as progression-free survive at Week 24 if their PFS time is at least 24 weeks with no progression event prior to Week 24 (ie, overall visit response is complete response (CR), partial response (PR) or stable disease (SD) at a tumour assessment at least 24 weeks after randomization). Overall visit response is assessed according to the RECIST version 1.1. %PFS is the proportion of patients with PFS."}],"start_date":"February 26, 2010","primary_completion_date":"September 19, 2012","completion_date":"November 20, 2017","first_posted":"February 23, 2010","results_first_posted":"January 10, 2014","last_update_posted":"December 12, 2018"},{"nctid":"NCT00008411","version_a":9,"version_b":10,"version_a_date":"2008-07-23","version_b_date":"2010-08-02","pom_a":[],"pom_b":[{"label":"1.","content":"Objective Tumor Response Rate[ Time Frame: Weekly ]"}],"start_date":"December 1999","primary_completion_date":"March 2006","completion_date":"January 2007","first_posted":"January 27, 2003","last_update_posted":"July 30, 2012"},{"nctid":"NCT03562637","version_a":16,"version_b":17,"version_a_date":"2020-03-02","version_b_date":"2020-07-29","pom_a":[{"label":"1.","content":"Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.[ Time Frame: 5 years ]IDFS is defined as the time interval from the \\"date of randomization to the date of objective invasive tumor recurrence\\" i.e., the appearance of any new invasive lesion(s), during or after study treatment."}],"pom_b":[{"label":"1.","content":"Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.[ Time Frame: 5 years ]The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of secondary primary invasive cancer (breast or not), or the date of death from any cause."}],"start_date":"December 5, 2018","primary_completion_date":"December 30, 2025","completion_date":"December 30, 2027","first_posted":"June 19, 2018","last_update_posted":"July 7, 2022"},{"nctid":"NCT04499924","version_a":8,"version_b":9,"version_a_date":"2021-04-12","version_b_date":"2021-04-28","pom_a":[{"label":"1.","content":"Overall survival (OS) (Phase 3 only)[ Time Frame: 60 months ]OS is defined as the time from randomization to death due to any cause"},{"label":"2.","content":"Progression-free survival (PFS) per RECIST version 1.1 according to investigator assessment (Phase 3 only)[ Time Frame: 36 months ]PFS is defined as the time from randomization to the date of disease progression or death from any cause"},{"label":"3.","content":"Incidence of dose-limiting toxicities (DLTs) (Phase 2 only)[ Time Frame: During first cycle of treatment; up to one month ]"},{"label":"4.","content":"Incidence of adverse events (AEs) (Phase 2 only)[ Time Frame: 18 months ]"},{"label":"5.","content":"Incidence of dose modifications (Phase 2 only)[ Time Frame: 18 months ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) (Phase 3 only)[ Time Frame: 60 months ]OS is defined as the time from randomization to death due to any cause"},{"label":"2.","content":"Progression-free survival (PFS) per Response evaluation criteria in solid tumors (RECIST) version 1.1 according to investigator assessment (Phase 3 only)[ Time Frame: 36 months ]PFS is defined as the time from randomization to the date of disease progression or death from any cause"},{"label":"3.","content":"Incidence of dose-limiting toxicities (DLTs) (Phase 2 only)[ Time Frame: During first cycle of treatment; up to one month ]"},{"label":"4.","content":"Incidence of adverse events (AEs) (Phase 2 only)[ Time Frame: 18 months ]An adverse event is any untoward medical occurrence in a subject or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."},{"label":"5.","content":"Incidence of laboratory abnormalities (Phase 2 only)[ Time Frame: 18 months ]To be summarized using descriptive statistics."},{"label":"6.","content":"Incidence of dose modifications (Phase 2 only)[ Time Frame: 18 months ]"}],"start_date":"March 22, 2021","primary_completion_date":"May 31, 2025","completion_date":"March 31, 2027","first_posted":"August 5, 2020","last_update_posted":"August 26, 2022"},{"nctid":"NCT02563561","version_a":11,"version_b":12,"version_a_date":"2020-11-11","version_b_date":"2021-08-30","pom_a":[{"label":"1.","content":"Time to Recurrence[ Time Frame: 2 Years ]To evaluate the Time to Recurrence with either a one instillation of 4 mg apaziquone or two instillations of 4 mg apaziquone relative to placebo instillation following TURBT in patients with non-muscle invasive bladder cancer (NMIBC) who receive transurethral resection bladder tumor (TURBT)"}],"pom_b":[{"label":"1.","content":"Time to Recurrence[ Time Frame: From randomization to the date of first histologically confirmed recurrence of bladder cancer (up to 1.5 years) ]Time from randomization to the date of histologically confirmed recurrence of bladder cancer. A recurrence was defined as any pathologically confirmed disease of \u2265Ta tumor histology or carcinoma in situ (CIS) post-treatment."}],"start_date":"October 9, 2015","primary_completion_date":"March 10, 2017","completion_date":"March 10, 2017","first_posted":"September 30, 2015","results_first_posted":"September 27, 2021","last_update_posted":"October 27, 2021"},{"nctid":"NCT01732913","version_a":2,"version_b":3,"version_a_date":"2013-01-10","version_b_date":"2013-02-18","pom_a":[{"label":"1.","content":"Progression Free SurvivalTo evaluate the effect of the addition of GS-1101 to rituximab on progression-free survival in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Every 12 weeks ]To evaluate the effect of the addition of GS-1101 to rituximab on progression-free survival in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)"}],"start_date":"January 16, 2013","primary_completion_date":"May 18, 2016","completion_date":"May 18, 2016","first_posted":"November 26, 2012","results_first_posted":"May 11, 2017","last_update_posted":"November 16, 2018"},{"nctid":"NCT01732913","version_a":3,"version_b":4,"version_a_date":"2013-02-18","version_b_date":"2013-02-22","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Every 12 weeks ]To evaluate the effect of the addition of GS-1101 to rituximab on progression-free survival in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Every 12 weeks ]To evaluate the effect of the addition of idelalisib (GS-1101) to rituximab on progression-free survival in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)"}],"start_date":"January 16, 2013","primary_completion_date":"May 18, 2016","completion_date":"May 18, 2016","first_posted":"November 26, 2012","results_first_posted":"May 11, 2017","last_update_posted":"November 16, 2018"},{"nctid":"NCT01732913","version_a":22,"version_b":23,"version_a_date":"2014-07-01","version_b_date":"2014-09-10","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Every 12 weeks ]To evaluate the effect of the addition of idelalisib (GS-1101) to rituximab on progression-free survival in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL)"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Up to 8 years ]Progression-free survival (PFS) is defined as the interval from initial randomization to the earlier of the first documentation of definitive iNHL disease progression or death from any cause; definitive iNHL disease progression is progression based on standard criteria."}],"start_date":"January 16, 2013","primary_completion_date":"May 18, 2016","completion_date":"May 18, 2016","first_posted":"November 26, 2012","results_first_posted":"May 11, 2017","last_update_posted":"November 16, 2018"},{"nctid":"NCT01732913","version_a":39,"version_b":40,"version_a_date":"2016-05-25","version_b_date":"2017-03-30","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Up to 8 years ]Progression-free survival (PFS) is defined as the interval from initial randomization to the earlier of the first documentation of definitive iNHL disease progression or death from any cause; definitive iNHL disease progression is progression based on standard criteria."}],"pom_b":[{"label":"1.","content":"Progression Free SurvivalProgression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive indolent non-Hodgkin lymphoma (iNHL) disease progression or death from any cause. PFS was to be assessed by an independent review committee (IRC)."}],"start_date":"January 16, 2013","primary_completion_date":"May 18, 2016","completion_date":"May 18, 2016","first_posted":"November 26, 2012","results_first_posted":"May 11, 2017","last_update_posted":"November 16, 2018"},{"nctid":"NCT03927027","version_a":1,"version_b":2,"version_a_date":"2019-04-24","version_b_date":"2019-04-26","pom_a":[{"label":"1.","content":"Incidence of upper extremity (UE) lymphedema[ Time Frame: Up to 36 months post surgery ]A patient will be considered to have developed UE lymphedema if there is a 10% increase in the volume of her ipsilateral UE from its pre-surgery volume after adjusting for percent change in body mass index (BMI). Physician diagnosed lymphedema will still need to be confirmed by arm circumference measurements. The cumulative incidence of lymphedema at 12, 24, and 36 months post-surgery will be estimated by treatment group using the cumulative incidence function treating death as a competing risk. Will compare between the two study groups using a two-sample test of proportions (i.e. a Z-test using a normal approximation), at a two-sided 5% significance level."}],"pom_b":[{"label":"1.","content":"Incidence of upper extremity (UE) lymphedema[ Time Frame: Up to 36 months post surgery ]Will be assessed by the Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A). The LSIDS-A questionnaire contains two different scales for intensity and distress measured from 1 (slight) to 5 (severe). The LSIDS-A questionnaire scores for swelling in the arm, decreased physical activity, pain in the arm, and loss of confidence in one\'s body will be evaluated for the change of baseline to 36 months using a two-sample, two-sided t-test."}],"start_date":"May 31, 2019","primary_completion_date":"September 2023","completion_date":"January 2024","first_posted":"April 25, 2019","last_update_posted":"March 24, 2022"},{"nctid":"NCT01863550","version_a":7,"version_b":8,"version_a_date":"2017-12-07","version_b_date":"2018-01-26","pom_a":[{"label":"1.","content":"Overall survival for the maintenance analysis[ Time Frame: From the maintenance randomization to death due to any cause or, censored at the date last known alive, assessed up to 15 years ]The Kaplan-Meier (KM) method will be used to describe the overall survival function by arm."}],"pom_b":[{"label":"1.","content":"Overall survival (OS) for the maintenance analysis[ Time Frame: From the maintenance randomization to death due to any cause or, censored at the date last known alive, assessed up to 15 years ]The Kaplan-Meier (KM) method will be used to describe the overall survival function by arm. Sensitivity analysis will be done to evaluate OS in the subset of eligible patients and censoring patients at time of non-protocol therapy."},{"label":"2.","content":"Progression-free survival for the induction analysis[ Time Frame: From the induction randomization until the earlier of progression or death due to any cause, assessed up to 15 years ]The Kaplan-Meier method will be used to describe the progression-free survival function by arm using all data while ignoring maintenance."}],"start_date":"December 2, 2013","primary_completion_date":"November 1, 2023","completion_date":"February 5, 2034","first_posted":"May 29, 2013","last_update_posted":"January 3, 2022"},{"nctid":"NCT01077518","version_a":1,"version_b":2,"version_a_date":"2010-02-25","version_b_date":"2010-08-31","pom_a":[{"label":"1.","content":"Progression-free-survival following ofatumumab and bendamustine combination therapy[ Time Frame: 62 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free-survival following ofatumumab and bendamustine combination therapy[ Time Frame: 68 months ]"}],"start_date":"August 26, 2010","primary_completion_date":"January 3, 2018","completion_date":"December 26, 2018","first_posted":"March 1, 2010","results_first_posted":"March 27, 2020","last_update_posted":"March 27, 2020"},{"nctid":"NCT01077518","version_a":130,"version_b":131,"version_a_date":"2017-05-25","version_b_date":"2017-06-28","pom_a":[{"label":"1.","content":"Progression-free-survival following ofatumumab and bendamustine combination therapy[ Time Frame: 68 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free-survival following ofatumumab and bendamustine combination therapy[ Time Frame: 89 months ]"}],"start_date":"August 26, 2010","primary_completion_date":"January 3, 2018","completion_date":"December 26, 2018","first_posted":"March 1, 2010","results_first_posted":"March 27, 2020","last_update_posted":"March 27, 2020"},{"nctid":"NCT01077518","version_a":139,"version_b":140,"version_a_date":"2019-10-16","version_b_date":"2020-03-25","pom_a":[{"label":"1.","content":"Progression-free-survival following ofatumumab and bendamustine combination therapy[ Time Frame: 89 months ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)[ Time Frame: From randomization to the date of first documented disease progression or death due to any cause (67.5 months) ]PFS is defined as the time interval between randomization until disease progression or death (due to any cause)."}],"start_date":"August 26, 2010","primary_completion_date":"January 3, 2018","completion_date":"December 26, 2018","first_posted":"March 1, 2010","results_first_posted":"March 27, 2020","last_update_posted":"March 27, 2020"},{"nctid":"NCT00720109","version_a":252,"version_b":253,"version_a_date":"2012-07-19","version_b_date":"2012-07-20","pom_a":[{"label":"1.","content":"Feasibility as assessed by examining the adverse events, delays in administering combination therapy, minimal residual disease (MRD) levels at the completion of induction therapy and consolidation therapy, and event-free survival (EFS)"},{"label":"2.","content":"Toxicity as assessed by NCI CTCAE v3.0"},{"label":"3.","content":"3-year event-free survival (EFS) of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy"}],"pom_b":[{"label":"1.","content":"Feasibility of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL assessed by examining adverse events[ Time Frame: Up to 131 weeks of study treatment ]Feasibility will be defined as the ability to safely add dasatinib to the AALL0031 chemotherapy backbone either when given discontinuously (in 2-week periods followed by 1 to 2 weeks off) or continuously."},{"label":"2.","content":"Toxicity of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: From the time of first treatment, assessed up to 10 years ]"},{"label":"3.","content":"EFS of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy[ Time Frame: At 3 years ]EFS curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."}],"start_date":"July 14, 2008","primary_completion_date":"December 31, 2014","completion_date":"March 31, 2020","first_posted":"July 22, 2008","results_first_posted":"October 7, 2016","last_update_posted":"April 13, 2020"},{"nctid":"NCT00720109","version_a":259,"version_b":260,"version_a_date":"2013-03-04","version_b_date":"2013-05-06","pom_a":[{"label":"1.","content":"Feasibility of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL assessed by examining adverse events[ Time Frame: Up to 131 weeks of study treatment ]Feasibility will be defined as the ability to safely add dasatinib to the AALL0031 chemotherapy backbone either when given discontinuously (in 2-week periods followed by 1 to 2 weeks off) or continuously."},{"label":"2.","content":"Toxicity of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: From the time of first treatment, assessed up to 10 years ]"},{"label":"3.","content":"EFS of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy[ Time Frame: At 3 years ]EFS curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."}],"pom_b":[{"label":"1.","content":"Feasibility of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL assessed by examining adverse events[ Time Frame: Up to 131 weeks of study treatment ]Feasibility will be defined as the ability to safely add dasatinib to the AALL0031 chemotherapy backbone either when given discontinuously (in 2-week periods followed by 1 to 2 weeks off) or continuously."},{"label":"2.","content":"Toxicity of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: From the time of first treatment, assessed up to 7 years ]"},{"label":"3.","content":"EFS of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy[ Time Frame: At 3 years ]EFS curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."}],"start_date":"July 14, 2008","primary_completion_date":"December 31, 2014","completion_date":"March 31, 2020","first_posted":"July 22, 2008","results_first_posted":"October 7, 2016","last_update_posted":"April 13, 2020"},{"nctid":"NCT00720109","version_a":285,"version_b":286,"version_a_date":"2015-02-09","version_b_date":"2015-04-09","pom_a":[{"label":"1.","content":"Feasibility of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL assessed by examining adverse events[ Time Frame: Up to 131 weeks of study treatment ]Feasibility will be defined as the ability to safely add dasatinib to the AALL0031 chemotherapy backbone either when given discontinuously (in 2-week periods followed by 1 to 2 weeks off) or continuously."},{"label":"2.","content":"Toxicity of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: From the time of first treatment, assessed up to 7 years ]"},{"label":"3.","content":"EFS of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy[ Time Frame: At 3 years ]EFS curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."}],"pom_b":[{"label":"1.","content":"EFS of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy[ Time Frame: At 3 years ]EFS curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."},{"label":"2.","content":"Feasibility of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL assessed by examining adverse events[ Time Frame: Up to 131 weeks of study treatment ]Feasibility will be defined as the ability to safely add dasatinib to the AALL0031 chemotherapy backbone either when given discontinuously (in 2-week periods followed by 1 to 2 weeks off) or continuously."},{"label":"3.","content":"Toxicity of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: From the time of first treatment, assessed up to 7 years ]"}],"start_date":"July 14, 2008","primary_completion_date":"December 31, 2014","completion_date":"March 31, 2020","first_posted":"July 22, 2008","results_first_posted":"October 7, 2016","last_update_posted":"April 13, 2020"},{"nctid":"NCT00720109","version_a":300,"version_b":301,"version_a_date":"2016-03-25","version_b_date":"2016-09-08","pom_a":[{"label":"1.","content":"EFS of patients with standard-risk disease treated with dasatinib in combination with intensified chemotherapy[ Time Frame: At 3 years ]EFS curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."},{"label":"2.","content":"Feasibility of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL assessed by examining adverse events[ Time Frame: Up to 131 weeks of study treatment ]Feasibility will be defined as the ability to safely add dasatinib to the AALL0031 chemotherapy backbone either when given discontinuously (in 2-week periods followed by 1 to 2 weeks off) or continuously."},{"label":"3.","content":"Toxicity of an intensified chemotherapeutic regimen incorporating dasatinib for treatment of children and adolescents with Ph+ ALL as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0[ Time Frame: From the time of first treatment, assessed up to 7 years ]"}],"pom_b":[{"label":"1.","content":"Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy[ Time Frame: At 3 years ]Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed."},{"label":"2.","content":"Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events[ Time Frame: Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1) ]Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay)"}],"start_date":"July 14, 2008","primary_completion_date":"December 31, 2014","completion_date":"March 31, 2020","first_posted":"July 22, 2008","results_first_posted":"October 7, 2016","last_update_posted":"April 13, 2020"},{"nctid":"NCT00003139","version_a":10,"version_b":11,"version_a_date":"2009-05-09","version_b_date":"2013-12-11","pom_a":[],"pom_b":[{"label":"1.","content":"Acute salivary gland toxicity[ Time Frame: From the start of treatment to 13 weeks ]"}],"start_date":"March 1998","primary_completion_date":"January 2001","completion_date":"October 2002","first_posted":"September 6, 2004","last_update_posted":"November 17, 2015"},{"nctid":"NCT03662126","version_a":10,"version_b":11,"version_a_date":"2019-11-22","version_b_date":"2021-01-28","pom_a":[{"label":"1.","content":"To determine spleen response[ Time Frame: 24 weeks ]The proportion of patients achieving a \u2265 35% spleen volume reduction from Baseline to Week 24, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scan"}],"pom_b":[{"label":"1.","content":"(Part A Only) Spleen Volume Reduction (SVR)[ Time Frame: 24 weeks ]The proportion of subjects achieving a \u2265 35% spleen volume reduction (SVR) from Baseline to Week 24, as assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scan"},{"label":"2.","content":"(Part B Only) Spleen Volume Reduction (SVR)[ Time Frame: 24 Weeks ]The proportion of subjects achieving SVR of \u2265 35% at Week 24 by MRI/CT scan (central review)"}],"start_date":"January 15, 2019","primary_completion_date":"December 31, 2023","completion_date":"December 31, 2025","first_posted":"September 7, 2018","last_update_posted":"August 15, 2022"},{"nctid":"NCT00869206","version_a":409,"version_b":410,"version_a_date":"2012-04-17","version_b_date":"2015-07-20","pom_a":[{"label":"1.","content":"Proportion of patients with \u2265 1 skeletal-related event within 2 years after randomization"}],"pom_b":[{"label":"1.","content":"Proportion of patients with at least one skeletal-related event (SRE) within 2 years after randomization[ Time Frame: 2 years ]SRE is defined as a pathologic fracture, spinal cord compression, surgery to bone and radiation therapy to bone. The Kaplan-Meier method and a stratified Cox regression analysis will be used to compare time to first SRE between treatment arms. The Cochran-Mantel-Haenszel test, stratified by randomization factors, will be used to compare the proportion of patients with at least one SRE at 24 months between treatment groups. Logistic regression models will be used to assess the relationship with treatment arms, while adjusting for any imbalances of patient-specific covariates at baseline."}],"start_date":"March 2009","primary_completion_date":"June 2014","completion_date":"January 2017","first_posted":"March 25, 2009","results_first_posted":"November 7, 2018","last_update_posted":"November 7, 2018"},{"nctid":"NCT00869206","version_a":410,"version_b":411,"version_a_date":"2015-07-20","version_b_date":"2015-07-23","pom_a":[{"label":"1.","content":"Proportion of patients with at least one skeletal-related event (SRE) within 2 years after randomization[ Time Frame: 2 years ]SRE is defined as a pathologic fracture, spinal cord compression, surgery to bone and radiation therapy to bone. The Kaplan-Meier method and a stratified Cox regression analysis will be used to compare time to first SRE between treatment arms. The Cochran-Mantel-Haenszel test, stratified by randomization factors, will be used to compare the proportion of patients with at least one SRE at 24 months between treatment groups. Logistic regression models will be used to assess the relationship with treatment arms, while adjusting for any imbalances of patient-specific covariates at baseline."}],"pom_b":[{"label":"1.","content":"Proportion of patients with at least one skeletal-related event (SRE) within 2 years after randomization[ Time Frame: 2 years ]"}],"start_date":"March 2009","primary_completion_date":"June 2014","completion_date":"January 2017","first_posted":"March 25, 2009","results_first_posted":"November 7, 2018","last_update_posted":"November 7, 2018"},{"nctid":"NCT00869206","version_a":413,"version_b":414,"version_a_date":"2016-10-04","version_b_date":"2018-10-08","pom_a":[{"label":"1.","content":"Proportion of patients with at least one skeletal-related event (SRE) within 2 years after randomization[ Time Frame: 2 years ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization[ Time Frame: 2 years ]To determine whether every-12-week therapy with zoledronic acid is not inferior to every-4-week therapy for patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma involving bone, as measured by the proportion of patients who would have experienced at least one skeletal related event within 24 months after randomization."}],"start_date":"March 2009","primary_completion_date":"June 2014","completion_date":"January 2017","first_posted":"March 25, 2009","results_first_posted":"November 7, 2018","last_update_posted":"November 7, 2018"},{"nctid":"NCT00304070","version_a":11,"version_b":12,"version_a_date":"2006-12-20","version_b_date":"2006-12-27","pom_a":[],"pom_b":[{"label":"1.","content":"Primary tumor measurement"},{"label":"2.","content":"Measurable metastatic disease"},{"label":"3.","content":"Response of metastatic target lesions"},{"label":"4.","content":"Nonmeasurable metastatic disease"},{"label":"5.","content":"Overall response"}],"start_date":"September 18, 2006","primary_completion_date":"December 31, 2015","first_posted":"March 17, 2006","results_first_posted":"June 12, 2017","last_update_posted":"March 25, 2022"},{"nctid":"NCT00304070","version_a":248,"version_b":249,"version_a_date":"2012-11-03","version_b_date":"2013-06-14","pom_a":[{"label":"1.","content":"Primary tumor measurement"},{"label":"2.","content":"Measurable metastatic disease"},{"label":"3.","content":"Response of metastatic target lesions"},{"label":"4.","content":"Nonmeasurable metastatic disease"},{"label":"5.","content":"Overall response"}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: At 2 years ]The model used for comparison will be an exponential model with a constant failure rate of 0.053 (stratum I), 0.347 (stratum II), 0.602 (stratum III and IV) per year for the first two years and 0 after that. The one-sample one-sided log-rank test comparing the observed data with the hypothesized model (Woolson, 1981) of size 0.05 will be used to assess whether the data are consistent with the target models. Since this test has independent increments, the method of Lan and DeMets will be used to derive the p-values for testing procedure."}],"start_date":"September 18, 2006","primary_completion_date":"December 31, 2015","first_posted":"March 17, 2006","results_first_posted":"June 12, 2017","last_update_posted":"March 25, 2022"},{"nctid":"NCT00304070","version_a":252,"version_b":253,"version_a_date":"2016-03-17","version_b_date":"2017-05-11","pom_a":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: At 2 years ]The model used for comparison will be an exponential model with a constant failure rate of 0.053 (stratum I), 0.347 (stratum II), 0.602 (stratum III and IV) per year for the first two years and 0 after that. The one-sample one-sided log-rank test comparing the observed data with the hypothesized model (Woolson, 1981) of size 0.05 will be used to assess whether the data are consistent with the target models. Since this test has independent increments, the method of Lan and DeMets will be used to derive the p-values for testing procedure."}],"pom_b":[{"label":"1.","content":"Five Year Event-free Survival (EFS)[ Time Frame: Up to five years after enrollment ]The model used for comparison will be an exponential model with a constant failure rate of 0.053 (stratum I), 0.347 (stratum II), 0.602 (stratum III and IV) per year for the first two years and 0 after that. The one-sample one-sided log-rank test comparing the observed data with the hypothesized model (Woolson, 1981) of size 0.05 will be used to assess whether the data are consistent with the target models. Since this test has independent increments, the method of Lan and DeMets will be used to derive the p-values for testing procedure."}],"start_date":"September 18, 2006","primary_completion_date":"December 31, 2015","first_posted":"March 17, 2006","results_first_posted":"June 12, 2017","last_update_posted":"March 25, 2022"},{"nctid":"NCT02166463","version_a":5,"version_b":6,"version_a_date":"2014-12-12","version_b_date":"2015-01-23","pom_a":[{"label":"1.","content":"EFS where events include disease progression or relapse, second malignancy, or death[ Time Frame: Up to 48 months ]Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle."}],"pom_b":[{"label":"1.","content":"EFS, where events include disease progression or relapse, second malignancy, or death[ Time Frame: Up to 48 months ]Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle."}],"start_date":"March 16, 2015","primary_completion_date":"December 31, 2021","completion_date":"January 14, 2023","first_posted":"June 18, 2014","last_update_posted":"September 19, 2022"},{"nctid":"NCT02166463","version_a":214,"version_b":215,"version_a_date":"2017-07-17","version_b_date":"2017-08-03","pom_a":[{"label":"1.","content":"EFS, where events include disease progression or relapse, second malignancy, or death[ Time Frame: Up to 48 months ]Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle."}],"pom_b":[{"label":"1.","content":"Event free survival (EFS), where events include disease progression or relapse, second malignancy, or death[ Time Frame: Up to 48 months ]Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle."}],"start_date":"March 16, 2015","primary_completion_date":"December 31, 2021","completion_date":"January 14, 2023","first_posted":"June 18, 2014","last_update_posted":"September 19, 2022"},{"nctid":"NCT02166463","version_a":439,"version_b":440,"version_a_date":"2022-04-05","version_b_date":"2022-04-28","pom_a":[{"label":"1.","content":"Event free survival (EFS), where events include disease progression or relapse, second malignancy, or death[ Time Frame: Up to 48 months ]Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle."}],"pom_b":[{"label":"1.","content":"Event free survival (EFS), where events include disease progression or relapse, second malignancy, or death[ Time Frame: Up to 48 months after the last enrollment ]Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle."}],"start_date":"March 16, 2015","primary_completion_date":"December 31, 2021","completion_date":"January 14, 2023","first_posted":"June 18, 2014","last_update_posted":"September 19, 2022"},{"nctid":"NCT03794440","version_a":2,"version_b":3,"version_a_date":"2019-02-11","version_b_date":"2020-07-13","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: up to 24 months after randomization ]"},{"label":"2.","content":"Objective response rate (ORR)[ Time Frame: up to 24 months after randomization ]Objective response rate (ORR) in two arms based on RECIST V1.1 by Independent Radiological Review Committee,IRRC ."}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: up to 24 months after randomization ]"},{"label":"2.","content":"Progression-free survival (PFS)[ Time Frame: up to 24 months after randomization ]Progression-free survival (PFS) in two arms based on RECIST V1.1 by Independent Radiological Review Committee, IRRC."}],"start_date":"February 11, 2019","primary_completion_date":"December 2022","completion_date":"December 2022","first_posted":"January 7, 2019","last_update_posted":"January 22, 2021"},{"nctid":"NCT00047008","version_a":16,"version_b":17,"version_a_date":"2012-06-26","version_b_date":"2013-06-26","pom_a":[],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization to date of death or last follow-up. Analysis occurs after 309 deaths have been reported. ]"}],"start_date":"July 2002","primary_completion_date":"June 2010","completion_date":"May 20, 2022","first_posted":"January 27, 2003","results_first_posted":"August 15, 2014","last_update_posted":"June 14, 2022"},{"nctid":"NCT00047008","version_a":17,"version_b":18,"version_a_date":"2013-06-26","version_b_date":"2014-07-28","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization to date of death or last follow-up. Analysis occurs after 309 deaths have been reported. ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (3-year Rate)[ Time Frame: From randomization to date of death or last follow-up. Analysis occurs after 309 deaths have been reported. ]Time from randomization to death due to any cause or last known date alive. Median survival was not reached, therefore 3-year survival rates are reported."}],"start_date":"July 2002","primary_completion_date":"June 2010","completion_date":"May 20, 2022","first_posted":"January 27, 2003","results_first_posted":"August 15, 2014","last_update_posted":"June 14, 2022"},{"nctid":"NCT00032084","version_a":11,"version_b":12,"version_a_date":"2009-02-06","version_b_date":"2013-03-08","pom_a":[],"pom_b":[{"label":"1.","content":"To compare the effect on 12 month quit rates of adding an anti-depressant versus placebo in a double blind to an intervention and nicotine replacement in complete resected Stage I and II non-small cell lung cancer patients who are current smokers[ Time Frame: 12 months ]"}],"start_date":"January 2002","primary_completion_date":"February 2004","completion_date":"February 2004","first_posted":"January 27, 2003","last_update_posted":"March 11, 2013"},{"nctid":"NCT00671034","version_a":106,"version_b":107,"version_a_date":"2012-07-19","version_b_date":"2013-03-14","pom_a":[{"label":"1.","content":"Pharmacokinetics of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy"}],"pom_b":[{"label":"1.","content":"Pharmacokinetics of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: 2 years ]Determine the PK of EZN-2285 and Oncaspar\xae during Induction and during Consolidation therapy in patients with high-risk ALL receiving augmented BFM therapy and receiving EZN-2285 or Oncaspar\xae."}],"start_date":"July 21, 2008","primary_completion_date":"February 1, 2011","completion_date":"March 31, 2021","first_posted":"May 2, 2008","results_first_posted":"September 6, 2018","last_update_posted":"April 27, 2021"},{"nctid":"NCT00671034","version_a":107,"version_b":108,"version_a_date":"2013-03-14","version_b_date":"2014-02-27","pom_a":[{"label":"1.","content":"Pharmacokinetics of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: 2 years ]Determine the PK of EZN-2285 and Oncaspar\xae during Induction and during Consolidation therapy in patients with high-risk ALL receiving augmented BFM therapy and receiving EZN-2285 or Oncaspar\xae."}],"pom_b":[{"label":"1.","content":"Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: At baseline and days 4, 5, 6, 8, 15, 22 and 29 of induction, and days 15, 16, 17, 22, 29, 36 and 43 of consolidation ]For statistical comparisons and other analyses, study results of EZN-2285 2100 IU/m^2 and EZN-2285 2500 IU/m^2 will be tabulated separately, whereas results of Oncaspar\xae 2500 IU/m^2 throughout the entire study will be combined, unless otherwise specified. Descriptive statistics including mean, standard deviation, coefficient of variation, median, and minimum and maximum will be computed for each PK parameter for the induction and for the consolidation data. In addition, mean and median plasma concentration versus time graphs will be provided."}],"start_date":"July 21, 2008","primary_completion_date":"February 1, 2011","completion_date":"March 31, 2021","first_posted":"May 2, 2008","results_first_posted":"September 6, 2018","last_update_posted":"April 27, 2021"},{"nctid":"NCT00671034","version_a":111,"version_b":112,"version_a_date":"2016-07-11","version_b_date":"2016-11-14","pom_a":[{"label":"1.","content":"Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: At baseline and days 4, 5, 6, 8, 15, 22 and 29 of induction, and days 15, 16, 17, 22, 29, 36 and 43 of consolidation ]For statistical comparisons and other analyses, study results of EZN-2285 2100 IU/m^2 and EZN-2285 2500 IU/m^2 will be tabulated separately, whereas results of Oncaspar\xae 2500 IU/m^2 throughout the entire study will be combined, unless otherwise specified. Descriptive statistics including mean, standard deviation, coefficient of variation, median, and minimum and maximum will be computed for each PK parameter for the induction and for the consolidation data. In addition, mean and median plasma concentration versus time graphs will be provided."}],"pom_b":[{"label":"1.","content":"Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: At day 25 of induction, and day 25 of consolidation ]For statistical comparisons and other analyses, study results of EZN-2285 2100 IU/m^2 and EZN-2285 2500 IU/m^2 will be tabulated separately, whereas results of Oncaspar\xae 2500 IU/m^2 throughout the entire study will be combined, unless otherwise specified. Descriptive statistics including mean, standard deviation, coefficient of variation, median, and minimum and maximum will be computed for each PK parameter for the induction and for the consolidation data. In addition, mean and median plasma concentration versus time graphs will be provided."}],"start_date":"July 21, 2008","primary_completion_date":"February 1, 2011","completion_date":"March 31, 2021","first_posted":"May 2, 2008","results_first_posted":"September 6, 2018","last_update_posted":"April 27, 2021"},{"nctid":"NCT00671034","version_a":113,"version_b":114,"version_a_date":"2016-11-21","version_b_date":"2016-12-13","pom_a":[{"label":"1.","content":"Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: At day 25 of induction, and day 25 of consolidation ]For statistical comparisons and other analyses, study results of EZN-2285 2100 IU/m^2 and EZN-2285 2500 IU/m^2 will be tabulated separately, whereas results of Oncaspar\xae 2500 IU/m^2 throughout the entire study will be combined, unless otherwise specified. Descriptive statistics including mean, standard deviation, coefficient of variation, median, and minimum and maximum will be computed for each PK parameter for the induction and for the consolidation data. In addition, mean and median plasma concentration versus time graphs will be provided."}],"pom_b":[{"label":"1.","content":"Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: Up to Day 29 of Induction and Up to Day 43 of Consolidation ]For statistical comparisons and other analyses, study results of EZN-2285 2100 IU/m^2 and EZN-2285 2500 IU/m^2 will be tabulated separately, whereas results of Oncaspar\xae 2500 IU/m^2 throughout the entire study will be combined, unless otherwise specified. Descriptive statistics including mean, standard deviation, coefficient of variation, median, and minimum and maximum will be computed for each PK parameter for the induction and for the consolidation data. In addition, mean and median plasma concentration versus time graphs will be provided."}],"start_date":"July 21, 2008","primary_completion_date":"February 1, 2011","completion_date":"March 31, 2021","first_posted":"May 2, 2008","results_first_posted":"September 6, 2018","last_update_posted":"April 27, 2021"},{"nctid":"NCT00671034","version_a":115,"version_b":116,"version_a_date":"2016-12-14","version_b_date":"2018-09-04","pom_a":[{"label":"1.","content":"Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy[ Time Frame: Up to Day 29 of Induction and Up to Day 43 of Consolidation ]For statistical comparisons and other analyses, study results of EZN-2285 2100 IU/m^2 and EZN-2285 2500 IU/m^2 will be tabulated separately, whereas results of Oncaspar\xae 2500 IU/m^2 throughout the entire study will be combined, unless otherwise specified. Descriptive statistics including mean, standard deviation, coefficient of variation, median, and minimum and maximum will be computed for each PK parameter for the induction and for the consolidation data. In addition, mean and median plasma concentration versus time graphs will be provided."}],"pom_b":[{"label":"1.","content":"Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)[ Time Frame: Post Day 29 of Induction and Post Day 22 of Consolidation ]Mean half-life of plasma asparaginase during consolidation and Induction; half-life is defined as the time taken for drug concentration to decrease by half."}],"start_date":"July 21, 2008","primary_completion_date":"February 1, 2011","completion_date":"March 31, 2021","first_posted":"May 2, 2008","results_first_posted":"September 6, 2018","last_update_posted":"April 27, 2021"},{"nctid":"NCT01342965","version_a":53,"version_b":54,"version_a_date":"2014-11-10","version_b_date":"2015-02-05","pom_a":[{"label":"1.","content":"Progression-free survival (tumor assessments according to RECIST criteria)[ Time Frame: approximately 21 months ]"}],"pom_b":[{"label":"1.","content":"Investigator-assessed Duration of Progression-free Survival[ Time Frame: Baseline to the data cut-off date of 20 Jul 2012 (1 year, 4 months) ]The duration of progression-free survival was defined as the time from randomization to disease progression (PD) or death from any cause, whichever occurs first. PD was defined as: (1) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this may include the baseline sum). The sum must also demonstrate an absolute increase of at least 5 mm. (2) An unequivocal progression of existing non-target lesions. When the patient has measurable disease, the overall tumor burden must have increased sufficiently to merit discontinuation of therapy. When the patient has only non-measurable disease, the increase in overall disease burden should be comparable in magnitude to the increase that would be required to declare PD for measurable disease. (3) The appearance of new malignant lesions."}],"start_date":"March 2011","primary_completion_date":"July 2012","completion_date":"April 2014","first_posted":"April 27, 2011","results_first_posted":"February 24, 2015","last_update_posted":"February 24, 2015"},{"nctid":"NCT00722566","version_a":12,"version_b":13,"version_a_date":"2011-02-18","version_b_date":"2011-08-30","pom_a":[{"label":"1.","content":"Overall response rate[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]"}],"pom_b":[{"label":"1.","content":"Overall Response Rate (Complete Response + Partial Response)[ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]Disease response was measured according to European Group for Blood and Marrow Transplantation (EBMT) criteria with the addition of the response categories of nCR and VGPR.Complete response requires disappearance of monoclonal protein from the blood and urine and <5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks.Partial Response requires \u226550% reduction in serum m-protein for at least 2 determinations at least 6 weeks apart and if present, reduction in 24-hour urinary light chain excretion by either \u226590% or to <200 mg"}],"start_date":"July 2008","primary_completion_date":"August 2010","completion_date":"September 2010","first_posted":"July 25, 2008","results_first_posted":"October 4, 2011","last_update_posted":"October 10, 2011"},{"nctid":"NCT00722566","version_a":13,"version_b":14,"version_a_date":"2011-08-30","version_b_date":"2011-10-06","pom_a":[{"label":"1.","content":"Overall Response Rate (Complete Response + Partial Response)[ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]Disease response was measured according to European Group for Blood and Marrow Transplantation (EBMT) criteria with the addition of the response categories of nCR and VGPR.Complete response requires disappearance of monoclonal protein from the blood and urine and <5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks.Partial Response requires \u226550% reduction in serum m-protein for at least 2 determinations at least 6 weeks apart and if present, reduction in 24-hour urinary light chain excretion by either \u226590% or to <200 mg"}],"pom_b":[{"label":"1.","content":"Number of Patients With Overall Response (Complete Response + Partial Response)[ Time Frame: Over 4 cycles (prior to the addition of dexamethasone) ]Disease response was measured according to European Group for Blood and Marrow Transplantation (EBMT) criteria with the addition of the response categories of nCR and VGPR.Complete response requires disappearance of monoclonal protein from the blood and urine and <5% plasma cells in the bone marrow on at least 2 determinations for a minimum of 6 weeks.Partial Response requires \u226550% reduction in serum m-protein for at least 2 determinations at least 6 weeks apart and if present, reduction in 24-hour urinary light chain excretion by either \u226590% or to <200 mg"}],"start_date":"July 2008","primary_completion_date":"August 2010","completion_date":"September 2010","first_posted":"July 25, 2008","results_first_posted":"October 4, 2011","last_update_posted":"October 10, 2011"},{"nctid":"NCT00005007","version_a":4,"version_b":5,"version_a_date":"2007-04-26","version_b_date":"2007-12-19","pom_a":[],"pom_b":[{"label":"1.","content":"Number of patients in the two treatment arms who achieve sustained remissions as measured by the Birmingham Vasculitis Activity Score (BVAS) for WG[ Time Frame: Measured at study completion ]"}],"start_date":"June 2000","primary_completion_date":"March 2003","completion_date":"March 2003","first_posted":"March 27, 2000","last_update_posted":"December 28, 2007"},{"nctid":"NCT00006392","version_a":9,"version_b":10,"version_a_date":"2007-08-08","version_b_date":"2007-08-14","pom_a":[],"pom_b":[{"label":"1.","content":"Effect on the clinical incidence of cancer"},{"label":"2.","content":"Effect on cancer-free survival, overall survival and serious cardiovascular events"},{"label":"3.","content":"Quality of life"},{"label":"4.","content":"Association of biological molecular markers with cancer risk"},{"label":"5.","content":"Relationship between effects on cancer risk and genetic factors"},{"label":"6.","content":"Effects in terms of intake of other nutrients, foods, and dietary supplements"},{"label":"7.","content":"Effect of other dietary nutrients and dietary patterns on cancer risk"},{"label":"8.","content":"Effects on the reduction of Alzheimer\'s disease incidence"},{"label":"9.","content":"Reduction in the risk of age-related macular degeneration or cataract"}],"start_date":"July 2001","primary_completion_date":"May 2011","completion_date":"September 2012","first_posted":"January 27, 2003","results_first_posted":"November 6, 2012","last_update_posted":"November 20, 2015"},{"nctid":"NCT00006392","version_a":25,"version_b":26,"version_a_date":"2011-07-21","version_b_date":"2012-10-05","pom_a":[{"label":"1.","content":"Effect on the clinical incidence of cancer"},{"label":"2.","content":"Effect on cancer-free survival, overall survival and serious cardiovascular events"},{"label":"3.","content":"Quality of life"},{"label":"4.","content":"Association of biological molecular markers with cancer risk"},{"label":"5.","content":"Relationship between effects on cancer risk and genetic factors"},{"label":"6.","content":"Effects in terms of intake of other nutrients, foods, and dietary supplements"},{"label":"7.","content":"Effect of other dietary nutrients and dietary patterns on cancer risk"},{"label":"8.","content":"Effects on the reduction of Alzheimer\'s disease incidence"},{"label":"9.","content":"Reduction in the risk of age-related macular degeneration or cataract"}],"pom_b":[{"label":"1.","content":"Number of Participants With Prostate Cancer[ Time Frame: Every six months for 7 to 12 years depending on when the participant was randomized. ]Participants are seen at the study site every six month for an update of medical events. Prostate cancer diagnosis is based on participant report followed by the submission of a pathologic sample to central pathology review for confirmation."}],"start_date":"July 2001","primary_completion_date":"May 2011","completion_date":"September 2012","first_posted":"January 27, 2003","results_first_posted":"November 6, 2012","last_update_posted":"November 20, 2015"},{"nctid":"NCT03834493","version_a":96,"version_b":97,"version_a_date":"2021-10-08","version_b_date":"2021-11-09","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 52 months ]Time from randomization to death due to any cause"},{"label":"2.","content":"Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review[ Time Frame: Up to approximately 52 months ]Time from randomization to radiographic progression, or death due to any cause, whichever occurs first"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 56 months ]Time from randomization to death due to any cause"},{"label":"2.","content":"Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review[ Time Frame: Up to approximately 56 months ]Time from randomization to radiographic progression, or death due to any cause, whichever occurs first"}],"start_date":"July 28, 2019","primary_completion_date":"November 12, 2023","completion_date":"February 28, 2025","first_posted":"February 8, 2019","last_update_posted":"June 21, 2022"},{"nctid":"NCT03834493","version_a":119,"version_b":120,"version_a_date":"2022-05-10","version_b_date":"2022-06-15","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 56 months ]Time from randomization to death due to any cause"},{"label":"2.","content":"Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review[ Time Frame: Up to approximately 56 months ]Time from randomization to radiographic progression, or death due to any cause, whichever occurs first"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to ~ 51 months ]Time from randomization to death due to any cause"},{"label":"2.","content":"Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review[ Time Frame: Up to ~ 51 months ]Time from randomization to radiographic progression, or death due to any cause, whichever occurs first"}],"start_date":"July 28, 2019","primary_completion_date":"November 12, 2023","completion_date":"February 28, 2025","first_posted":"February 8, 2019","last_update_posted":"June 21, 2022"},{"nctid":"NCT02019277","version_a":54,"version_b":55,"version_a_date":"2016-09-01","version_b_date":"2016-10-11","pom_a":[{"label":"1.","content":"Incidence of adverse events (AEs)[ Time Frame: Up to 24 months ]"},{"label":"2.","content":"Incidence of serious AEs[ Time Frame: Up to 24 months ]"},{"label":"3.","content":"Evidence of cardiac dysfunction as measured by decreases in left ventricular ejection fraction (LVEF).[ Time Frame: Up to 24 months ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Premature Discontinuation[ Time Frame: Baseline up to 36 months ]"},{"label":"2.","content":"Percentage of Participants With Cardiac AEs[ Time Frame: Baseline up to 36 months ]"},{"label":"3.","content":"Percentage of Participants with Congestive Heart Failure (CHF), According to NCI CTCAE Version 4.0 and New York Heart Association Classification (NYHA)[ Time Frame: Baseline up to 36 months ]"},{"label":"4.","content":"Percentage of Participants with Asymptomatic Decline in Left Ventricular Ejection Fraction (LVEF), Assessed Using Echocardiography (ECHO) or Multiple-gated Acquisition (MUGA) Scan[ Time Frame: Baseline up to 28 days after last dose (up to 36 months) ]"}],"start_date":"December 5, 2013","primary_completion_date":"November 4, 2016","completion_date":"November 4, 2016","first_posted":"December 24, 2013","results_first_posted":"July 23, 2018","last_update_posted":"September 13, 2018"},{"nctid":"NCT02019277","version_a":57,"version_b":58,"version_a_date":"2017-08-25","version_b_date":"2017-10-10","pom_a":[{"label":"1.","content":"Percentage of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Premature Discontinuation[ Time Frame: Baseline up to 36 months ]"},{"label":"2.","content":"Percentage of Participants With Cardiac AEs[ Time Frame: Baseline up to 36 months ]"},{"label":"3.","content":"Percentage of Participants with Congestive Heart Failure (CHF), According to NCI CTCAE Version 4.0 and New York Heart Association Classification (NYHA)[ Time Frame: Baseline up to 36 months ]"},{"label":"4.","content":"Percentage of Participants with Asymptomatic Decline in Left Ventricular Ejection Fraction (LVEF), Assessed Using Echocardiography (ECHO) or Multiple-gated Acquisition (MUGA) Scan[ Time Frame: Baseline up to 28 days after last dose (up to 36 months) ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Adverse Events (AEs) and Serious AEs[ Time Frame: Baseline up to 28 days after last study drug administration (up to 36 months) ]An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs and SAEs was reported. AEs included both SAEs and non-SAEs. The 95% confidence interval (CI) was computed using Clopper-Pearson method."},{"label":"2.","content":"Percentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades[ Time Frame: Baseline up to 28 days after last study drug administration (up to 36 months) ]An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of AEs were graded according to NCI CTCAE version 4.0 on a 5-point scale: Grade 1=Mild, intervention not indicated; Grade 2=Moderate, local or noninvasive intervention indicated; Grade 3=Severe or medically significant but not immediately life-threatening; Grade 4= Life-threatening consequences, urgent intervention indicated; and Grade 5=Death related to AE. Percentage of participants with AEs by maximum severity grades was reported."},{"label":"3.","content":"Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)[ Time Frame: Baseline up to 28 days after last study drug administration (up to 36 months) ]An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs leading to premature discontinuation of IMPs (pertuzumab and trastuzumab) was reported. AEs included both SAEs and non-SAEs. The 95% CI was computed using Clopper-Pearson method."},{"label":"4.","content":"Percentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA)[ Time Frame: Baseline up to 28 days after last study drug administration (up to 36 months) ]NYHA functional classification includes: Class I (no limitation in physical activity; ordinary physical activity does not cause fatigue, breathlessness or palpitation), Class II (slight limitation of physical activity; ordinary physical activity results in fatigue, palpitation, breathlessness or angina pectoris), Class III (marked limitation of physical activity; less than ordinary activity will lead to symptomatically \'moderate\' heart failure) and Class IV (inability to carry out any physical activity without discomfort; symptoms of congestive cardiac failure are present even at rest). Percentage of participants with AEs suspected to be of cardiac origin by maximum NYHA classification was reported."},{"label":"5.","content":"Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%[ Time Frame: Baseline up to 28 days after last study drug administration (up to 36 months) ]LVEF was assessed using echocardiography (ECHO) or multiple-gated acquisition (MUGA) scans. Percentage of participants with LVEF below 50% at any time during the study was reported."}],"start_date":"December 5, 2013","primary_completion_date":"November 4, 2016","completion_date":"November 4, 2016","first_posted":"December 24, 2013","results_first_posted":"July 23, 2018","last_update_posted":"September 13, 2018"},{"nctid":"NCT00770874","version_a":21,"version_b":22,"version_a_date":"2017-02-03","version_b_date":"2019-03-18","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Once every 3 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From the date of randomization to death from any cause, assessed up to 296 events or the end of November 2015, whichever was earlier, each three months ]"}],"start_date":"September 2008","primary_completion_date":"December 2015","completion_date":"April 2016","first_posted":"October 10, 2008","results_first_posted":"June 21, 2019","last_update_posted":"June 21, 2019"},{"nctid":"NCT01200758","version_a":93,"version_b":94,"version_a_date":"2015-04-02","version_b_date":"2015-07-07","pom_a":[{"label":"1.","content":"Stage I: To estimate the ratio of trough serum concentrations of MabThera after subcutaneous administration to that obtained after intravenous administration[ Time Frame: Day 21 ]"},{"label":"2.","content":"Stage II: To estimate the overall response rate in each treatment arm at the end of induction treatment[ Time Frame: Week 24 (Cycle 8) ]"}],"pom_b":[{"label":"1.","content":"Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab[ Time Frame: Stage I: Cycle 7 Day 21 (within 2 hours pre-dose on Cycle 8) of induction treatment ]Number of participants = participants analyzed for this endpoint."},{"label":"2.","content":"Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage II: up to end of induction treatment Cycle 8 (24 weeks) ]Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (\u2265) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper."},{"label":"3.","content":"Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage I and II: Baseline up to end of induction treatment Cycle 8 (24 weeks) ]Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD; PR: \u226550% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper."}],"start_date":"February 15, 2011","primary_completion_date":"June 12, 2012","completion_date":"October 31, 2017","first_posted":"September 14, 2010","results_first_posted":"August 5, 2015","last_update_posted":"November 27, 2018"},{"nctid":"NCT01200758","version_a":95,"version_b":96,"version_a_date":"2015-08-07","version_b_date":"2017-01-23","pom_a":[{"label":"1.","content":"Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab[ Time Frame: Stage I: Cycle 7 Day 21 (within 2 hours pre-dose on Cycle 8) of induction treatment ]Number of participants = participants analyzed for this endpoint."},{"label":"2.","content":"Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage II: up to end of induction treatment Cycle 8 (24 weeks) ]Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (\u2265) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper."},{"label":"3.","content":"Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage I and II: Baseline up to end of induction treatment Cycle 8 (24 weeks) ]Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD; PR: \u226550% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper."}],"pom_b":[{"label":"1.","content":"Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab[ Time Frame: Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours [hrs] predose on Cy 8) of induction treatment (1 Cy=3 weeks) ]Number of participants = participants analyzed for this endpoint."},{"label":"2.","content":"Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks) ]Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (\u2265) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper."},{"label":"3.","content":"Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage I and II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks) ]Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD; PR: \u226550% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper."}],"start_date":"February 15, 2011","primary_completion_date":"June 12, 2012","completion_date":"October 31, 2017","first_posted":"September 14, 2010","results_first_posted":"August 5, 2015","last_update_posted":"November 27, 2018"},{"nctid":"NCT01200758","version_a":96,"version_b":97,"version_a_date":"2017-01-23","version_b_date":"2017-05-30","pom_a":[{"label":"1.","content":"Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab[ Time Frame: Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours [hrs] predose on Cy 8) of induction treatment (1 Cy=3 weeks) ]Number of participants = participants analyzed for this endpoint."},{"label":"2.","content":"Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks) ]Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for Non-Hodgkin lymphoma (NHL). CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (\u2265) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper."},{"label":"3.","content":"Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment[ Time Frame: Stage I and II: Baseline up to end of induction treatment Cy 8 (24 weeks) (1 Cy=3 weeks) ]Overall Response comprised of CR, CRu, or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and CT scans. Assessment of tumour response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by >75% in SPD; PR: \u226550% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI for the response rates was estimated for one sample binomial using Pearson-Clopper."}],"pom_b":[{"label":"1.","content":"Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab[ Time Frame: Stage I: Cycle (Cy) 7 Day (D) 21 (within 2 hours predose on Cy8) of induction treatment (1 Cy=3 weeks) ]"},{"label":"2.","content":"Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment Assessed Using International Working Group Response Criteria for Non-Hodgkin Lymphoma (NHL)[ Time Frame: Stage II: Baseline up to end of induction treatment Cy8 (24 weeks) (1 Cy=3 weeks) ]Overall Response comprised complete response (CR), CR unconfirmed (CRu), or PR. A participant was defined as a responder if they sustained a CR, CRu or PR at the end of induction treatment. Response assessment was based on clinical examination and computed tomography (CT) scans. Assessment of tumor response was performed according to the International Working Group response criteria for NHL. CR: complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy; CRu: CR along with regression in lymph node mass by more than (>) 75% in the sum of the products of greatest diameters (SPD); PR: Greater than or equal to (\u2265) 50% decrease in SPD of 6 largest dominant nodes or nodal masses. The 95% CI was estimated for one sample binomial using Pearson-Clopper."}],"start_date":"February 15, 2011","primary_completion_date":"June 12, 2012","completion_date":"October 31, 2017","first_posted":"September 14, 2010","results_first_posted":"August 5, 2015","last_update_posted":"November 27, 2018"},{"nctid":"NCT01349881","version_a":6,"version_b":7,"version_a_date":"2012-11-09","version_b_date":"2013-04-08","pom_a":[{"label":"1.","content":"3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)[ Time Frame: 3 years ]The primary objective is to assess whether elfornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate, defined as high risk adenoma or 2nd primary colorectal cancer, in Stage 0, I, II, and III colon cancer patients."}],"pom_b":[{"label":"1.","content":"3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)[ Time Frame: 3 years ]The primary objective is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate, defined as high risk adenoma or 2nd primary colorectal cancer, in Stage 0, I, II, and III colon cancer patients."}],"start_date":"March 1, 2013","primary_completion_date":"February 1, 2027","completion_date":"February 1, 2032","first_posted":"May 9, 2011","last_update_posted":"August 24, 2022"},{"nctid":"NCT01349881","version_a":24,"version_b":25,"version_a_date":"2018-08-29","version_b_date":"2018-12-19","pom_a":[{"label":"1.","content":"3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)[ Time Frame: 3 years ]The primary objective is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate, defined as high risk adenoma or 2nd primary colorectal cancer, in Stage 0, I, II, and III colon cancer patients."}],"pom_b":[{"label":"1.","content":"3-year event rate after registration among Stage 0-III colon or rectal cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)[ Time Frame: 3 years ]The primary objective is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg is effective in reducing the 3-year event rate, defined as high risk adenoma or 2nd primary colorectal cancer, in patients with previously treated Stage 0, I, II, and III colon or rectal cancer."}],"start_date":"March 1, 2013","primary_completion_date":"February 1, 2027","completion_date":"February 1, 2032","first_posted":"May 9, 2011","last_update_posted":"August 24, 2022"},{"nctid":"NCT01349881","version_a":28,"version_b":29,"version_a_date":"2020-03-02","version_b_date":"2020-08-19","pom_a":[{"label":"1.","content":"3-year event rate after registration among Stage 0-III colon or rectal cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.)[ Time Frame: 3 years ]The primary objective is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg is effective in reducing the 3-year event rate, defined as high risk adenoma or 2nd primary colorectal cancer, in patients with previously treated Stage 0, I, II, and III colon or rectal cancer."}],"pom_b":[{"label":"1.","content":"Event rate, defined as rate of high-risk adenoma or second primary colorectal cancer (CRC)[ Time Frame: 3 years after registration ]High risk adenoma is defined as either advanced adenoma (villous or tubulovillous histology, size >= 1 cm, or high grade dysplasia) or multiple adenomas (3 or more each > 0.3 cm). The primary analysis of the 3-year event rate will be performed using logistic regression, testing the main effect of treatment and adjusting for the baseline stratification factor. A two-arm binomial design without continuity correction will be used."}],"start_date":"March 1, 2013","primary_completion_date":"February 1, 2027","completion_date":"February 1, 2032","first_posted":"May 9, 2011","last_update_posted":"August 24, 2022"},{"nctid":"NCT00042848","version_a":15,"version_b":16,"version_a_date":"2006-08-16","version_b_date":"2006-11-08","pom_a":[],"pom_b":[{"label":"1.","content":"Efficacy to reduce fatigue during chemotherapy as assessed by the Brief Fatigue Inventory at course 4"}],"start_date":"August 2002","primary_completion_date":"April 2007","completion_date":"October 2007","first_posted":"January 27, 2003","last_update_posted":"October 15, 2015"},{"nctid":"NCT00910910","version_a":31,"version_b":32,"version_a_date":"2014-06-03","version_b_date":"2014-06-05","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Every 28 days ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Every 28 days ]Number of participants who survive without progressing"},{"label":"2.","content":"Safety [type, frequency, and severity of adverse events (AEs)][ Time Frame: Up to 105 months; every 28 days ]An adverse event (AE) is any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a patient during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairmentof the patient\'s health, including laboratory test values (as specified by the criteria below), regardless of etiology. Any medical condition that was present prior to study treatment and that remains unchanged or improved should not be recorded as an AE. If there is a worsening of thatmedical condition, this should be considered an AE."},{"label":"3.","content":"Overall Survival[ Time Frame: Up to 105 months ]Overall Survival is defined as the time between randomization and death"},{"label":"4.","content":"Number of anti-cancer therapies obtained from randomized participants[ Time Frame: Up to 105 months ]Anti-cancer therapies administered to all randomized study participants during the follow up period"}],"start_date":"October 13, 2009","primary_completion_date":"March 31, 2014","completion_date":"May 9, 2018","first_posted":"June 1, 2009","results_first_posted":"December 21, 2016","last_update_posted":"July 9, 2019"},{"nctid":"NCT00910910","version_a":35,"version_b":36,"version_a_date":"2015-05-12","version_b_date":"2016-10-27","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Every 28 days ]Number of participants who survive without progressing"},{"label":"2.","content":"Safety [type, frequency, and severity of adverse events (AEs)][ Time Frame: Up to 105 months; every 28 days ]An adverse event (AE) is any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a patient during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairmentof the patient\'s health, including laboratory test values (as specified by the criteria below), regardless of etiology. Any medical condition that was present prior to study treatment and that remains unchanged or improved should not be recorded as an AE. If there is a worsening of thatmedical condition, this should be considered an AE."},{"label":"3.","content":"Overall Survival[ Time Frame: Up to 105 months ]Overall Survival is defined as the time between randomization and death"},{"label":"4.","content":"Number of anti-cancer therapies obtained from randomized participants[ Time Frame: Up to 105 months ]Anti-cancer therapies administered to all randomized study participants during the follow up period"}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off of 31 March 2014[ Time Frame: Data cut-off of 31 March 2014; up to approximately 53 months ]Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator\'s assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression."},{"label":"2.","content":"Kaplan-Meier Estimate of Progression Free Survival (PFS)[ Time Frame: Data cut-off of 18 Feb 2013; up to approximately 39 months ]Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator\'s assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression"}],"start_date":"October 13, 2009","primary_completion_date":"March 31, 2014","completion_date":"May 9, 2018","first_posted":"June 1, 2009","results_first_posted":"December 21, 2016","last_update_posted":"July 9, 2019"},{"nctid":"NCT00910910","version_a":39,"version_b":40,"version_a_date":"2018-12-14","version_b_date":"2019-06-14","pom_a":[{"label":"1.","content":"Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off of 31 March 2014[ Time Frame: Data cut-off of 31 March 2014; up to approximately 53 months ]Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator\'s assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression."},{"label":"2.","content":"Kaplan-Meier Estimate of Progression Free Survival (PFS)[ Time Frame: Data cut-off of 18 Feb 2013; up to approximately 39 months ]Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator\'s assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression"}],"pom_b":[{"label":"1.","content":"Kaplan-Meier Estimate of Progression Free Survival (PFS)[ Time Frame: From first dose of study drug to date of data cut-off of 18 Feb 2013; up to approximately 39 months ]Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator\'s assessment or death due to any cause on study, whichever occurred first. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression"},{"label":"2.","content":"Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off Date of 14 March 2014[ Time Frame: From randomization to data cut off date of 31 March 2014; median follow up time for all participants was 12.6 months ]Progression-free survival was defined as the time from randomization to the first documented progression confirmed per investigator\'s assessment or death due to any cause on study, whichever occurred first. Progressive disease included lymphadenopathy, an appearance of any new lesion such as enlarged lymph nodes (> 1.5 cm), splenomegaly, hepatomegaly or other organ infiltrates, an increase by 50% or more in greatest determined diameter of any previous site or an increase by 50% or more in the sum of the product of diameters of multiple nodes. The progression date was assigned to the earliest time when any progression was observed without prior missing assessments. If withdrawal of consent or lost to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression."}],"start_date":"October 13, 2009","primary_completion_date":"March 31, 2014","completion_date":"May 9, 2018","first_posted":"June 1, 2009","results_first_posted":"December 21, 2016","last_update_posted":"July 9, 2019"},{"nctid":"NCT01665144","version_a":1,"version_b":2,"version_a_date":"2012-08-14","version_b_date":"2012-08-16","pom_a":[{"label":"1.","content":"The delay in time to confirmed disability progression as measured by EDSS.[ Time Frame: up to the maximum of 60 months ]Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5."}],"pom_b":[{"label":"1.","content":"The delay in time to confirmed disability progression as measured by EDSS.[ Time Frame: Baseline, every 3 month up to the maximum of 60 months ]Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5."}],"start_date":"December 20, 2012","primary_completion_date":"April 29, 2016","completion_date":"March 1, 2024","first_posted":"August 15, 2012","results_first_posted":"October 31, 2018","last_update_posted":"August 10, 2022"},{"nctid":"NCT01665144","version_a":14,"version_b":15,"version_a_date":"2015-08-18","version_b_date":"2016-01-12","pom_a":[{"label":"1.","content":"The delay in time to confirmed disability progression as measured by EDSS.[ Time Frame: Baseline, every 3 month up to the maximum of 60 months ]Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5."}],"pom_b":[{"label":"1.","content":"The delay in time to confirmed disability progression as measured by EDSS.[ Time Frame: Baseline, every 3 month up to the maximum of approximately 3 years ]Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5."}],"start_date":"December 20, 2012","primary_completion_date":"April 29, 2016","completion_date":"March 1, 2024","first_posted":"August 15, 2012","results_first_posted":"October 31, 2018","last_update_posted":"August 10, 2022"},{"nctid":"NCT01665144","version_a":23,"version_b":24,"version_a_date":"2018-06-08","version_b_date":"2018-10-04","pom_a":[{"label":"1.","content":"The delay in time to confirmed disability progression as measured by EDSS.[ Time Frame: Baseline, every 3 month up to the maximum of approximately 3 years ]Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5."}],"pom_b":[{"label":"1.","content":"Percentage of Participants With 3-month Confirmed Disibility Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)[ Time Frame: Baseline, every 3 month up to the maximum of approximately 3 years ]The EDSS uses an ordinal scale to assess neurologic impairment in MS based on a neurological examination. Scores in each of 7 functional systems (Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, and Cerebral) and an ambulation score were combined to determine the EDSS steps, ranging from 0 (normal) to 10 (death due to MS). Confirmed disability is defined as an increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5."}],"start_date":"December 20, 2012","primary_completion_date":"April 29, 2016","completion_date":"March 1, 2024","first_posted":"August 15, 2012","results_first_posted":"October 31, 2018","last_update_posted":"August 10, 2022"},{"nctid":"NCT03743064","version_a":12,"version_b":13,"version_a_date":"2020-12-03","version_b_date":"2021-05-18","pom_a":[{"label":"1.","content":"Composite Clinical Response (CCR)[ Time Frame: from baseline to week 9 ]CCR is a composite measure including both a \u2265 5% body weight gain from baseline and increase \u2265 2 points (meaning a clinically relevant improvement) in the 5-item Anorexia Symptom Scale score from baseline) in patients who survive until Day 64."}],"pom_b":[{"label":"1.","content":"Duration of clinically meaningful treatment benefit in weight[ Time Frame: From baseline until week 12 ]The duration of treatment benefit is measured as the duration for which the patient observed a change from baseline superior or equal to the predefined threshold of clinical meaningfulness."},{"label":"2.","content":"Duration of clinically meaningful treatment benefit in 5-item Anorexia Symptom Subscale[ Time Frame: From baseline until week 12 ]The duration of treatment benefit is measured as the duration for which the patient observed a change from baseline superior or equal to the predefined threshold of clinical meaningfulness."}],"start_date":"December 18, 2018","primary_completion_date":"July 4, 2022","completion_date":"January 31, 2023","first_posted":"November 15, 2018","last_update_posted":"August 4, 2022"},{"nctid":"NCT03743064","version_a":16,"version_b":17,"version_a_date":"2022-01-14","version_b_date":"2022-08-02","pom_a":[{"label":"1.","content":"Duration of clinically meaningful treatment benefit in weight[ Time Frame: From baseline until week 12 ]The duration of treatment benefit is measured as the duration for which the patient observed a change from baseline superior or equal to the predefined threshold of clinical meaningfulness."},{"label":"2.","content":"Duration of clinically meaningful treatment benefit in 5-item Anorexia Symptom Subscale[ Time Frame: From baseline until week 12 ]The duration of treatment benefit is measured as the duration for which the patient observed a change from baseline superior or equal to the predefined threshold of clinical meaningfulness."}],"pom_b":[{"label":"1.","content":"body weight[ Time Frame: From baseline until week 12 ]Mean change in body weight"},{"label":"2.","content":"5 item Anorexia Symptom Subscale[ Time Frame: From baseline until week 12 ]Mean change in 5-item Anorexia Symptom Subscale"}],"start_date":"December 18, 2018","primary_completion_date":"July 4, 2022","completion_date":"January 31, 2023","first_posted":"November 15, 2018","last_update_posted":"August 4, 2022"},{"nctid":"NCT00950911","version_a":11,"version_b":12,"version_a_date":"2011-09-29","version_b_date":"2013-12-19","pom_a":[{"label":"1.","content":"To describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa\xae) or denosumab.[ Time Frame: Two years ]"}],"pom_b":[{"label":"1.","content":"Number of Participants Survived[ Time Frame: 2 years ]"}],"start_date":"July 2009","primary_completion_date":"February 2012","completion_date":"April 2012","first_posted":"August 3, 2009","results_first_posted":"February 11, 2014","last_update_posted":"February 11, 2014"},{"nctid":"NCT00016432","version_a":14,"version_b":15,"version_a_date":"2009-08-10","version_b_date":"2009-10-07","pom_a":[],"pom_b":[{"label":"1.","content":"Disease-free survival[ Time Frame: Every 12 months until breast cancer recurrence, second primary cancer or death from any cause. ]"}],"start_date":"May 2001","primary_completion_date":"October 2003","completion_date":"February 2011","first_posted":"January 27, 2003","last_update_posted":"April 19, 2011"},{"nctid":"NCT01183858","version_a":66,"version_b":67,"version_a_date":"2014-11-10","version_b_date":"2015-02-05","pom_a":[{"label":"1.","content":"To compare the efficacy of two dose levels of Tarceva on progression-free survival[ Time Frame: Tumor assessments every 6 weeks ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization to Clinical Cutoff: 28 October 2013 (Up to 68.7 Weeks) ]PFS is defined as the time from randomization to the date of first occurrence of disease progression or death. For target lesions, Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions."}],"start_date":"October 2010","primary_completion_date":"October 2013","completion_date":"February 2014","first_posted":"August 18, 2010","results_first_posted":"February 23, 2015","last_update_posted":"August 19, 2015"},{"nctid":"NCT01183858","version_a":67,"version_b":68,"version_a_date":"2015-02-05","version_b_date":"2015-07-23","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization to Clinical Cutoff: 28 October 2013 (Up to 68.7 Weeks) ]PFS is defined as the time from randomization to the date of first occurrence of disease progression or death. For target lesions, Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 Months) ]PFS is defined as the time from randomization to the date of first occurrence of disease progression or death. For target lesions, Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions."},{"label":"2.","content":"Progression-Free Survival (PFS) at the End of Study[ Time Frame: Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months) ]PFS is defined as the time from randomization to the date of first occurrence of disease progression or death. For target lesions, Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions."}],"start_date":"October 2010","primary_completion_date":"October 2013","completion_date":"February 2014","first_posted":"August 18, 2010","results_first_posted":"February 23, 2015","last_update_posted":"August 19, 2015"},{"nctid":"NCT00732641","version_a":29,"version_b":30,"version_a_date":"2011-01-25","version_b_date":"2011-03-01","pom_a":[{"label":"1.","content":"Response duration as assessed by progression-free survival of a maintenance therapy using Peginterferon \u03b1-2b vs control (no treatment) in subjects with multiple myeloma who responded to a prior induction therapy.[ Time Frame: Every 3 months for 5 years or until disease relapse/progression ]"}],"pom_b":[{"label":"1.","content":"Number of participants with progression free survival[ Time Frame: Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse) ]"}],"start_date":"December 2000","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"August 12, 2008","results_first_posted":"December 2, 2011","last_update_posted":"April 4, 2017"},{"nctid":"NCT00732641","version_a":30,"version_b":31,"version_a_date":"2011-03-01","version_b_date":"2011-10-27","pom_a":[{"label":"1.","content":"Number of participants with progression free survival[ Time Frame: Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse) ]"}],"pom_b":[{"label":"1.","content":"Number of Days With Progression Free Survival (PFS)[ Time Frame: Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse) ]PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse.PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse."}],"start_date":"December 2000","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"August 12, 2008","results_first_posted":"December 2, 2011","last_update_posted":"April 4, 2017"},{"nctid":"NCT00185393","version_a":5,"version_b":6,"version_a_date":"2007-04-30","version_b_date":"2008-11-26","pom_a":[{"label":"1.","content":"Progression free survival"}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: End of study ]"}],"start_date":"August 2001","completion_date":"February 2007","first_posted":"September 16, 2005","last_update_posted":"December 1, 2008"},{"nctid":"NCT02584478","version_a":8,"version_b":9,"version_a_date":"2019-06-17","version_b_date":"2021-03-31","pom_a":[{"label":"1.","content":"Recommended Phase 2 Dose (RP2D) - Part 1 (Phase 1b)[ Time Frame: Cycle 1 (21-days) ]Determine the Recommended Phase 2 Dose (RP2D) via evaluation of dose limiting toxicity (DLT) events."},{"label":"2.","content":"Objective Response Rates (ORR) - Part 2 (Phase 2a)[ Time Frame: 12 months ]Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST, v1.1) criteria after three complete 21-day cycles in the first 9 cycles then once every 6 cycles for up to 12 months. ORR is measured by the number of complete (CR) and partial responses (PR)"}],"pom_b":[{"label":"1.","content":"Recommended Phase 2 Dose (RP2D) - Part 1 (Phase 1b)[ Time Frame: Cycle 1 (21-days) ]Determine the Recommended Phase 2 Dose (RP2D) via evaluation of dose limiting toxicity (DLT) events."},{"label":"2.","content":"Objective Response Rates (ORR) - Part 2 (Phase 2a)[ Time Frame: 12 months ]Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST, v1.1) criteria after three complete 21-day cycles in the first 9 cycles then once every 6 cycles for up to 12 months. ORR is measured by the number of complete (CR) and partial responses (PR)"},{"label":"3.","content":"Measure the Progression Free Survival (PFS)- Part 3 ( Phase 3)[ Time Frame: 12 Months ]To evaluate the efficacy between the Active Arm (AL3818 in combination with background chemotherapy) and Control Arm (background chemotherapy alone arm) as measured by the primary endpoint of Progression Free Survival (PFS)."}],"start_date":"December 2015","primary_completion_date":"October 2024","completion_date":"December 2024","first_posted":"October 22, 2015","last_update_posted":"July 12, 2022"},{"nctid":"NCT00036881","version_a":13,"version_b":14,"version_a_date":"2007-04-11","version_b_date":"2007-06-04","pom_a":[],"pom_b":[{"label":"1.","content":"Prolongation of the time to onset of altered taste by zinc sulfate"}],"start_date":"May 2002","primary_completion_date":"April 2007","completion_date":"June 2007","first_posted":"January 27, 2003","last_update_posted":"July 14, 2016"},{"nctid":"NCT00036881","version_a":28,"version_b":29,"version_a_date":"2009-05-09","version_b_date":"2015-07-07","pom_a":[{"label":"1.","content":"Prolongation of the time to onset of altered taste by zinc sulfate"}],"pom_b":[{"label":"1.","content":"Prolongation of the time to onset of altered taste by zinc sulfate[ Time Frame: Up to 1.5 years ]"}],"start_date":"May 2002","primary_completion_date":"April 2007","completion_date":"June 2007","first_posted":"January 27, 2003","last_update_posted":"July 14, 2016"},{"nctid":"NCT03851445","version_a":1,"version_b":2,"version_a_date":"2019-02-20","version_b_date":"2019-02-22","pom_a":[{"label":"1.","content":"Screening Success (Tissue Submission)[ Time Frame: Up to 3 years ]The tissue submission will be measured by the proportion of patients who register to this screening study for whom a tissue sample is submitted."},{"label":"2.","content":"Screening Success (Adequate Tissue)[ Time Frame: Up to 3 years ]Adequate tissue will be measured by the proportion of patients who submitted a specimen for whom genomic results were successfully obtained, if multiple platforms are being used (e.g. both FMI and IHC), these rates will be summarized by the individual assays and combined. These rates are summarized for the entire screened population and by screening type (screened at progression versus pre-screened prior to progression). The rates are evaluated for both the initial submission success rates and the overall success rate accounting for new tissue submisions following an unsuccessful result."},{"label":"3.","content":"Screening Success (Prescreening-to-sub-study Assignment)[ Time Frame: Up to 3 years ]Pre-screening-to-sub-study assignment will be measured among pre-screened patients and the proportion of patients assigned to a sub-study (which is triggered by the submission of the notice of progression form, see Section 14.0). Note: Patients screened at progression are notified of their sub-study assignment within 1 day of the biomarker results being reported to SWOG."},{"label":"4.","content":"Screening Success (Notice of Intention Not to Register Submission)[ Time Frame: Up to 3 years ]Screening success will be measured by the reasons for non-participation collection on the LungMAP Notice of Intention not to Register Form. The proportions of patients with this form submitted are summarized overall and by screening type. The reasons for submission are summarized overall and by screening type."},{"label":"5.","content":"Screening Success (Match to Biomarker-Driven Sub-Study)[ Time Frame: Up to 3 years ]Match to Biomarker-Driven Sub-Study will be measured by successful biomarker screening, the proportion assigned to a biomarker-driven substudy."},{"label":"6.","content":"Screening Success (Assignment Success)[ Time Frame: Up to 3 years ]Assignment Success will be measured by the proportion of patients assigned to a sub-study who are registered to a sub-study, these rates are summarized overall and among biomarker-driven and non-match sub-study assignments, separately. In addition, these rates are summarized by screening type."}],"pom_b":[{"label":"1.","content":"Screening Success (Tissue Submission)[ Time Frame: Up to 3 years ]The tissue submission will be measured by the proportion of patients who register to this screening study for whom a tissue sample is submitted."},{"label":"2.","content":"Screening Success (Adequate Tissue)[ Time Frame: Up to 3 years ]Adequate tissue will be measured by the proportion of patients who submitted a specimen for whom genomic results were successfully obtained, if multiple platforms are being used (e.g. both FMI and IHC), these rates will be summarized by the individual assays and combined. These rates are summarized for the entire screened population and by screening type (screened at progression versus pre-screened prior to progression). The rates are evaluated for both the initial submission success rates and the overall success rate accounting for new tissue submissions following an unsuccessful result."},{"label":"3.","content":"Screening Success (Prescreening-to-sub-study Assignment)[ Time Frame: Up to 3 years ]Pre-screening-to-sub-study assignment will be measured among pre-screened patients and the proportion of patients assigned to a sub-study (which is triggered by the submission of the notice of progression form, see Section 14.0). Note: Patients screened at progression are notified of their sub-study assignment within 1 day of the biomarker results being reported to SWOG."},{"label":"4.","content":"Screening Success (Notice of Intention Not to Register Submission)[ Time Frame: Up to 3 years ]Screening success will be measured by the reasons for non-participation collection on the LungMAP Notice of Intention not to Register Form. The proportions of patients with this form submitted are summarized overall and by screening type. The reasons for submission are summarized overall and by screening type."},{"label":"5.","content":"Screening Success (Match to Biomarker-Driven Sub-Study)[ Time Frame: Up to 3 years ]Match to Biomarker-Driven Sub-Study will be measured by successful biomarker screening, the proportion assigned to a biomarker-driven substudy."},{"label":"6.","content":"Screening Success (Assignment Success)[ Time Frame: Up to 3 years ]Assignment Success will be measured by the proportion of patients assigned to a sub-study who are registered to a sub-study, these rates are summarized overall and among biomarker-driven and non-match sub-study assignments, separately. In addition, these rates are summarized by screening type."}],"start_date":"January 28, 2019","primary_completion_date":"January 28, 2029","completion_date":"January 28, 2029","first_posted":"February 22, 2019","last_update_posted":"May 5, 2022"},{"nctid":"NCT00956007","version_a":303,"version_b":304,"version_a_date":"2012-09-25","version_b_date":"2013-06-12","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: From randomization to date of death or last follow-up. Analysis occurs after 372 events have been reported. ]"}],"start_date":"November 2009","primary_completion_date":"December 2022","completion_date":"August 2026","first_posted":"August 11, 2009","last_update_posted":"August 4, 2021"},{"nctid":"NCT02697734","version_a":44,"version_b":45,"version_a_date":"2021-07-06","version_b_date":"2021-09-21","pom_a":[{"label":"1.","content":"Percentage of randomized participants with a complete response[ Time Frame: at Week 12 ]To demonstrate the superiority of osilodrostat compared to placebo in achieving a complete response mean urine free cortisol \u2264 upper limit of normal (mUFC \u2264 ULN) at Week 12."}],"pom_b":[{"label":"1.","content":"Percentage of Randomized Participants With a Complete Response[ Time Frame: at Week 12 ]A complete responder at week 12 is defined as a participant who had a mean urine free cortisol \u2264 upper limit of normal (mUFC \u2264 ULN) at Week 12.Participants who had a missing mUFC assessment at Week 12 were counted as non-responders for the primary endpoint."}],"start_date":"October 3, 2016","primary_completion_date":"June 19, 2019","completion_date":"December 31, 2020","first_posted":"March 3, 2016","results_first_posted":"October 19, 2021","last_update_posted":"November 1, 2021"},{"nctid":"NCT00134030","version_a":44,"version_b":45,"version_a_date":"2007-05-08","version_b_date":"2007-05-16","pom_a":[],"pom_b":[{"label":"1.","content":"Event-free survival"}],"start_date":"November 14, 2005","primary_completion_date":"January 31, 2015","first_posted":"August 24, 2005","last_update_posted":"June 8, 2018"},{"nctid":"NCT00134030","version_a":398,"version_b":399,"version_a_date":"2012-08-03","version_b_date":"2013-06-12","pom_a":[{"label":"1.","content":"Event-free survival"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: From date of randomization to date of the event, assessed up to 10 years ]Will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals."}],"start_date":"November 14, 2005","primary_completion_date":"January 31, 2015","first_posted":"August 24, 2005","last_update_posted":"June 8, 2018"},{"nctid":"NCT02101788","version_a":147,"version_b":148,"version_a_date":"2015-11-25","version_b_date":"2015-12-11","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: Time from study entry to time of progression or death, whichever occurs first, assessed up to 10 years ]Patients will be grouped by their randomized treatment for intention-to-treat analyses (ITT)."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time from study entry to time of progression or death, whichever occurs first, assessed up to 10 years ]Patients will be grouped by their randomized treatment for intention-to-treat analyses."}],"start_date":"April 11, 2014","primary_completion_date":"April 4, 2019","first_posted":"April 2, 2014","results_first_posted":"September 29, 2020","last_update_posted":"January 12, 2022"},{"nctid":"NCT02101788","version_a":663,"version_b":664,"version_a_date":"2020-03-02","version_b_date":"2020-09-08","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Time from study entry to time of progression or death, whichever occurs first, assessed up to 10 years ]Patients will be grouped by their randomized treatment for intention-to-treat analyses."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B ]Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last followup were censored on the date of last CT Scan.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the PFS endpoint definition."}],"start_date":"April 11, 2014","primary_completion_date":"April 4, 2019","first_posted":"April 2, 2014","results_first_posted":"September 29, 2020","last_update_posted":"January 12, 2022"},{"nctid":"NCT04396860","version_a":66,"version_b":67,"version_a_date":"2021-02-26","version_b_date":"2021-02-27","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization to disease progress or death, assessed up to 4 years ]PFS will be defined as time from randomization to disease progress or death. This analysis will be performed on the intent-to-treat basis. PFS distributions for each treatment group will be estimated via the Kaplan-Meier survival function. Will utilize the \\"PFS resolution\\" guidance provided in the ALLIANCE A071102 study, the updated Response Assessment in Neuro-Oncology Criteria (RANO) criteria."},{"label":"2.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization to death from any cause, assessed up to 4 years ]OS will be defined as time from randomization to death from any cause. Will be performed on the intent-to-treat basis. Overall survival distributions for each treatment group will be estimated via the Kaplan-Meier survival function."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) (Phase II)[ Time Frame: From randomization to disease progress or death, assessed up to 4 years ]Analysis will be performed on the intent-to-treat basis. PFS distributions for each treatment group will be estimated via the Kaplan-Meier survival function. Will utilize the \\"PFS resolution\\" guidance provided in the ALLIANCE A071102 (NCT02152982) study, the updated Response Assessment in Neuro-Oncology Criteria (RANO) criteria."},{"label":"2.","content":"Overall survival (OS) (Phase III)[ Time Frame: From randomization to death from any cause, assessed up to 4 years ]Analysis will be performed on the intent-to-treat basis. Overall survival distributions for each treatment group will be estimated via the Kaplan-Meier survival function."}],"start_date":"August 6, 2020","primary_completion_date":"August 23, 2024","completion_date":"August 23, 2024","first_posted":"May 21, 2020","last_update_posted":"August 25, 2022"},{"nctid":"NCT00427310","version_a":12,"version_b":13,"version_a_date":"2010-08-07","version_b_date":"2012-12-31","pom_a":[],"pom_b":[{"label":"1.","content":"Disease free interval[ Time Frame: From randomization up to 4 years. ]Evidence of treatment failure (presence of tumor in local/regional or distant sites, confirmed by either biopsy or other acceptable evidence."},{"label":"2.","content":"Survival[ Time Frame: From randomization up to 4 years. ]"}],"start_date":"March 1984","primary_completion_date":"September 1989","completion_date":"February 2001","first_posted":"January 29, 2007","last_update_posted":"January 3, 2013"},{"nctid":"NCT01556776","version_a":2,"version_b":3,"version_a_date":"2012-08-27","version_b_date":"2014-12-02","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: up to 5 years ]Efficacy:All measurements will be compared with baseline values:Lymph nodes, spleen and liver measurements by physical examinationComplete blood count (CBC)Peripheral blood smearFlow cytometry of peripheral blood for MRD assessmentBone marrow aspirate/biopsy for standard histopathology and flow cytometry for MRD assessmentComputed tomography (CT) scans if clinically indicatedECOG Performance StatusAssessment of constitutional symptoms"}],"pom_b":[{"label":"1.","content":"Progression free survival[ Time Frame: up to 6 years ]Efficacy:All measurements will be compared with baseline values:Lymph nodes, spleen and liver measurements by physical examinationComplete blood count (CBC)Peripheral blood smearFlow cytometry of peripheral blood for MRD assessmentBone marrow aspirate/biopsy for standard histopathology and flow cytometry for MRD assessmentComputed tomography (CT) scans if clinically indicatedECOG Performance StatusAssessment of constitutional symptoms"}],"start_date":"July 20, 2012","primary_completion_date":"March 2016","completion_date":"January 14, 2021","first_posted":"March 16, 2012","last_update_posted":"January 5, 2022"},{"nctid":"NCT01556776","version_a":12,"version_b":13,"version_a_date":"2018-05-09","version_b_date":"2019-07-30","pom_a":[{"label":"1.","content":"Progression free survival[ Time Frame: up to 6 years ]Efficacy:All measurements will be compared with baseline values:Lymph nodes, spleen and liver measurements by physical examinationComplete blood count (CBC)Peripheral blood smearFlow cytometry of peripheral blood for MRD assessmentBone marrow aspirate/biopsy for standard histopathology and flow cytometry for MRD assessmentComputed tomography (CT) scans if clinically indicatedECOG Performance StatusAssessment of constitutional symptoms"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) based on independent review committee[ Time Frame: up to 6 years ]Time from the date of randomization to the date of first documented disease progression (as defined by the iWCLL response criteria, see section 4.11.1.2) or death by any cause, whichever occurs first."}],"start_date":"July 20, 2012","primary_completion_date":"March 2016","completion_date":"January 14, 2021","first_posted":"March 16, 2012","last_update_posted":"January 5, 2022"},{"nctid":"NCT02555657","version_a":39,"version_b":40,"version_a_date":"2017-03-15","version_b_date":"2017-04-20","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: Up to 28 months ]"},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to 28 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to 32 months ]"}],"start_date":"October 13, 2015","primary_completion_date":"April 11, 2019","completion_date":"November 10, 2020","first_posted":"September 21, 2015","results_first_posted":"May 4, 2020","last_update_posted":"December 10, 2021"},{"nctid":"NCT02555657","version_a":41,"version_b":42,"version_a_date":"2017-08-18","version_b_date":"2017-09-22","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to 32 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to 37 months ]"}],"start_date":"October 13, 2015","primary_completion_date":"April 11, 2019","completion_date":"November 10, 2020","first_posted":"September 21, 2015","results_first_posted":"May 4, 2020","last_update_posted":"December 10, 2021"},{"nctid":"NCT02555657","version_a":42,"version_b":43,"version_a_date":"2017-09-22","version_b_date":"2019-01-22","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to 37 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to 42 months ]"}],"start_date":"October 13, 2015","primary_completion_date":"April 11, 2019","completion_date":"November 10, 2020","first_posted":"September 21, 2015","results_first_posted":"May 4, 2020","last_update_posted":"December 10, 2021"},{"nctid":"NCT02555657","version_a":46,"version_b":47,"version_a_date":"2020-02-25","version_b_date":"2020-04-22","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Up to 42 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) \u226510[ Time Frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) ]Overall survival (OS) was defined as the time from randomization to death due to any cause."},{"label":"2.","content":"Overall Survival in Participants With PD-L1 CPS \u22651[ Time Frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) ]Overall survival (OS) was defined as the time from randomization to death due to any cause."},{"label":"3.","content":"Overall Survival in All Participants[ Time Frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019) ]Overall survival (OS) was defined as the time from randomization to death due to any cause."}],"start_date":"October 13, 2015","primary_completion_date":"April 11, 2019","completion_date":"November 10, 2020","first_posted":"September 21, 2015","results_first_posted":"May 4, 2020","last_update_posted":"December 10, 2021"},{"nctid":"NCT01905592","version_a":35,"version_b":36,"version_a_date":"2014-09-10","version_b_date":"2014-09-18","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: After 96 PFS events (40%) have been documented. Anticipated in about 16 months from first patient enrolled ]The primary objective of this study is to compare progression-free survival as determined by central, blinded review, of patients with advanced/metastatic HER2-negative breast cancer who have a gBRCAmut when treated with niraparib as compared to those treated with physician\'s choice"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: December 2015 ]The primary objective of this study is to compare progression-free survival as determined by central, blinded review, of patients with advanced/metastatic HER2-negative breast cancer who have a gBRCAmut when treated with niraparib as compared to those treated with physician\'s choice"}],"start_date":"February 25, 2014","primary_completion_date":"May 23, 2018","completion_date":"October 26, 2021","first_posted":"July 23, 2013","results_first_posted":"August 27, 2020","last_update_posted":"November 5, 2021"},{"nctid":"NCT01905592","version_a":67,"version_b":68,"version_a_date":"2019-04-25","version_b_date":"2020-08-10","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: December 2015 ]The primary objective of this study is to compare progression-free survival as determined by central, blinded review, of patients with advanced/metastatic HER2-negative breast cancer who have a gBRCAmut when treated with niraparib as compared to those treated with physician\'s choice"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS) - Central Review Assessment[ Time Frame: From the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier, up to 4 years ]The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of patients with advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gBRCAmut breast cancer when treated with niraparib as compared to those treated with physician\'s choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine). PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per Response evaluation criteria in solid tumors (RECIST) version 1.1 as determined by central review assessment."}],"start_date":"February 25, 2014","primary_completion_date":"May 23, 2018","completion_date":"October 26, 2021","first_posted":"July 23, 2013","results_first_posted":"August 27, 2020","last_update_posted":"November 5, 2021"},{"nctid":"NCT00876915","version_a":9,"version_b":10,"version_a_date":"2014-04-04","version_b_date":"2015-09-09","pom_a":[{"label":"1.","content":"To conduct a prospective, randomized clinical trial comparing the safety and efficacy of prophylaxis with dalteparin to no treatment in reducing VTE in high-risk ambulatory cancer patients initiating chemotherapy.[ Time Frame: 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Percentage of Patients With Venous Thromboembolisms[ Time Frame: 12 weeks ]The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT."},{"label":"2.","content":"Percentage of Patients Who Experienced Clinically Significant Bleeding Events.[ Time Frame: 13 weeks ]The percentage of patients who experienced a clinically significant bleeding event were recorded (including major and clinically significant non-major bleeding) over 13 weeks (12 weeks of study and an additional week of observation). Major bleeding was defined as being clinically overt and satisfying one of the following: decrease in hemoglobin of 2.0 g/dL, leading to transfusion of 2 or more units of blood or packed red cells, occurring in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leading to death. Clinically significant non-major bleeding was defined as clinically overt, not meeting criteria for major bleeding and with one of the following characteristics: multiple-source, spontaneous hematoma > 25 cm\xb2, epistaxis > 5 mins, macroscopic hematuria not related to instrumentation, spontaneous rectal bleeding, gingival bleeding > 5 mins, hemoptysis, hematemesis or prolonged bleeding (> 5 minutes) after venipuncture."}],"start_date":"July 2009","primary_completion_date":"July 2014","completion_date":"December 2014","first_posted":"April 7, 2009","results_first_posted":"October 12, 2015","last_update_posted":"November 24, 2015"},{"nctid":"NCT04093362","version_a":2,"version_b":3,"version_a_date":"2019-09-18","version_b_date":"2020-02-06","pom_a":[{"label":"1.","content":"Measurements of disease will be performed using RECIST guidelines. Tumor assessments CT or MRI will be performed at baseline and at the end of every 2 cycles up to Cycle 4 and every 3 cycles beyond cycle 4 (or as clinically indicated).[ Time Frame: 10 months ]Response assessments will be made based on RECIST guidelines (version 1.1, 2009) for solid tumors"}],"pom_b":[{"label":"1.","content":"PFS[ Time Frame: up to 12 months ]defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first."}],"start_date":"March 1, 2020","primary_completion_date":"April 2027","completion_date":"April 2028","first_posted":"September 18, 2019","last_update_posted":"August 8, 2022"},{"nctid":"NCT04093362","version_a":5,"version_b":6,"version_a_date":"2021-04-09","version_b_date":"2021-12-23","pom_a":[{"label":"1.","content":"PFS[ Time Frame: up to 12 months ]defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first."}],"pom_b":[{"label":"1.","content":"PFS: defined as the time from date of randomization to the date of documentation of disease progression by ICR per RECIST (version 1.1, 2009) or date of death, whichever comes first.[ Time Frame: up to 12 months ]Response assessments will be made based on RECIST guidelines (version 1.1, 2009) for solid tumors"}],"start_date":"March 1, 2020","primary_completion_date":"April 2027","completion_date":"April 2028","first_posted":"September 18, 2019","last_update_posted":"August 8, 2022"},{"nctid":"NCT00124748","version_a":7,"version_b":8,"version_a_date":"2006-05-16","version_b_date":"2006-08-14","pom_a":[],"pom_b":[{"label":"1.","content":"Efficacy"}],"start_date":"June 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"July 28, 2005","results_first_posted":"February 3, 2012","last_update_posted":"February 3, 2012"},{"nctid":"NCT00124748","version_a":13,"version_b":14,"version_a_date":"2009-11-20","version_b_date":"2010-09-13","pom_a":[{"label":"1.","content":"Efficacy"}],"pom_b":[{"label":"1.","content":"Efficacy - rate of MMR[ Time Frame: at 12 months ]"}],"start_date":"June 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"July 28, 2005","results_first_posted":"February 3, 2012","last_update_posted":"February 3, 2012"},{"nctid":"NCT00124748","version_a":18,"version_b":19,"version_a_date":"2011-09-28","version_b_date":"2012-01-05","pom_a":[{"label":"1.","content":"Efficacy - rate of MMR[ Time Frame: at 12 months ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months[ Time Frame: 12 months ]MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region [Bcr] gene and Abelson proto-oncogene [Abl] genes) transcript ratio \u22640.1% (\u2265 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction [RT-PCR] (performed centrally)."}],"start_date":"June 2005","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"July 28, 2005","results_first_posted":"February 3, 2012","last_update_posted":"February 3, 2012"},{"nctid":"NCT03092674","version_a":14,"version_b":15,"version_a_date":"2017-12-28","version_b_date":"2018-01-12","pom_a":[{"label":"1.","content":"OS (Phase III)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]Will compare OS between the control arm and experimental arm(s) selected in the Phase II study. An efficacy test will be done using a stratified log-rank test with a one-sided alpha of 0.5%. A futility test will be done using a stratified log-rank test (modified to test the alternative HR) with a one-sided alpha of 1.0%. Each final test (stratified log-rank test of the null hypothesis) of an experimental arm versus azacitidine will be done with a two-sided alpha of 4.8%."},{"label":"2.","content":"Overall survival (OS) (Phase II)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]A stratified log-rank test of the null hypothesis (HR=1) with a one-sided alpha of 15% will be used to test an experimental arm versus azacitidine for further phase III testing."}],"pom_b":[{"label":"1.","content":"OS (Phase III)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]Will compare OS between the control arm and experimental arm(s) selected in the Phase II study. An efficacy test will be done using a stratified log-rank test with a one-sided alpha of 0.5%. A futility test will be done using a stratified log-rank test (modified to test the alternative HR) with a one-sided alpha of 1.0%. Each final test (stratified log-rank test of the null hypothesis) of an experimental arm versus azacitidine will be done with a two-sided alpha of 4.8%."},{"label":"2.","content":"Overall survival (OS) (Phase II)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]A stratified log-rank test of the null hypothesis (hazard ratio=1) with a one-sided alpha of 15% will be used to test an experimental arm versus azacitidine for further phase III testing."}],"start_date":"December 22, 2017","primary_completion_date":"August 1, 2023","completion_date":"August 1, 2023","first_posted":"March 28, 2017","last_update_posted":"August 31, 2022"},{"nctid":"NCT03092674","version_a":26,"version_b":27,"version_a_date":"2018-02-15","version_b_date":"2018-03-06","pom_a":[{"label":"1.","content":"OS (Phase III)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]Will compare OS between the control arm and experimental arm(s) selected in the Phase II study. An efficacy test will be done using a stratified log-rank test with a one-sided alpha of 0.5%. A futility test will be done using a stratified log-rank test (modified to test the alternative HR) with a one-sided alpha of 1.0%. Each final test (stratified log-rank test of the null hypothesis) of an experimental arm versus azacitidine will be done with a two-sided alpha of 4.8%."},{"label":"2.","content":"Overall survival (OS) (Phase II)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]A stratified log-rank test of the null hypothesis (hazard ratio=1) with a one-sided alpha of 15% will be used to test an experimental arm versus azacitidine for further phase III testing."}],"pom_b":[{"label":"1.","content":"Overall survival (OS) (Phase II)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]A stratified log-rank test of the null hypothesis (hazard ratio=1) with a one-sided alpha of 15% will be used to test an experimental arm versus azacitidine for further phase III testing."},{"label":"2.","content":"OS (Phase III)[ Time Frame: Day of registration on study until death from any cause, assessed for up to 5 years ]Will compare OS between the control arm and experimental arm(s) selected in the Phase II study. An efficacy test will be done using a stratified log-rank test with a one-sided alpha of 0.5%. A futility test will be done using a stratified log-rank test (modified to test the alternative HR) with a one-sided alpha of 1.0%. Each final test (stratified log-rank test of the null hypothesis) of an experimental arm versus azacitidine will be done with a two-sided alpha of 4.8%."}],"start_date":"December 22, 2017","primary_completion_date":"August 1, 2023","completion_date":"August 1, 2023","first_posted":"March 28, 2017","last_update_posted":"August 31, 2022"},{"nctid":"NCT00005090","version_a":19,"version_b":20,"version_a_date":"2011-07-21","version_b_date":"2012-01-11","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: every 3 months while on protocol treatment, then every 6 months for 2 years, then annually thereafter ]"}],"start_date":"April 2000","primary_completion_date":"May 2005","completion_date":"May 2005","first_posted":"August 28, 2003","last_update_posted":"January 24, 2013"},{"nctid":"NCT03734016","version_a":21,"version_b":22,"version_a_date":"2019-12-05","version_b_date":"2020-02-27","pom_a":[{"label":"1.","content":"Overall response rate determined by independent central review[ Time Frame: 29 months ]"}],"pom_b":[{"label":"1.","content":"Overall response rate determined by investigator assessment[ Time Frame: Up to 36 months ]"}],"start_date":"November 1, 2018","primary_completion_date":"January 2023","completion_date":"August 2023","first_posted":"November 7, 2018","last_update_posted":"December 6, 2021"},{"nctid":"NCT03734016","version_a":25,"version_b":26,"version_a_date":"2020-05-04","version_b_date":"2020-06-10","pom_a":[{"label":"1.","content":"Overall response rate determined by investigator assessment[ Time Frame: Up to 36 months ]"}],"pom_b":[{"label":"1.","content":"Overall response rate determined by investigator assessment[ Time Frame: Up to 50 months ]"}],"start_date":"November 1, 2018","primary_completion_date":"January 2023","completion_date":"August 2023","first_posted":"November 7, 2018","last_update_posted":"December 6, 2021"},{"nctid":"NCT01322490","version_a":22,"version_b":23,"version_a_date":"2012-10-22","version_b_date":"2012-12-18","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Survival will be assessed over the life of the study or approximately 5 years. ]Overall survival will be measured for all patients until the required number of events per comparison arm is reached (approximately 534 events per comparison arm)."}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Survival will be assessed over the life of the study ]Overall survival will be measured for all patients until the required number of events per comparison arm is reached."}],"start_date":"November 28, 2011","primary_completion_date":"September 25, 2017","completion_date":"December 15, 2017","first_posted":"March 24, 2011","results_first_posted":"August 8, 2019","last_update_posted":"September 4, 2019"},{"nctid":"NCT01322490","version_a":53,"version_b":54,"version_a_date":"2019-03-12","version_b_date":"2019-07-16","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Survival will be assessed over the life of the study ]Overall survival will be measured for all patients until the required number of events per comparison arm is reached."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Randomization through long term follow-up. ]The time between the date of randomization and the date of death due to any cause. Subjects who did not experience death or the competing events of \\"definite\\" loss to follow-up or withdrawal of consent were right censored at the date of last contact. OS was calculated using the formula: OS = Date of death/competing event/censoring - date of randomization + 1."}],"start_date":"November 28, 2011","primary_completion_date":"September 25, 2017","completion_date":"December 15, 2017","first_posted":"March 24, 2011","results_first_posted":"August 8, 2019","last_update_posted":"September 4, 2019"},{"nctid":"NCT01322490","version_a":54,"version_b":55,"version_a_date":"2019-07-16","version_b_date":"2019-08-09","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Randomization through long term follow-up. ]The time between the date of randomization and the date of death due to any cause. Subjects who did not experience death or the competing events of \\"definite\\" loss to follow-up or withdrawal of consent were right censored at the date of last contact. OS was calculated using the formula: OS = Date of death/competing event/censoring - date of randomization + 1."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Randomization through the date of death due to any cause. Subjects were followed up for approximately 6 years from the first subject randomized to the completion of the study. ]The time between the date of randomization and the date of death due to any cause. Subjects who did not experience death or the competing events of \\"definite\\" loss to follow-up or withdrawal of consent were right censored at the date of last contact. OS was calculated using the formula: OS = Date of death/competing event/censoring - date of randomization + 1."}],"start_date":"November 28, 2011","primary_completion_date":"September 25, 2017","completion_date":"December 15, 2017","first_posted":"March 24, 2011","results_first_posted":"August 8, 2019","last_update_posted":"September 4, 2019"},{"nctid":"NCT00388726","version_a":10,"version_b":11,"version_a_date":"2007-08-22","version_b_date":"2008-04-24","pom_a":[{"label":"1.","content":"Overall survival."}],"pom_b":[{"label":"1.","content":"Overall survival.[ Time Frame: Until end of study. ]"}],"start_date":"November 2006","primary_completion_date":"May 2009","completion_date":"June 2013","first_posted":"October 17, 2006","results_first_posted":"January 30, 2012","last_update_posted":"January 7, 2020"},{"nctid":"NCT00388726","version_a":11,"version_b":12,"version_a_date":"2008-04-24","version_b_date":"2009-03-12","pom_a":[{"label":"1.","content":"Overall survival.[ Time Frame: Until end of study. ]"}],"pom_b":[{"label":"1.","content":"Overall survival.[ Time Frame: Until the date of death or the last date the patient is known to be alive. ]"}],"start_date":"November 2006","primary_completion_date":"May 2009","completion_date":"June 2013","first_posted":"October 17, 2006","results_first_posted":"January 30, 2012","last_update_posted":"January 7, 2020"},{"nctid":"NCT00388726","version_a":14,"version_b":15,"version_a_date":"2011-05-09","version_b_date":"2011-12-22","pom_a":[{"label":"1.","content":"Overall survival.[ Time Frame: Until the date of death or the last date the patient is known to be alive. ]"}],"pom_b":[{"label":"1.","content":"Overall Survival.[ Time Frame: Until the date of death or the last date the patient is known to be alive. ]"}],"start_date":"November 2006","primary_completion_date":"May 2009","completion_date":"June 2013","first_posted":"October 17, 2006","results_first_posted":"January 30, 2012","last_update_posted":"January 7, 2020"},{"nctid":"NCT00388726","version_a":15,"version_b":16,"version_a_date":"2011-12-22","version_b_date":"2012-03-19","pom_a":[{"label":"1.","content":"Overall Survival.[ Time Frame: Until the date of death or the last date the patient is known to be alive. ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From date of randomization until death from any cause ]Defined as the time from the date of randomization until the date of death from any cause."}],"start_date":"November 2006","primary_completion_date":"May 2009","completion_date":"June 2013","first_posted":"October 17, 2006","results_first_posted":"January 30, 2012","last_update_posted":"January 7, 2020"},{"nctid":"NCT00519090","version_a":2,"version_b":3,"version_a_date":"2007-09-27","version_b_date":"2008-01-17","pom_a":[{"label":"1.","content":"Rate of complete cytogenetic response (CCyR) after 12 months of treatment assessed by bone marrow to measure the degree of elimination of the cells that carry the Bcr-Abl protein in the bone marrow."}],"pom_b":[{"label":"1.","content":"Rate of complete cytogenetic response (CCyR) after 12 months of treatment"}],"start_date":"October 2007","primary_completion_date":"October 2008","completion_date":"October 2008","first_posted":"August 21, 2007","results_first_posted":"May 10, 2011","last_update_posted":"November 6, 2011"},{"nctid":"NCT00519090","version_a":7,"version_b":8,"version_a_date":"2009-09-18","version_b_date":"2009-10-23","pom_a":[{"label":"1.","content":"Rate of complete cytogenetic response (CCyR) after 12 months of treatment"}],"pom_b":[{"label":"1.","content":"Rate of complete cytogenetic response (CCyR) after 12 months of treatment[ Time Frame: 12 months ]"}],"start_date":"October 2007","primary_completion_date":"October 2008","completion_date":"October 2008","first_posted":"August 21, 2007","results_first_posted":"May 10, 2011","last_update_posted":"November 6, 2011"},{"nctid":"NCT00519090","version_a":13,"version_b":14,"version_a_date":"2010-10-27","version_b_date":"2011-04-07","pom_a":[{"label":"1.","content":"Rate of complete cytogenetic response (CCyR) after 12 months of treatment[ Time Frame: 12 months ]"}],"pom_b":[{"label":"1.","content":"Complete Cytogenetic Response Rate(CCyR) in Patients Who Had a Suboptimal Cytogenetic Response on Imatinib[ Time Frame: 12 months ]Due to early termination of the trial, the number of patients was too small and imbalanced and therefore analysis was not performed."}],"start_date":"October 2007","primary_completion_date":"October 2008","completion_date":"October 2008","first_posted":"August 21, 2007","results_first_posted":"May 10, 2011","last_update_posted":"November 6, 2011"},{"nctid":"NCT00119613","version_a":3,"version_b":4,"version_a_date":"2005-07-22","version_b_date":"2005-08-25","pom_a":[],"pom_b":[{"label":"1.","content":"*Change in hemoglobin concentration, *Survival"}],"start_date":"December 2002","primary_completion_date":"January 2007","completion_date":"April 2007","first_posted":"July 14, 2005","last_update_posted":"August 8, 2008"},{"nctid":"NCT00119613","version_a":5,"version_b":6,"version_a_date":"2006-03-17","version_b_date":"2006-11-16","pom_a":[{"label":"1.","content":"*Change in hemoglobin concentration, *Survival"}],"pom_b":[{"label":"1.","content":"Change in hemoglobin concentration, *Survival"}],"start_date":"December 2002","primary_completion_date":"January 2007","completion_date":"April 2007","first_posted":"July 14, 2005","last_update_posted":"August 8, 2008"},{"nctid":"NCT00119613","version_a":10,"version_b":11,"version_a_date":"2007-06-08","version_b_date":"2007-09-06","pom_a":[{"label":"1.","content":"Change in hemoglobin concentration, *Survival"}],"pom_b":[{"label":"1.","content":"Mean hemoglobin concentration during the chemotherapy treatment period"}],"start_date":"December 2002","primary_completion_date":"January 2007","completion_date":"April 2007","first_posted":"July 14, 2005","last_update_posted":"August 8, 2008"},{"nctid":"NCT00119613","version_a":12,"version_b":13,"version_a_date":"2007-12-20","version_b_date":"2008-02-01","pom_a":[{"label":"1.","content":"Mean hemoglobin concentration during the chemotherapy treatment period"}],"pom_b":[{"label":"1.","content":"Change in hemoglobin concentration from baseline to the end of the chemotherapy treatment period[ Time Frame: from baseline to the end of the chemotherapy treatment period ]"},{"label":"2.","content":"Survival time"}],"start_date":"December 2002","primary_completion_date":"January 2007","completion_date":"April 2007","first_posted":"July 14, 2005","last_update_posted":"August 8, 2008"},{"nctid":"NCT00186888","version_a":7,"version_b":8,"version_a_date":"2007-04-30","version_b_date":"2007-12-03","pom_a":[{"label":"1.","content":"To find out how many participants with retinoblastoma will respond to the individualized therapies given in this study"},{"label":"2.","content":"To learn more about the changes in vision in patients with retinoblastoma"},{"label":"3.","content":"To learn more about the intellectual, social and emotional development of children with retinoblastoma during the first five years of life"},{"label":"4.","content":"To learn more about the genetic make up of retinoblastoma tumors"}],"pom_b":[{"label":"1.","content":"To find out how many participants with retinoblastoma will respond to the individualized therapies given in this study[ Time Frame: 5 years ]"},{"label":"2.","content":"To learn more about the changes in vision in patients with retinoblastoma[ Time Frame: 5 years ]"},{"label":"3.","content":"To learn more about the intellectual, social and emotional development of children with retinoblastoma during the first five years of life[ Time Frame: 5 years ]"},{"label":"4.","content":"To learn more about the genetic make up of retinoblastoma tumors[ Time Frame: 5 years ]"}],"start_date":"April 7, 2005","primary_completion_date":"November 2013","completion_date":"January 2024","first_posted":"September 16, 2005","results_first_posted":"August 30, 2011","last_update_posted":"January 19, 2022"},{"nctid":"NCT00186888","version_a":16,"version_b":17,"version_a_date":"2010-11-24","version_b_date":"2011-07-28","pom_a":[{"label":"1.","content":"To find out how many participants with retinoblastoma will respond to the individualized therapies given in this study[ Time Frame: 5 years ]"},{"label":"2.","content":"To learn more about the changes in vision in patients with retinoblastoma[ Time Frame: 5 years ]"},{"label":"3.","content":"To learn more about the intellectual, social and emotional development of children with retinoblastoma during the first five years of life[ Time Frame: 5 years ]"},{"label":"4.","content":"To learn more about the genetic make up of retinoblastoma tumors[ Time Frame: 5 years ]"}],"pom_b":[{"label":"1.","content":"Stratum B Response to Window Therapy[ Time Frame: Six weeks post window therapy ]The primary outcome is to estimate the proportion of stratum B patients responding to 2 courses of window therapy consisting of vincristine and topotecan. Complete Response is the complete regression of all apparent tumor masses in the funduscopic examination and by MRI and ultrasound (US). Partial Response is defined as greater than 50% (but less than 100%) reduction of the tumor masses in the funduscopic examination and by US and MRI, without the appearance of any new lesions. The response must persist for at least 4 weeks. Stratum A and C did not receive window therapy."}],"start_date":"April 7, 2005","primary_completion_date":"November 2013","completion_date":"January 2024","first_posted":"September 16, 2005","results_first_posted":"August 30, 2011","last_update_posted":"January 19, 2022"},{"nctid":"NCT00394992","version_a":2,"version_b":3,"version_a_date":"2007-06-26","version_b_date":"2008-09-05","pom_a":[{"label":"1.","content":"3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation."}],"pom_b":[{"label":"1.","content":"3-year disease free survival, defined as the percentage of disease free patients 3 year after randomisation.[ Time Frame: study duration ]"}],"start_date":"December 2006","primary_completion_date":"August 2013","completion_date":"August 2013","first_posted":"November 2, 2006","last_update_posted":"February 4, 2014"},{"nctid":"NCT02438722","version_a":13,"version_b":14,"version_a_date":"2020-04-03","version_b_date":"2021-02-23","pom_a":[{"label":"1.","content":"OS (phase III)[ Time Frame: From date of registration to date of death due to any cause, assessed up to 3 years ]"},{"label":"2.","content":"PFS (phase II)[ Time Frame: From date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 3 years ]"}],"pom_b":[{"label":"1.","content":"2-year Overall Survival Rate[ Time Frame: Up to 3 years post registration ]Percentage of participants still alive 2 years post registration.KM estimate at 2 years is presented, Overall Survival assessed for a total of 3 years in order to calculate value."},{"label":"2.","content":"Progression-Free Survival[ Time Frame: up to 3 years post registration ]From date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed, as well as an absolute increase of at least 0.5 cm. Unequivocal progression of non-measurable disease in the opinion of treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration."}],"start_date":"March 25, 2015","primary_completion_date":"September 25, 2018","completion_date":"October 12, 2022","first_posted":"May 8, 2015","results_first_posted":"March 17, 2021","last_update_posted":"May 24, 2022"},{"nctid":"NCT01369329","version_a":10,"version_b":11,"version_a_date":"2012-02-23","version_b_date":"2012-03-08","pom_a":[{"label":"1.","content":"Clinical Response[ Time Frame: Week 6 ]"}],"pom_b":[{"label":"1.","content":"Clinical Response[ Time Frame: Week 6 ]The number of patients in clinical response, as measured by the reduction from baseline in the Crohn\'s Disease Activity Index (CDAI), which is assessed by collecting information on extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being."}],"start_date":"July 2011","primary_completion_date":"June 2013","completion_date":"July 2013","first_posted":"June 8, 2011","results_first_posted":"December 7, 2016","last_update_posted":"December 7, 2016"},{"nctid":"NCT01369329","version_a":39,"version_b":40,"version_a_date":"2015-07-01","version_b_date":"2016-10-14","pom_a":[{"label":"1.","content":"Clinical Response[ Time Frame: Week 6 ]The number of patients in clinical response, as measured by the reduction from baseline in the Crohn\'s Disease Activity Index (CDAI), which is assessed by collecting information on extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being."}],"pom_b":[{"label":"1.","content":"Number of Participants With Clinical Response at Week 6[ Time Frame: Baseline and Week 6 ]Clinical response at Week 6 was defined as a reduction from baseline in the Crohn\'s Disease Activity Index score of greater than or equal (>=) 100 points (in general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities). Participants with a baseline CDAI score of > = 220 to less than or equal (< =) 248 were considered to be in clinical response if a CDAI score of less than (<) 150 was attained. A CDAI score of less than 150 indicates clinical remission. A decrease in CDAI score over time indicates improvement in disease activity."}],"start_date":"July 2011","primary_completion_date":"June 2013","completion_date":"July 2013","first_posted":"June 8, 2011","results_first_posted":"December 7, 2016","last_update_posted":"December 7, 2016"},{"nctid":"NCT00507416","version_a":1,"version_b":2,"version_a_date":"2007-07-25","version_b_date":"2008-03-12","pom_a":[{"label":"1.","content":"Progression Free Survival."}],"pom_b":[{"label":"1.","content":"Progression Free Survival.[ Time Frame: Up to 3 years after treatment is completed ]"}],"start_date":"June 2007","primary_completion_date":"March 2013","completion_date":"March 2013","first_posted":"July 26, 2007","results_first_posted":"May 1, 2014","last_update_posted":"May 1, 2014"},{"nctid":"NCT00507416","version_a":19,"version_b":20,"version_a_date":"2013-07-01","version_b_date":"2014-03-28","pom_a":[{"label":"1.","content":"Progression Free Survival.[ Time Frame: Up to 3 years after treatment is completed ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: From randomization until disease progression. Median follow-up time was 43 months. ]PFS is defined as the time from randomization to disease progression or death, whichever occurs first. Participants who did not progress and were still alive at the cut-off date were censored at the date of last contact. Response was assessed by the Investigator using the International Myeloma Working Group (IMWG) uniform response criteria.Progressive disease requires 1 of the following:Increase of \u2265 25% from nadir in:Serum M-component (absolute increase \u2265 0.5 g/dl)Urine M-component (absolute increase \u2265 200 mg/24 hours)In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 100 mg/dl)Bone marrow plasma cell percentage (absolute % \u2265 10%)Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease"}],"start_date":"June 2007","primary_completion_date":"March 2013","completion_date":"March 2013","first_posted":"July 26, 2007","results_first_posted":"May 1, 2014","last_update_posted":"May 1, 2014"},{"nctid":"NCT02414165","version_a":1,"version_b":2,"version_a_date":"2015-04-07","version_b_date":"2015-04-14","pom_a":[{"label":"1.","content":"Compare overall survival between two arms (requires 91 events)[ Time Frame: 21 months from first patient randomized ]"}],"pom_b":[{"label":"1.","content":"Compare overall survival between two arms (requires 116 events)[ Time Frame: 21 months from first patient randomized ]"}],"start_date":"November 30, 2015","primary_completion_date":"May 31, 2019","completion_date":"December 20, 2019","first_posted":"April 10, 2015","last_update_posted":"February 7, 2020"},{"nctid":"NCT02414165","version_a":60,"version_b":61,"version_a_date":"2017-10-24","version_b_date":"2017-10-26","pom_a":[{"label":"1.","content":"Compare overall survival between two arms (requires 116 events)[ Time Frame: 21 months from first patient randomized ]"}],"pom_b":[{"label":"1.","content":"To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma[ Time Frame: 49 months from first patient randomized ]"}],"start_date":"November 30, 2015","primary_completion_date":"May 31, 2019","completion_date":"December 20, 2019","first_posted":"April 10, 2015","last_update_posted":"February 7, 2020"},{"nctid":"NCT02414165","version_a":61,"version_b":62,"version_a_date":"2017-10-26","version_b_date":"2017-10-30","pom_a":[{"label":"1.","content":"To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma[ Time Frame: 49 months from first patient randomized ]"}],"pom_b":[{"label":"1.","content":"To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma[ Time Frame: 30 December 2019 ]"}],"start_date":"November 30, 2015","primary_completion_date":"May 31, 2019","completion_date":"December 20, 2019","first_posted":"April 10, 2015","last_update_posted":"February 7, 2020"},{"nctid":"NCT02414165","version_a":62,"version_b":63,"version_a_date":"2017-10-30","version_b_date":"2017-10-31","pom_a":[{"label":"1.","content":"To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma[ Time Frame: 30 December 2019 ]"}],"pom_b":[{"label":"1.","content":"To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma[ Time Frame: 30 December 2019 ]Time from randomization date to death due to any cause"}],"start_date":"November 30, 2015","primary_completion_date":"May 31, 2019","completion_date":"December 20, 2019","first_posted":"April 10, 2015","last_update_posted":"February 7, 2020"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,C.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,j.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,j.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,j.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,D.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,c=n.breakpoints,u=[];r&&(u=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,c,t));var d=[];return c.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,j.Z)(u),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var c="".concat(Math.round(t/l*1e8)/1e6,"%"),u={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var f="calc(".concat(c," + ").concat(ie(d),")");u={flexBasis:f,maxWidth:f}}}i=(0,r.Z)({flexBasis:c,flexGrow:0,maxWidth:c},u)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ce=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,c=[];n&&(c=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var u=[];l.forEach((function(t){var n=e[t];n&&u.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,j.Z)(c),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],u)};return(0,T.Z)(d,te,t)},ue=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,V.Z)(m.Z).breakpoints,s=H(o),l=s.className,c=s.columns,u=s.columnSpacing,d=s.component,p=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,b=s.direction,y=void 0===b?"row":b,g=s.item,_=void 0!==g&&g,S=s.rowSpacing,C=s.spacing,T=void 0===C?0:C,x=s.wrap,F=void 0===x?"wrap":x,P=s.zeroMinWidth,E=void 0!==P&&P,R=(0,w.Z)(s,oe),A=S||T,N=u||T,I=e.useContext(X),O=v?c||12:I,D={},M=(0,r.Z)({},R);i.keys.forEach((function(e){null!=R[e]&&(D[e]=R[e],delete M[e])}));var z=(0,r.Z)({},s,{columns:O,container:v,direction:y,item:_,rowSpacing:A,columnSpacing:N,wrap:F,zeroMinWidth:E,spacing:T},D,{breakpoints:i.keys}),L=ce(z);return(0,f.jsx)(X.Provider,{value:O,children:(0,f.jsx)(le,(0,r.Z)({ownerState:z,className:(0,k.Z)(L.root,l),as:p,ref:n},M))})})),de=ue,fe=n(2065);function pe(e){return(0,C.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,D.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,fe.Fq)("#fff",he(a.elevation)),", ").concat((0,fe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),be=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,c=void 0===l?1:l,u=n.square,d=void 0!==u&&u,p=n.variant,m=void 0===p?"elevation":p,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:c,square:d,variant:m}),b=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,T.Z)(o,pe,a)}(v);return(0,f.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,k.Z)(b.root,o),ref:t},h))}));function ye(e){return(0,C.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,D.ZP)(be,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),c=(0,r.Z)({},n,{raised:s}),u=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},ye,t)}(c);return(0,f.jsx)(_e,(0,r.Z)({className:(0,k.Z)(u.root,o),elevation:s?8:void 0,ref:t,ownerState:c},l))}));function ke(e){return(0,C.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var Se=["className","component"],Ce=(0,D.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),Te=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,Se),c=(0,r.Z)({},n,{component:s}),u=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},ke,t)}(c);return(0,f.jsx)(Ce,(0,r.Z)({as:s,className:(0,k.Z)(u.root,o),ownerState:c,ref:t},l))}));function xe(e){return(0,C.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var Fe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Pe=(0,D.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,O.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Ee={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Re={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Ae=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Re[e]||e}(n.color),i=H((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,c=i.className,u=i.component,d=i.gutterBottom,p=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,b=void 0!==v&&v,y=i.variant,g=void 0===y?"body1":y,_=i.variantMapping,S=void 0===_?Ee:_,C=(0,w.Z)(i,Fe),x=(0,r.Z)({},i,{align:l,color:o,className:c,component:u,gutterBottom:p,noWrap:h,paragraph:b,variant:g,variantMapping:S}),F=u||(b?"p":S[g]||Ee[g])||"span",P=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,O.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,T.Z)(s,xe,i)}(x);return(0,f.jsx)(Pe,(0,r.Z)({as:F,ref:t,ownerState:x,className:(0,k.Z)(P.root,c)},C))})),Ne=n(5682),Ie=["component","direction","spacing","divider","children"];function Oe(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var De=(0,D.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Ne.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,B.Z)(a,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Ne.NA)(o,e))};var r})))}return a=(0,Y.dt)(n.breakpoints,a)})),Me=e.forwardRef((function(e,t){var n=H((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,c=n.spacing,u=void 0===c?0:c,d=n.divider,p=n.children,m=(0,w.Z)(n,Ie),h={direction:l,spacing:u};return(0,f.jsx)(De,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Oe(p,d):p}))})),ze=Me,Le=n(1774),Ze=n.n(Le);var je=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,f.jsx)(we,{children:(0,f.jsx)(Te,{children:(0,f.jsxs)(Ae,{children:[(0,f.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,f.jsxs)(de,{container:!0,spacing:2,children:[(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsx)(Te,{children:(0,f.jsxs)(de,{container:!0,children:[(0,f.jsxs)(de,{item:!0,xs:4,children:[(0,f.jsxs)(Ae,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,f.jsxs)(Ae,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,f.jsxs)(Ae,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,f.jsxs)(Ae,{children:["Start Date: ",t.start_date]}):null]}),(0,f.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,f.jsxs)(Ae,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,f.jsxs)(Ae,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Te,{children:[(0,f.jsxs)(Ae,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,f.jsx)(Ae,{variant:"caption"}),(0,f.jsx)(ze,{spacing:1,children:l(t.pom_a)})]})})}),(0,f.jsx)(de,{item:!0,xs:6,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Te,{children:[(0,f.jsxs)(Ae,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,f.jsx)(ze,{spacing:1,children:l(t.pom_b)})]})})}),(0,f.jsx)(de,{item:!0,xs:12,children:(0,f.jsx)(we,{children:(0,f.jsxs)(Te,{children:[(0,f.jsx)(Ae,{variant:"h6",children:"Compare the Raw Text"}),(0,f.jsx)(Ze(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Le.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Be(e){return(0,C.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var We=["className","color","enableColorOnDark","position"],Ue=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},He=(0,D.ZP)(be,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,O.Z)(n.position))],t["color".concat((0,O.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Ue(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Ue(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),Ve=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,c=void 0!==l&&l,u=n.position,d=void 0===u?"fixed":u,p=(0,w.Z)(n,We),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:c}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,O.Z)(t)),"position".concat((0,O.Z)(n))]};return(0,T.Z)(a,Be,r)}(m);return(0,f.jsx)(He,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,k.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},p))}));function Je(e){return(0,C.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var $e=["className","component","disableGutters","variant"],Ge=(0,D.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,c=void 0!==l&&l,u=n.variant,d=void 0===u?"regular":u,p=(0,w.Z)(n,$e),m=(0,r.Z)({},n,{component:s,disableGutters:c,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,T.Z)(n,Je,t)}(m);return(0,f.jsx)(Ge,(0,r.Z)({as:s,className:(0,k.Z)(h.root,o),ref:t,ownerState:m},p))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var c=a[l][r];s[a[l][r]]=n(c)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,c=i in a,u=n[i],d=(0,e.isValidElement)(u)&&!u.props.in;!c||l&&!d?c||!l||d?c&&l&&(0,e.isValidElement)(u)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:u.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,c=t.in,u=t.onExited,d=t.timeout,p=e.useState(!1),m=(0,g.Z)(p,2),h=m[0],v=m[1],b=(0,k.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),y={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,k.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return c||h||v(!0),e.useEffect((function(){if(!c&&null!=u){var e=setTimeout(u,d);return function(){clearTimeout(e)}}}),[u,c,d]),(0,f.jsx)("span",{className:b,style:y,children:(0,f.jsx)("span",{className:_})})};var ct,ut,dt,ft,pt,mt,ht,vt,bt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),yt=["center","classes","className"],gt=d(pt||(pt=ct||(ct=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ut||(ut=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),kt=(0,D.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),St=(0,D.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=ft||(ft=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),bt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),bt.child,bt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Ct=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,c=void 0===l?{}:l,u=o.className,d=(0,w.Z)(o,yt),p=e.useState([]),m=(0,g.Z)(p,2),h=m[0],v=m[1],b=e.useRef(0),y=e.useRef(null);e.useEffect((function(){y.current&&(y.current(),y.current=null)}),[h]);var _=e.useRef(!1),S=e.useRef(null),C=e.useRef(null),T=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(S.current)}}),[]);var x=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,j.Z)(e),[(0,f.jsx)(St,{classes:{ripple:(0,k.Z)(c.ripple,bt.ripple),rippleVisible:(0,k.Z)(c.rippleVisible,bt.rippleVisible),ripplePulsate:(0,k.Z)(c.ripplePulsate,bt.ripplePulsate),child:(0,k.Z)(c.child,bt.child),childLeaving:(0,k.Z)(c.childLeaving,bt.childLeaving),childPulsate:(0,k.Z)(c.childPulsate,bt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},b.current)])})),b.current+=1,y.current=o}),[c]),F=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,c=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var u,d,f,p=c?null:T.current,m=p?p.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)u=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,b=h.clientY;u=Math.round(v-m.left),d=Math.round(b-m.top)}if(i)(f=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(f+=1);else{var y=2*Math.max(Math.abs((p?p.clientWidth:0)-u),u)+2,g=2*Math.max(Math.abs((p?p.clientHeight:0)-d),d)+2;f=Math.sqrt(Math.pow(y,2)+Math.pow(g,2))}null!=e&&e.touches?null===C.current&&(C.current=function(){x({pulsate:a,rippleX:u,rippleY:d,rippleSize:f,cb:n})},S.current=setTimeout((function(){C.current&&(C.current(),C.current=null)}),80)):x({pulsate:a,rippleX:u,rippleY:d,rippleSize:f,cb:n})}}),[s,x]),P=e.useCallback((function(){F({},{pulsate:!0})}),[F]),E=e.useCallback((function(e,t){if(clearTimeout(S.current),"touchend"===(null==e?void 0:e.type)&&C.current)return C.current(),C.current=null,void(S.current=setTimeout((function(){E(e,t)})));C.current=null,v((function(e){return e.length>0?e.slice(1):e})),y.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:P,start:F,stop:E}}),[P,F,E]),(0,f.jsx)(kt,(0,r.Z)({className:(0,k.Z)(bt.root,c.root,u),ref:T},d,{children:(0,f.jsx)(st,{component:null,exit:!0,children:h})}))})),Tt=Ct;function xt(e){return(0,C.Z)("MuiButtonBase",e)}var Ft,Pt=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),Et=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Rt=(0,D.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((Ft={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(Ft,"&.".concat(Pt.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(Ft,"@media print",{colorAdjust:"exact"}),Ft)),At=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,c=o.children,u=o.className,d=o.component,p=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,b=void 0!==v&&v,y=o.disableTouchRipple,_=void 0!==y&&y,S=o.focusRipple,C=void 0!==S&&S,x=o.LinkComponent,F=void 0===x?"a":x,P=o.onBlur,E=o.onClick,R=o.onContextMenu,A=o.onDragLeave,N=o.onFocus,I=o.onFocusVisible,O=o.onKeyDown,D=o.onKeyUp,M=o.onMouseDown,z=o.onMouseLeave,L=o.onMouseUp,Z=o.onTouchEnd,j=o.onTouchMove,B=o.onTouchStart,W=o.tabIndex,U=void 0===W?0:W,H=o.TouchRippleProps,V=o.touchRippleRef,J=o.type,$=(0,w.Z)(o,Et),G=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,V),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),G.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ce=se[1];e.useEffect((function(){ce(!0)}),[]);var ue=le&&!b&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&C&&!b&&le&&q.current.pulsate()}),[b,C,ae,le]);var fe=de("start",M),pe=de("stop",R),me=de("stop",A),he=de("stop",L),ve=de("stop",(function(e){ae&&e.preventDefault(),z&&z(e)})),be=de("start",B),ye=de("stop",Z),ge=de("stop",j),_e=de("stop",(function(e){ee(e),!1===Y.current&&oe(!1),P&&P(e)}),!1),we=(0,Qe.Z)((function(e){G.current||(G.current=e.currentTarget),X(e),!0===Y.current&&(oe(!0),I&&I(e)),N&&N(e)})),ke=function(){var e=G.current;return p&&"button"!==p&&!("A"===e.tagName&&e.href)},Se=e.useRef(!1),Ce=(0,Qe.Z)((function(e){C&&!Se.current&&ae&&q.current&&" "===e.key&&(Se.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&ke()&&" "===e.key&&e.preventDefault(),O&&O(e),e.target===e.currentTarget&&ke()&&"Enter"===e.key&&!h&&(e.preventDefault(),E&&E(e))})),Te=(0,Qe.Z)((function(e){C&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(Se.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),D&&D(e),E&&e.target===e.currentTarget&&ke()&&" "===e.key&&!e.defaultPrevented&&E(e)})),xe=p;"button"===xe&&($.href||$.to)&&(xe=F);var Fe={};"button"===xe?(Fe.type=void 0===J?"button":J,Fe.disabled=h):($.href||$.to||(Fe.role="button"),h&&(Fe["aria-disabled"]=h));var Pe=(0,Ke.Z)(te,G),Ee=(0,Ke.Z)(n,Pe);var Re=(0,r.Z)({},o,{centerRipple:l,component:p,disabled:h,disableRipple:b,disableTouchRipple:_,focusRipple:C,tabIndex:U,focusVisible:ae}),Ae=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,T.Z)(o,xt,a);return n&&r&&(i.root+=" ".concat(r)),i}(Re);return(0,f.jsxs)(Rt,(0,r.Z)({as:xe,className:(0,k.Z)(Ae.root,u),ownerState:Re,onBlur:_e,onClick:E,onContextMenu:pe,onFocus:we,onKeyDown:Ce,onKeyUp:Te,onMouseDown:fe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:ye,onTouchMove:ge,onTouchStart:be,ref:Ee,tabIndex:h?-1:U,type:J},Fe,$,{children:[c,ue?(0,f.jsx)(Tt,(0,r.Z)({ref:K,center:l},H)):null]}))})),Nt=At;function It(e){return(0,C.Z)("MuiIconButton",e)}var Ot=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Dt=["edge","children","className","color","disabled","disableFocusRipple","size"],Mt=(0,D.ZP)(Nt,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,O.Z)(n.color))],n.edge&&t["edge".concat((0,O.Z)(n.edge))],t["size".concat((0,O.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,fe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Ot.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),zt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,c=n.color,u=void 0===c?"default":c,d=n.disabled,p=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,b=void 0===v?"medium":v,y=(0,w.Z)(n,Dt),g=(0,r.Z)({},n,{edge:i,color:u,disabled:p,disableFocusRipple:h,size:b}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,O.Z)(r)),a&&"edge".concat((0,O.Z)(a)),"size".concat((0,O.Z)(o))]};return(0,T.Z)(i,It,t)}(g);return(0,f.jsx)(Mt,(0,r.Z)({className:(0,k.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:p,ref:t,ownerState:g},y,{children:s}))})),Lt=n(2156),Zt=n(5129);n(8472),(0,G.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function jt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,f.jsx)(K,{sx:{flexGrow:1},children:(0,f.jsx)(Ve,{position:"static",children:(0,f.jsxs)(qe,{children:[(0,f.jsxs)(Ae,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,f.jsxs)(Ae,{component:"div",children:[t>0?(0,f.jsx)(zt,{color:"inherit",variant:"text",onClick:o,children:(0,f.jsx)(Lt.Z,{})}):null,t<r-1?(0,f.jsx)(zt,{color:"inherit",variant:"text",onClick:i,children:(0,f.jsx)(Zt.Z,{})}):null]})]})})})}for(var Bt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Wt=[],Ut=Q.e,Ht=Q.C,Vt=Ht.length,Jt=0;Jt<Vt;Jt++)Wt.push("");var $t=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Ht[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],c=(0,e.useState)(Wt),u=(0,g.Z)(c,2),d=u[0],p=u[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],b=h[1];return(0,e.useEffect)((function(){l(Ht[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Vt;t++){var n={};n.nctid=Ht[t].nctid,n.version_a=Ht[t].version_a,n.version_b=Ht[t].version_b,n.classification_number=d[t],n.classification_meaning=Bt[d[t]],e.push(n)}b(e)}),[d]),(0,f.jsxs)(e.Fragment,{children:[(0,f.jsx)(jt,{datumNumber:r,setDatumNumber:a,numComparisons:Vt,outputData:v,batchNum:Ut}),(0,f.jsx)(z,{children:(0,f.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,f.jsx)(je,{datum:s,datumNumber:r,results:d,setResults:p})})})]})};t.createRoot(document.getElementById("root")).render((0,f.jsxs)(e.StrictMode,{children:[(0,f.jsx)(y,{}),(0,f.jsx)($t,{})]}))}()}();
//# sourceMappingURL=main.a4f15c66.js.map